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Abstract 
Several types of cells actively involved in atherosclerosis undergo a metabolic reprogramming 
that comprises an accelerated glycolytic flux to the detriment of mitochondrial oxidative 
phosphorylation. This phenomenon, known as the Warburg effect, allows cells to produce 
ample energy and biomass with negligible oxygen consumption, resulting in uncontrolled 
high-speed proliferation. This phenotypic dysfunction underlies both inflammation and 
angiogenesis, two processes that are foundation of the pathological behaviour of the plaque 
and promote its destabilisation. The preponderant kinase domain of inducible PFKFB3 
enzyme catalyses the synthesis of F2,6P, which simultaneously promotes glycolysis and 
inhibits gluconeogenesis. PFKFB3 has been found to be one of the most abundant and overly 
expressed isoenzymes in the Warburg effect, suggesting its key role in the pathology. From a 
clinical perspective, PFKFB3 represents an emerging biological target, and its inhibition would 
be an innovative therapeutic strategy for the treatment of atherosclerotic lesions. 
Our study revolves around the identification of new PFKFB3 kinase inhibitors. The rational 
design was carried out with the aid of computational methods, based on the 3D-structures of 
both PFKFB3 protein and known active ligands. In particular, two classes of inhibitors were 
used as reference ligands for the development of two distinct virtual screening workflows 
that led to the identification of two generations of candidate inhibitors. The first hierarchical 
workflow consisted of a pharmacophore-based library filtration, followed by molecular 
docking and molecular dynamic simulations, whereas the second consisted of a ligand-
optimisation process based on the design of a focussed synthesisable library of analogues 
that were submitted to molecular docking along with a concomitant similarity search for 
scaffold hopping. The first- and the second-generation candidate compounds, which were 
predicted to have good in silico affinity towards PFKFB3, were synthesised and biologically 
evaluated through kinase assay, providing further insights about these selected drug-like 
molecules and new structure-activity relationship information. 
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 1    Introduction 
 1.1   Biological background 
 
 1.1.1  Atherosclerosis 
 
Atherosclerosis is a chronic life-threatening inflammatory condition characterised 
by the build-up of a waxy substance, called plaque, inside the arterial walls. Atherosclerotic 
plaque is predominantly made of lipids and, over time, can grow, leading to peripheral 
artery diseases and serious cardiovascular complications. The swelling of plaque causes the 
arteries to harden and narrow, which disrupts and limits the flow of oxygen-rich blood to 
the heart and to the rest of the body. Eventually, an area of the plaque may break open 
after intra-plaque hemorrhages, leading to a clotting cascade and occlusive thrombosis 
with, at times, fatal complications. In fact, thrombosis-prone areas of the plaque often arise 
in unpredictable myocardial infarction and sudden ischemic stroke. Experimental work has 
elucidated some key molecular and cellular pathways that promote atherogenesis, as well 
as critical factors, such as inflammation and angiogenesis that contribute to the progression 
of the plaque. Nonetheless, atherosclerosis still represents a widespread health problem 
and an unmet medical need, as it causes cardiovascular diseases that continue to be the 
major cause of death in the Western world.1–5 
Atherosclerosis starts when the endothelium, namely the thin layer of cells (i.e. 
endothelial cells, ECs) that keeps the artery smooth and allows blood to flow, becomes 
damaged. The main risk factors causing such dysfunction of the endothelium include 
hypertension, diabetes, high levels of cholesterol and sugar in the blood, toxins from 
cigarette smoking and accelerated vascular aging. Those areas of the endothelium that are 
injured are likely to undergo a build-up of plaque, initiating a process called atheroma 
formation or atherogenesis. Specifically, the activation of inflammation among ECs, along 
with several other compensatory responses, augment the vascular permeability of the 
endothelium. As a consequence, lipids and low-density lipoproteins (LDL) (i.e. the so-called 
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“bad” cholesterol) are able to enter and then accumulate under the injured endothelium, 
in the tunica intima layer.4 This instigates mononuclear phagocyte cells and other 
leukocytes to stream in and differentiate into tissue macrophages to internalise the lipid 
and lipoprotein particles through phagocytosis. Once trapped in the artery, LDL and fatty 
acids particles can undergo progressive oxidation, triggering an uncontrolled and relentless 
inflammatory process. The hallmark of a nascent atheroma, indeed, arises from the 
oxidation of cholesterol that causes the death of macrophage cells and the formation of 
voluminous foam cells, initiating the vicious inflammatory cycle.5 
Expanding lesions are also promoted by signalling proteins such as chemokines, pro-
inflammatory cytokines, reactive oxygen species (ROS) and other mediators secreted by 
macrophages and apoptotic foam cells. These substances not only contribute to the 
recruitment of further inflammatory cells which augment the pre-existing inflammatory 
environment, but also stimulate the migration and proliferation of vascular smooth muscle 
cells (VSMCs) into the tunica intima.6 VSMCs secrete extracellular macromolecules, such as 
collagen, elastin and fibrin, that harden and enclose the plaque. Alongside this process of 
fibrosis, an increment of intracellular concentration of calcium is also observed, causing the 
calcification of the necrotic core.7,8 
A mature atherosclerotic plaque is made up of a mass of intracellular and 
extracellular lipids and lipoproteins forming the “fatty steak” (comprising cholesterol 
esters, free cholesterol crystals, phospholipids, triglycerides), a high number of 
inflammatory phagocytic cells such as monocytes, macrophages and other immune cells 
(T-lymphocytes), foam cells and debris, VSMCs and their waste productions, as well as 
apoptotic cells which constitute the necrotic core. This cluttered heap is stuck under the 
endothelium, in the tunica intima layer, covered by a fibrous cap, predominately composed 
of VSMCs and collagen proteoglycan matrix (Figure 1).3,7,9,10 
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Figure 1: (left) Overview of mature atherosclerotic plaque constituents including a lipid-rich 
necrotic core, foam cells, immune cells such as macrophages (Mϕs) and activated Mϕs, as well as 
T-lymphocytes. These are encapsulated by a fibrous cap which is mainly made of vascular smooth 
muscle cells (SMCs) and fibrous tissues (collagen, elastin and fibrin). (right) Prototype of vulnerable 
and active thrombogenic plaque characterised by a thin-cap fibroatheroma. Intra-plaque 
microhemorrhages due to neovascularisation (angiogenesis) and consequent intrusion of 
erythrocytes inside the plaque (intra-plaque bleeding). Plaque rupture with extravasation of blood 
and thrombus formation. (Image was adapted with permission from reference [11]). 
 
 
Plaque rupture mainly occurs among lesions of unstable areas defined as “thin-cap 
fibroatheromas” or “vulnerable plaque”. These areas are characterised by particularly thin 
fibrous caps (< 65 µm) consisting of few collagen bundles and rare VSMCs (Figure 1).5,10–13 
The mechanisms by which the fibrous caps thin, predisposing the plaque to rupture, include 
the death by apoptosis of VSMCs and the consequent breakdown of the collagen and 
extracellular matrix synthesis.14 Macrophages are also pivotally involved in weakening and 
degrading the already thin fibrous cap, through secretion of proteolytic enzymes such as 
matrix metalloproteinases (MMP).12 
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In addition to the thickness of the fibrous cap and the degree of inflammation, the 
pathological angiogenesis promoted by ECs contributes to render the atherosclerotic 
plaque unstable and thus prone to rupture.9,15–18 In fact, neovascularisation occurs to 
nurture the atherosclerotic plaque and the newly formed blood vessels and microvessels 
are inherently immature and leaky, causing intra-plaque microhemorrhages. This permits 
the influx of blood constituents, such as plasma proteins and erythrocytes into the sub-
endothelial space of the artery, as well as the infiltration of macrophages which further 
aggravate the inflammation. 
When plaque rupture occurs, the local extravasation of blood, and the consequent 
interaction of overlying blood with plaque constituents, induces thrombotic changes 
resulting in the activation of a clotting cascade. In particular, when plasma enters into 
contact with the necrotic core, tissue factor procoagulants instigate the aggregation of 
platelets and the coagulation at the affected area, forming blood clots and resulting in 
luminal narrowing. A large blood clot can partially or completely obstruct the blood flow 
through the artery. Complicated thrombogenic plaques frequently show signs of multiple 
ruptures and repairs, and severe luminal thrombosis often occurs in patients dying of acute 
myocardial infarction or stroke.7,17,19,20 
 
 
 1.1.2  Metabolic dysfunction in atherosclerosis 
 
As outlined above (paragraph 1.1.1), several cellular mechanisms are involved in 
plaque progression, and specifically inflammation and angiogenesis are the primary and 
critical factors in the pathogenesis of atherosclerosis and its complications. Currently, 
therefore, the condition of atherosclerosis is incontrovertibly recognised as a dynamic 
inflammatory process, aggravated by pathological angiogenesis.4 
Macrophages play a fundamental role throughout all stages of the disease, driving 
the inflammation process. These activated immune cells are subjected to significant 
alterations in their metabolism and their glucose uptake.21 Specifically, it has been reported 
that proinflammatory macrophages rely greatly on glycolysis to fulfil the high energy 
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demand needed for the production of cytokines and ROS. In particular, the activation of 
macrophages is characterised by the switching of their metabolism from oxidative 
phosphorylation to anaerobic glycolysis, even in the presence of oxygen.22–26 Studies have 
shown that the excessive glycolytic rate is responsible for the consequent pathologic 
behaviour of macrophages in the plaque. 
Together with pro-inflammatory macrophages, ECs also actively partake in 
atherosclerosis by concomitantly directing pathological angiogenesis, thus contributing to 
intra-plaque bleeding and plaque destabilisation. Remarkably, also within this class of cells 
a similar metabolic change in favour of the glycolysis pathway is observed.27 In fact, it has 
been reported that, stimulated by angiogenic factors, ECs change from quiescence to 
proliferation,28 serving thereby to vascularise otherwise avascular tissues through 
sprouting and ensure presence of adenosine triphosphate (ATP) and oxygen also in intra-
plaque vasa vasorum.29,30 ECs have therefore a high bioenergetic demand in order to 
generate nimble filopodia and lamellipodia, and they rely on glycolysis to meet this 
demand.31 Specifically, the glycolytic flux in ECs increases from 1  % to 85 % activity, with 
lactate production, while oxygen consumption reduces despite its immediate availability in 
blood vessels. Likewise, it has been described that also the phenotypic modulation, leading 
VSMCs to undergo proliferation and migration in atherosclerosis, is associated with the 
induction of similar compensatory glycolytic disorder, supported by increased glycolytic 
protein expression and glucose uptake with lactate production.6,32–34 
 
 
 1.1.2.1 The Warburg effect 
 
Thereafter, inflammatory and angiogenic stimuli make macrophages, ECs and 
VSMCs opt for anaerobic glycolysis as their main source of energy, regardless that they are 
in the presence of a normal oxygen blood concentration (normoxic conditions). The 
propensity towards reliance on glycolysis for energy and biomass production, on the other 
hand, normally occurs as a defence mechanism against hypoxic conditions, namely when a 
tissue must function anaerobically. Eukaryotic cells produce energy in the form of ATP by 
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cellular respiration, which is a sum of interrelated metabolic pathways, including 
cytoplasmic glycolysis followed by the oxygen-dependent Krebs cycle (also known as 
tricarboxylic acid (TCA)-cycle) and oxidative phosphorylation. During hypoxia, however, 
due to the scarcity of oxygen, the pyruvate generated from the metabolism of glucose 
through the glycolysis process, cannot be converted into acetyl coenzyme A and then enter 
the mitochondrial (TCA)-cycle. In particular, pyruvate gets reduced to lactate, instead of 
being metabolised oxidatively in the mitochondria. This metabolic reprogramming allows 
cells to produce ATP even in a low oxygen environment.22 It is also well-known, however, 
that the efficiency of this alternative metabolic pathway, in terms of the number of 
synthesised ATP molecules per molecule of glucose, is far inferior to the normal aerobic 
glycolysis followed by oxidative phosphorylation. Indeed, the former process only provides 
two molecules of ATP per molecule of glucose, against the 36 ATP molecules produced by 
the latter. 
The metabolic switching of macrophages, ECs and VSMCs toward anaerobic 
glycolysis, despite the ready availability of oxygen in the artery, seems therefore 
contradictory, considering the low ATP yield of the glycolytic process. In principle, there are 
two ascribable reasons that make glycolysis preferable over oxidative phosphorylation. 
Firstly, glycolysis is a prompt process and about 100 times faster than oxidative 
metabolism. Secondly, the glycolytic pathway additionally provides i) the biosynthetic 
precursors used by macrophages for the production of the pro-inflammatory proteins35 and 
ii) the precursors required for cell proliferation.26,30 
The analogous behaviour, characterised by an anomalous metabolism shift towards 
glycolysis in a normoxic conditions, was already observed in tumour cells as early as 192336 
by Otto Warburg, who termed it the “Warburg effect”. Targeting the Warburg effect is in 
fact a known therapeutic strategy for fighting cancer and has been widely explored in vitro, 
in vivo and in clinical studies. Currently, multiple and growing lines of clinical evidence have 
identified this phenomenon as a common feature in several metabolic disorders and 
chronic morbidities, encompassing atherosclerosis and cardiovascular diseases.22,37,38 In 
particular, this phenomenon is observed, more generically, within cells in a rapid growth 
phase, where ample energy production and essential biosynthetic precursors are urgently 
required for a high-speed proliferation with a negligible oxygen consumption. Hence, from 
a clinical perspective, harnessing the Warburg effect via glycolysis modulation, may now 
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help target therapeutics not only for the oncology development but also for the treatment 
of inflammation or angiogenesis in atherosclerosis. 
Several biological targets have been identified for regulating glycolysis and thus, 
ultimately, the metabolic dysfunctions due to the Warburg effect.22 One emerging target is 
the tandem enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) 
which regulates the glycolytic rate (Figure 2). PFKFB3 has been thought to be responsible 
for the heightened glycolytic activity in cancer cells39–41 and some small molecule PFKFB3 
inhibitors have been developed to block the Warburg effect, mainly for cancer 
chemotherapy applications (paragraph 1.1.3.1). In recent years, however, PFKFB3 has also 
gained attention in the field of inflammatory dysfunctions and pathological angiogenesis, 
as it is overly expressed in macrophages26 and is the most abundant isoenzyme in various 
EC subtypes.29 In addition, a rise in PFKFB3 expression was also recently observed in 
proliferative VSMCs.32 
After inflammatory stimuli, macrophages up-regulate the expression of PFKFB3 in 
order to increase the glycolytic flux and promote pro-inflammatory activation. Recent 
studies have reported that inhibition of PFKFB3 expression results in a decrease of 
glycolytic activity in macrophages leading to a reduction of pro-inflammatory activation.26 
Likewise, knockdown of PFKFB3 not only lowers the rate of proliferation of ECs, but also 
accelerates endothelial apoptosis, indicating that this protein is important in the 
physiological activity of ECs.30,42 
Taken together, these arguments suggest that PFKFB3 should be considered as a 
promising target point for the treatment of atherosclerosis.  
 
 
 1.1.3  PFKFB3 Function 
 
One of the three rate-limiting steps (r.l.s.) of the glycolytic flux is the conversion of 
fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6P) catalysed by 6-
phosphofructo-1-kinase (PFK-1). The opposite reaction is the r.l.s. of the gluconeogenesis 
pathway, catalysed by fructose-1,6-bisphosphatase (FBPase). The isomeric metabolite of 
  Chapter 1: Introduction 
 
9 
F1,6P, fructose-2,6-bisphosphate (F2,6P), is a potent allosteric modulator of these 
controlling steps. Specifically, F2,6P guides both glycolytic and gluconeogenic pathways by 
respectively activating the gluconeogenic enzyme FBPase and inhibiting the glycolytic 
enzyme PFK-1 (Figure 2). Thus, an increased concentration of F2,6P would allow 
transformed cells to maintain a high glycolytic flux.43 
The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase enzymes (PFKFBs) 
constitute a family of four homodimeric bifunctional enzymes displaying two identical 
subunits. Each subunit comprises two functional domains which have mutually opposing 
catalytic activities: a kinase activity (Kase) in the N-terminal domain and a phosphatase 
activity (Pase) in the C-terminal domain. Hence, PFKFB enzymes modulate both i) the 
biosynthesis of F2,6P from the phosphoryl donor ATP where F6P is the phosphoryl acceptor 
(Kase reaction), and ii) the reverse reaction which is the hydrolysis of F2,6P with ADP to F6P 
and ATP (Pase reaction).43,44 The two catalytic activities of PFKFBs are subtly regulated. 
 
 
 
Figure 2: Allosteric modulation of the rate limiting steps (r.l.s.) of both the gluconeogenesis and 
glycolysis pathways by fructose-2,6-bisphosphate (F2,6P metabolite): inhibition of gluconeogenic 
fructose-1,6-bisphosphatase, (FBPase enzyme); activation of the glycolytic 6-phosphofructo-1-
kinase (PFK-1 enzyme). Mutually opposing catalysis function of the tandem dimeric enzyme PFKFB: 
biosynthesis of F2,6P, promoted by kinase domains (Kase); hydrolysis of F2,6P promoted by 
phosphatase domains (Pase). 
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As reported by Kim et al.,45 the Kase reaction mechanism proceeds through a direct 
substrate-substrate interaction between ATP and F6P that allows the phosphoryl transfer 
without formation of a phosphoenzyme intermediate. As a consequence, no significant 
conformational changes of the enzyme occur during the reaction. Also, the Pase reaction 
mechanism was outlined by the same authors through a crystallographic study.46 
Every mammalian cell presents one of the four isoforms of PFKFB according to a 
structure and tissue-specific regulation of distinct encoding genes. PFKFB1 is present in the 
liver, PFKFB2 in the heart, PFKFB4 in the testis, while PFKFB3 is defined as the inducible or 
the ubiquitous form, since it is expressed in all tissues after particular conditions (mainly 
hypoxic stress).30,47,48 Each isoform responds differently to various metabolic products, 
allosteric activators, and hormonal and growth factor signals that govern the final 
concentration of F2,6P and, ultimately, the rate of glycolysis.49,50 
Although the amino acid sequences in the core catalytic domains within the 
proteins of the PFKFB family have an elevated homology (85 %),51 peculiar structural 
features in each isoform differently tune their kinase vs. bisphosphatase activity ratio and 
the kinetic of their catalysis. Notably, the inducible isoform, PFKFB3, has unique sequence 
characteristics that make the Kase activity considerably predominant over the Pase activity. 
In particular, in contrast to the rather balanced activity ratio exhibited by the liver, heart 
and testis isoforms, PFKFB3 displays a kinase vs. bisphosphatase activity ratio larger than 
700.52,53 Crystallographic study revealed that only isoform PFKFB3 displays a β-hairpin 
structure in the N-terminal domain that appears to induce a self-inhibition of the Pase 
activity.46 Additionally, the phosphorylation of the amino acid residue, Ser460, by other 
enzymes, such as protein kinase A (PKA) or AMP-dependent protein kinase, can increase 
the ratio in the inducible form further to > 3000.54–56 
Taken together, these characteristics explain the reason why cells presenting an 
overexpression of the inducible isoform PFKFB3, have such a greatly enhanced glycolytic 
rate. 
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 1.1.3.1 PFKFB3 Kinase inhibitors 
 
Thus far only a few examples of small molecule inhibitors of the PFKFB3 kinase 
moiety have been reported in the literature. Both in silico and “traditional” high-
throughput screenings have been described in order to find new drug candidates.57–62 
Representative examples of small molecule inhibitors are depicted in Figure 3. 
The most studied inhibitors are undoubtedly 3-(3-pyridinyl)-1-(4-pyridinyl)-2-
propen-1-one (3PO; 1)63 and its analogues PFK15 and PFK158, (compounds 2 and 3) as well 
as the closely related benzo[e]indole 4 (Figure 3),64–66 which are able to decrease the level 
of F2,6P and the glucose uptake, both in vitro and in vivo. The virtual screening (VS) that 
led to the discovery of 3PO was based on a computational model of the enzyme that was 
obtained by homology modelling using the X-ray structure of the rat testes, isoform PFKFB4 
as a structural template. These compounds display rather poor drug-like properties such as 
low solubility and lack of selectivity. Nonetheless, the derivative 3, PFK158, a more potent 
inhibitor having better pharmacokinetic properties than 3PO, recently underwent phase I 
clinical trials as an antitumor agent.67 There is growing evidence, however, (including our 
internal data in the Moglynet Project Consortium) that the activity data previously reported 
for 3PO cannot be independently reproduced. Indeed, in repeated kinase assays with the 
isolated enzyme, 3PO resulted, contrarily, to be inactive.60–62,68 These results, along with 
the absence of literature indications confirming the actual receptor binding, suggest that 
all the reported biological activity of 3PO, such as reduction of glycolysis, cell cycle 
regulation and tumour growth inhibition, are very unlikely to be linked to the inhibition of 
PFKFB3, but are more probably due to some alternative nonspecific mechanisms. 
Seo et al. performed a structure-based virtual screen aimed at finding other 
inhibitors with high specificity. The study approach consisted of targeting the F6P binding 
site of PFKFB3, rather than the ATP binding site, in an attempt to avoid side effects due to 
cross activity with other kinases. The observed antiproliferative effect of the identified hit 
compound 5 N4A (Figure 3), however, was ascertained only for isoform PFKFB3 and the 
selectivity towards the other PFKFB isoforms was never assessed.58 
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Figure 3: Chemical structure of small molecules reported in the literature as PFKFB3 inhibitors. 
 
Another virtual screen on a rat PFKFB3 model led to a class of new aminofurazan-
triazole series designed as PFKFB3 regulators, theoretically binding either the kinase 
(glycolysis inhibitors) or the phosphatase active site (glycolysis activators), according to a 
docking study.69 The small molecule 6 represents a kinase inhibitor, able to reduce the 
lactate accumulation to 20 % compared to the control.69 The high topological polar surface 
areas (TPSA) and molecular weights (MW), however, render these small molecule 
modulators implausible lead compounds for a further optimisation. Similarly, the triazolo-
arylpyridazinone 7 was selected following an investigation of the structure-activity 
relationships (SAR) around a class of inhibitors discovered using high-throughput 
screening.60 Nonetheless, given the nature of the cellular in vitro assays used for testing 6, 
7 (Figure 3) and their derivatives, the authors of both studies also disclosed possible 
different modes of action, perhaps involving the interaction with other similar glycolytic 
enzymes. 
Other related compounds have been patented as PFKFB3 inhibitors but their 
binding sites are unknown and they are also characterised by a rather mediocre half 
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maximal inhibitory concentration (IC50).65,70,71 Moreover, due to the strong homology of the 
four isoforms of the PFKFBs family, the majority of these compounds show a general lack 
of selectivity. 
An important piece of work published by the pharmaceutical company AstraZeneca 
(AZ) describes the SAR study that led to the development of a new class of potent and 
selective derivatives, bearing a phenoxy-indole or phenoxy-indazole scaffold.68 These novel 
series of inhibitors (hereinafter referred to as the AZI compounds) are ATP competitors and 
display an IC50 in the low nanomolar (nM) concentration range. Furthermore, six chosen 
compounds from the AZI series (Table 1) were co-crystallised inside the human PFKFB3 
enzyme, confirming their binding at the ATP pocket (PDB IDs: 5AJX, 5AJY, 5AJZ, 5AJW, 5AJV, 
5AK0). 
Two years later, AZ published another paper concerning the identification via high-
throughput screening of a novel family of compounds having activity in the sub-µM 
concentration range and displaying promising lead-like properties.72 The active aromatic 
core of these ligands (hereinafter referred to as the AZPP compounds) is a 
dihydropyrrolopyrimidinone heterocycle. Four compounds of the AZPP series (Table 3) 
were also co-crystallised and provided as three-dimensional (3D) X-ray structures in the 
Protein Data Bank (PDB IDs: 4D4K, 4D4J, 4D4M, 4D4L). 
Both of these families of AZ compounds (i.e. the AZI and AZPP series), were used as primary 
reference ligands in the present research study for the rational design of new candidate 
PFKFB3 inhibitors following two distinct workflows (Chapters 3 - 4). 
Very recently, another two new entries in the group of PFKFB3 inhibitors were 
identified and biologically evaluated in vitro: the phenylsulfonamido salicylic acid 861 and 
the aminoquinoxaline 962 (Figure 3). Compound 8 represents the most active hit among 
50,000 compounds screened through high-throughput enzymatic and cellular assays. 
Confirmed by Saturation Transfer Difference NMR, this compound is an F6P competitor 
since it reversibly binds PFKFB3 at F6P binding site.61 Compound 9, meanwhile, is an ATP 
competitor that was developed after high-throughput screening, through an in silico hit-
optimisation process with blind molecular docking as well as the aid of crystallographic 
studies. 62 
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 1.2   Virtual Screening in drug discovery 
 
 1.2.1  Introduction 
 
The early stage of drug discovery comprises the identification of novel hit molecules 
that bind to a certain target, usually a protein, and exert the desired biological effect. The 
traditional approach consists of the high-throughput screening (HTS) of corporate libraries 
of compounds against the biological target of interest. Specifically, with the HTS approach, 
an extremely high number of experimental assays have to be performed until the 
identification of a hit. Although it remains a very effective process, it is extremely expensive 
and time-consuming. In this context, modern computational methods, such as virtual 
screening (VS), represent a powerful means for hastening this process, also considerably 
reducing the costs of the entire drug discovery campaign. The term “virtual screening” first 
appeared in the 1990s and, since then, VS has been increasingly employed, both by 
academic laboratories and pharmaceutical companies, as an effective tool in medicinal 
chemistry research and drug discovery and development. In fact, compared to the costly 
and lengthy HTS, the VS methods allow mining and evaluation of large in silico databases 
of compounds in a reasonable amount of time, using molecular modelling and without 
consuming pricey substance materials. The result of the search is a filtered or ranked 
database where the affinity of each ligand towards a biological target is calculated, then 
compared with the other ligands of the library and sorted accordingly.  
These computationally-aided predictions can be performed to complement the HTS, 
usually during a stage prior to the experimental screening. Indeed, one of the principal 
goals of VS is to enrich the starting search library and provide valuable clues to prioritise 
potential active molecules, in order to narrow down the actual number of compounds that 
are tested in experimental validation. 
To date, a tremendous number of chem- and bioinformatics tools have been 
developed and proven to be quite successful in drug discovery and drug design. The existing 
broad screening strategies are conventionally divided into two different subcategories: i) 
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ligand-based virtual screening (LBVS) and ii) structure-based virtual screening (SBVS). The 
first approach takes information from the structure and the properties of known active 
molecules, while the second approach takes information from the structure and the 
properties of a target receptor and its active site. LBVS methods are mainly based on 
similarity and diversity measures between molecules and reference active compound(s) 
that are assessed by comparing topological descriptors or putative pharmacophores to find 
new hypothetically active scaffolds. Whereas SBVS methods are based on the systematic 
measurements associated with the likelihood of a ligand to interact with a critical target in 
the disease of interest. Depending on the information available, the two methods can be 
used independently or in combination. Clearly, when both 3D structures of known active 
compounds and target protein are available, the combination of LBVS and SBVS can 
potentially be favourable to any individual screening method. However, a priori neither 
approach can be peremptorily considered better than the other, in terms of efficacy and 
efficiency.73–75 These methods are data hungry procedures and the workflow of the VS can 
vary depending on the availability of structures and the knowledge of experimental 
biological data. Today, however, a number of structure databases of small molecules and 
protein targets have been created and provided to the entire scientific community to 
respond to the need for chemical and biological information. 
 
 
 1.2.1.1 Molecular Database 
 
In any virtual screen, the choice of the initial chemical library (otherwise referred to 
as a chemical or molecular database, DB) to be scanned is of critical importance and can 
greatly affect the outcome of the drug discovery campaign. Both library size and extent of 
chemical diversity, which are key factors in the evaluation of the quality of a library, have 
to be set against the cost, time and the purposes of the VS method. For instance, databases 
embracing the chemical space as fully as possible will be more likely to contain true-active 
molecules but may be ‘heavy’ to manage and their screenings may necessitate massive 
computational cost and storage space. The estimated size of the chemical space is indeed 
greater than 1060 molecules, making it impossible to tackle with exhaustive search tools.76 
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On the other hand, small libraries displaying poor chemical diversity can only result in few 
redundant hits. Thus, clustering similar scaffolds within a screening library is usually 
necessary to reduce structural redundancy. Likewise, upfront filtering is also indispensable 
for prioritising molecules with appropriate physicochemical properties and for getting rid 
of problematic and reactive functionalities or improbable and non-synthesisable 
molecules. Traditional properties filters are, for example, based on the well-known 
Lipinski’s “Rule of Five” (Ro5)77 which delineates the portion of molecules in the chemical 
space that most likely can be flagged as “drug-like” molecules, namely having more chance 
to be orally bioavailable. There are also related rules adapted from Ro5, such as “Rule of 
Three”,78 or the guidelines suggested by Hann and Oprea for “lead-likeness”, regarding the 
suitability of a compound to undertake follow-up and optimisation processes.79,80  
Furthermore, databases formed by one (1D) or two-dimensional (2D) 
representations of molecules must typically undergo a 3D sampling and often require the 
generation of the possible multiconformers of each molecule, before performing the 
screen. In fact, in many VS methods, sampling represents a critical issue because, during 
the DB mining experiment, no new conformation is generated on-the-fly. Nonetheless, 
molecules are flexible entities and therefore pre-computed conformations must be already 
associated with the molecules in the input search DB. 
Along with a search library to be screened, often a suitable test DB is also needed 
to validate the screening technique. In fact, as described in the following paragraph 1.2.1.2, 
when looking for new hit compounds via VS, it is desirable to test the method in question 
with respect to its ability to enrich the search DB. Specifically, the VS method is applied to 
a dedicated set library comprising known active ligands and a benchmarking of inactive 
ligands. From the outcome it is then appreciated how the former would rank against the 
latter. Obviously, the validation of the screening method requires the knowledge of both 
active and non-active ligands. 
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 1.2.1.2 Validation of Virtual Screening Method 
 
The evaluation of the outcome of a virtual screening experiment corresponds to its 
ability to discriminate biologically active molecules (true positive, TP) over non-active 
molecules (true negative, TN), in relation to the number of overestimated non-actives (false 
positive, FP) and discarded actives (false negative, FN). In other words, the success of a 
screening method is quantified by the Enrichment Factor (EF, Equation 1). The EF of a VS is 
its capacity to enrich the maximum number of TP in a defined percentage of top-ranked 
ligands from the screened library with respect to a random approach to selecting 
molecules. It is determined through the following equation: 
 
                           EF = 
𝑻𝑷
𝑻𝑷+𝑭𝑵
 
𝑵
𝒏
                                Equation 1 
 
where N is the total number of molecules in the search database and n is the portion 
of molecules retrieved by the screening. 
Another forthright measure of that is expressed by the area under the curve value 
(AUC) derived from the Receiver Operating Characteristic curve (ROC). The ROC curve is the 
plot which correlates the ‘true positive rate’, also indicated as ‘Sensitivity’, with the ‘false 
positive rate’, also indicated as ‘1 – Specificity’. The Sensitivity is the ratio between the 
number of TP and the total number of active molecules (Equation 2), while Specificity is 
the ratio between the number of TN and the total number of non-active molecules 
(Equation 3). 
 
                                         Sensitivity = 
𝑻𝑷
𝑻𝑷+𝑭𝑵
                          Equation 2 
 
                                        Specificity = 
𝑻𝑵
𝑭𝑷+𝑻𝑵
                           Equation 3 
 
The maximum value of AUC is 1, which corresponds to the best possible 
performance in which the VS search returned every active and correctly excluded every 
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non-active compound (Sensitivity = Specificity = 1). While AUC values of 0.5, with a ROC 
curve corresponding to the bisecting diagonal line (true positive rate = false positive rate), 
indicate that the selection of hit molecules by the VS method is no better than a random 
guess.  
The following paragraphs describe the most common computer-aided drug design 
methods and techniques for both LBVS and SBVS, with a special focus on the methodologies 
used in the present work. 
 
 
 1.2.2  Similarity Searching 
 
One of the simplest and most widely used cheminformatics technique is similarity 
searching, in which a reference molecule is compared against a database of compounds. 
This field is extremely wide and encompasses numerous methods and applications.81 For 
example, similarity-based measures are frequently used to cluster redundant molecules of 
a large database into similarity groups for reducing chemotype bias, as mentioned above 
(paragraph 1.2.1.1). 
In the context of VS and drug discovery, similarity is a key concept and it is based 
on the assumption that similar molecules are likely to exhibit similar biological activity on 
a given target. This type of LBVS can be applied in a lead-optimisation campaign for the 
search for related compounds that are chemically similar to a given drug or lead molecule 
but may display improved potency and/or pharmacological properties or they may be more 
suitable for large-scale synthesis. Alternatively, one objective of a similarity search is to 
identify the nearest-neighbour molecules displaying similar physiochemical properties of a 
drug but having structurally novel molecular frameworks. This type of search has been 
termed ‘scaffold hopping’,82,83 since it facilitates the identification of novel hits with 
different chemical scaffolds. This strategy can be also a valid means to break out of a 
protected patent space and create new intellectual property, or to overcome a “flat” 
structure-activity relationship (SAR). 
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To date, a number of computational methods have been developed to capture and 
encode the properties of ligands and to compare them in a systematic and consistent 
manner, through similarity search algorithms.84 The search can be computed based upon 
topological indices, steric, electronic or physical properties, and can be grouped into two 
main categories: 2D and 3D methods.85 In 2D similarity methods, bit strings called 
‘molecular fingerprints’ are used to encode the compound chemical patterns. The 
Tanimoto coefficient (Tc) is probably the most widely used metric to compare the 
fingerprints of two molecules and quantify the degree of their similarity. It is defined by the 
fraction of shared chemical patterns, in the range between 0 (dissimilar molecules) and 1 
(identical or very similar molecules). Clearly, although they have the advantage of a short 
processing time, 2D approaches might be too simplistic for the purpose of scaffold hopping. 
In this context, the more exhaustive 3D molecular representations are generally 
preferentially used as the queries of reference, due to their additional conformational and 
shape information content.86–88 Some 3D methods define common substructures of 
molecules based on the spatial alignment of their sets of coordinates. These methods use 
iterative optimisation algorithms to stochastically search the maximal common 
substructure between molecules, taking into account the atomic nature.83,89,90 Similarly, 
other 3D approaches rely upon shape information or pharmacophoric descriptors.82,88 
 
 
 1.2.3  Pharmacophore-Based Virtual Screening 
 
The pharmacophore modelling technique is a powerful tool that has been used in 
medicinal chemistry for several years. The term pharmacophore is sometimes used 
incorrectly in this field, however. The consistent definition provided by the International 
Union of Pure and Applied Chemistry (IUPAC) is as follows:91 
“A pharmacophore is the ensemble of steric and electronic features that is necessary 
to ensure the optimal supramolecular interactions with a specific biological target 
structure and trigger (or to block) its biological response.” 
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And an additional note also elucidates that: 
“A pharmacophore does not represent a real molecule or a real association of 
functional groups, but a purely abstract concept that accounts for the common 
molecular interaction capacities of a group of compounds towards their target 
structure. The pharmacophore can be considered as the largest common 
denominator shared by a set of active molecules. This definition discards a misuse 
often found in the medicinal chemistry literature which consists of naming as 
pharmacophore simple functionalities such as guanidines, sulphonamides or 
dihydroimidazoles (formerly imidazolines), or typical structural skeletons such as 
flavones, phenothiazines, prostaglandins or steroids.” 
      As explained, a pharmacophore model is an abstract 3D map characterised by steric and 
electronic molecular features that depicts the physiochemical nature and the coordinate 
position of chemical functional groups that are involved in the ligand-protein interactions. 
Conversely, it is not a real molecule or chemical portion of an active ligand, as erroneously 
stated at times in the literature. Hydrogen bond donors (HBD), hydrogen bond acceptors 
(HBA), positively or negatively charged groups, hydrophobic regions, etc. are features 
typically annotated and used, along with their spatial location and orientation, as 
pharmacophoric representations of small molecules. Also, the shape of a molecule can be 
embodied in a pharmacophore query, in order to specify the suitable geometric constraint 
required to fit the active site of the protein target. 
Despite its apparent intuitive interpretation, a pharmacophore query model is 
never unequivocally designed, and its elucidation remains a conceptual challenge that 
requires knowledge and expertise of medicinal chemistry. Usually, to derive a 
pharmacophore model, a training set of active ligands is used as a template to determine 
which common features might be indispensable for the desired interaction with the 
protein. Preferably, the template ligands should be potent, chemically diverse and bind 
with similar modes in the same target pocket; however, theoretically only one active ligand 
could be sufficient to design a pharmacophore. Furthermore, if known, structural 
information about the conformation and the active site of the macromolecular target can 
also be of benefit for constructing or refining a good model. Hence, both ligand-based and 
structure-based strategies can be used for the expression of pharmacophore models.92,93 
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Currently there are several platforms being developed that facilitate the elucidation 
of a pharmacophore and that allow users to perform pharmacophore-based library 
screening.94–98 Each platform application has its distinct criteria for encoding features into 
3D queries, as well as different representations and customisation schemes. The software 
platform MOE (Molecular Operating Environment) of the Chemical Computing Group has 
different annotation schemes containing specific procedures for the abstraction of defined 
electronic and steric features.98 MOE also allows multiple query hypotheses to be 
constructed after the flexible alignment of a given training set of known ligands. Queries 
elucidated in this way are made up of shared features within the ligands that can 
theoretically explain their structure-activity data. 
Pharmacophore-based searching is a procedure for the screening of 3D libraries of 
small molecules that can be classified either as LBVS or SBVS, depending on the information 
used for the elucidation of the query map. In general, however, the search consists of 
aligning, with a certain tolerance, the ligand atoms onto the pharmacophoric site points, in 
order to retrieve only those molecules fitting the map. In this way, a pharmacophore can 
provide a powerful tool for pre-filtering large ligand libraries, potentially at any stage of the 
drug discovery process. 
Although the pharmacophore search per se can be very fast, the DB subjected to 
screening must provide a broad coverage of conformers, the generation of which can be 
very slow. In fact, a critical aspect for the quality of matching that must be ascribed in this 
type of VS, is the 3D conformational flexibility of the molecules. Only a few software 
applications are able to tweak the conformation on-the-fly during the fitting process,99 the 
majority treat the small molecules as rigid entities and hence pre-computed sampling of 
conformers is required. For instance, the MOE software application98 adopts a rigid-body 
alignment between conformer and pharmacophore model and only translational and 
strain-free rotational movements are allowed. Alternatively, albeit more rarely, some 
software packages, comprising MOE, can be supplemented with dedicated multi-
conformational databases. 
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 1.2.4  Molecular Docking 
 
Whenever the structure of a particular biochemical target is known, the molecular 
docking calculation is an SBVS method that has been very frequently adopted in drug 
discovery for hit identification and/or lead-optimisation campaigns. 
The 3D structures of the macromolecular targets are generally determined with X-
ray crystallography and/or nuclear magnetic resonance (NMR) spectroscopy and are 
deposited in the Protein Data Bank (PDB).100 For crystal structures, a preliminary 
preparation procedure is required before they can be used in subsequent calculations. In 
fact, although representing an excellent source of information, macromolecular X-ray 
structures often suffer from missing or poorly resolved atoms, alternative geometries, or 
other crystallographic artefacts that need to be addressed and corrected. For instance, 
because of their low electron density, hydrogen atoms only weakly scatter X-ray radiation, 
making their detection difficult. For these reasons, an upfront computational assignment 
of protonation states is necessary. In other cases, a 3D model can be constructed in silico 
(i.e. by homology modelling), combining the accessible structural information of related 
homologous proteins with the amino acid sequence of the target of interest. 
A 3D representation of the target can be used against a collection of compounds 
using molecular docking in order to predict their putative optimal binding mode and to 
calculate their tightness-to-fit. Docking algorithms involve the prediction of multiple 
conformations and orientations of a single ligand inside the binding site in order to select 
the most energetically preferred mode. This process is called ‘posing’, and its complexity is 
associated with the conformational degrees of freedom of the ligands. A computational 
scoring function is applied to achieve an approximate evaluation of how well the selected 
pose fits the binding site. The scoring function is a predictive mathematical model that 
produces a score which represents an estimation of the stability of the resulting docked 
ligand-protein complexes. In other words, the scoring function gives an approximation of 
the binding affinity on the basis of the tightness of the interaction, making it possible to 
prioritise the configuration of each ligand that would more likely bind to the receptor. 
Finally, in a post-processing step, the best geometries of the ligands are ranked according 
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to their assigned docking score in order to discriminate promising compounds to take 
further as candidate actives. 
Usually docking is site-specific, meaning that the centre coordinates and the radius 
of the binding pocket into which the ligands are docked are defined a priori. Alternatively, 
when the position of catalytic or allosteric sites of a target are not available, ‘blind docking’ 
is used also to find out which part of the receptor the ligands would more likely bind. 
Although the simulation of the true pose of the bound ligand is usually obtainable 
with relatively good reliability, the more advanced steps of scoring and ranking are still very 
challenging with the available docking methods. The scoring functions are designed to 
reproduce experimental data, such as the binding free energy, as a sum of several 
parameterised functions that represent the thermodynamics of interaction of the protein-
ligand system. Some of the difficulties with scoring functions come from the fact that 
several terms and events, for example some molecular interactions, are difficult to 
parameterise. However, relatively simple scoring functions continue to be heavily used for 
VS, especially because of their acceptable time-scale of computation. 
Other factors weakening accuracy may be due to a limited resolution of the X-ray 
target structure or to the disregard of possible pivotal participation of water molecules in 
the binding. ‘Cross-docking’, in which multiple models of the same protein are used to 
reproduce ligand pose in non-native structures, can provide more information than the 
docking calculations that rely on a single structure.  
The flexibility of the receptor can also be a crucial issue, especially while modelling 
induced fit systems. However, the inclusion of flexibility in the docking calculation (referred 
to as ‘soft docking’ or ‘flexible docking) is controversial because it is theoretically more 
accurate, yet computationally more expensive.101–104 For example, soft docking may be 
desirable when the bound protein (holo form) presents important conformational 
rearrangements with respect to the protein with an empty binding site (apo form). 
Nonetheless, to solve docking problems, ‘rigid docking’, using an unmoving protein, is most 
of the time preferred in order to reduce the computational cost. 
Methods for docking ligands have a long history, and in the literature there is a 
plethora of works and reviews describing the existing docking programs and their 
applications.101,105 Today there are a number of docking programs providing different 
conformational sampling algorithms and a variety of scoring functions.102,106–109 
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The docking methodology used in the PLANTS (Protein-Ligand ANT System) 
program, developed by Korb et al.,110,111 is based on a stochastic optimisation to find a 
minimum energy conformation of the ligands in a defined binding site. The empirical 
ChemPLP scoring function employed in PLANTS mainly takes into account steric 
complementarity and hydrogen bonding interactions between the protein and the ligands. 
It is characterised by variables that describe the degree of freedom (translational, 
rotational and torsional) of the ligands. To find the best ligand orientation and 
conformation, the PLANTS search algorithm minimises the scoring function by tuning the 
degree of freedom values through an iterative optimisation process. The optimisation 
technique uses the ant colony optimisation (ACO) metaheuristic algorithm. This 
mathematical method is inspired by the behaviour of real ants using pheromones to find 
the shortest path from their nest to a food source according to an iterative process. 
Similarly, PLANTS makes random pose changes and uses an “artificial pheromone” to mark 
low-energy ligand conformations that, in subsequent iterations, are modified, until an 
energy minimum is found.110,111 
PLANTS also provides ‘flexible receptor docking’ (or ‘soft docking’) that addresses 
flexibility to the part of the target protein that adapts its conformation to an incoming 
ligand (e.g. the amino acid side chains of the binding site).103 The program allows degrees 
of freedom in defined flexible side chains of amino acids by adopting the same ACO 
methods used to explore the conformational space of ligands. This approach can 
theoretically improve both pose prediction success and enrichment rates, especially if the 
holo form differs substantially from the apo form. As anticipated above in this paragraph, 
however, modelling the molecular flexibility of the target protein drastically increases the 
required computing time and cost. 
 
 1.2.5  Molecular Dynamic (MD) Simulations 
 
The docked conformers pre-selected through scoring functions, can be further 
evaluated (re-scored and re-ranked) using more complex ranking schemes. Specifically, 
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methods based on Molecular Dynamic (MD) simulations, involving a more detailed 
treatment of electrostatic and van der Waals interactions, and also capturing the solvation 
effect, might serve to improve the quality of affinity estimation. Moreover, the MD 
simulation of ligand-protein complex can also be used to validate and/or refine the posing 
outcome obtained with molecular docking, by analysing the stability of the trajectories of 
the atoms throughout the time of the simulation. 
MD physical methods were first developed in the late 1970s112 and classically have 
been used for studying the motion and the conformational rearrangements of molecules 
in evolving systems. In recent decades, however, they have been the subject of increasing 
interest and applications in drug discovery and VS. This is also due to the significant 
progress made in computational technology and in particular to the advent of the powerful 
hardware based on graphical processing unit (GPU). In fact, GPUs have substantially 
increased the affordability of very demanding computational calculations, such as the 
complex task of high-throughput simulation of macromolecular systems in SBVS. 
The MD simulation technique uses approximation based on Molecular Mechanic 
energies (MM) to estimate the forces acting between atoms and molecules, and applies 
the Newtonian laws to calculate the successive positions and velocities of atoms. MM 
potential energies are expressed as the sum of interactions arising between bonded atoms 
(stretching, bending and torsions) and non-bonded atoms (van der Waals and electrostatic 
interactions). To calculate the contribution of these forces, a series of parameters, referred 
to as the ‘force field’, describing chemical bonding, atomic angles, atomic radii, partial 
atomic charges, etc., is assigned. The forces are assumed to be constant during discrete 
intervals of time, defined time-steps. The integration of the Newtonian law of motion for 
each time-step gives successive time-dependent configurations that altogether produce 
the trajectories of the evolving system. Several force fields have been developed and are 
commonly used in MD simulations, such as AMBER,113,114 CHARMM,115 GROMOS116 and 
others, differing principally in their approach to parametrisation and their suitability to 
distinct type of systems. 
Usually, the simulation is produced for one protein-ligand complex in periodic 
boundary conditions (PBC) so as to better mimic a homogeneous bulk system in which an 
infinite number of complexes take part. The unit box containing the simulating complex 
immersed in the solvent, is evenly repeated in every direction of three-dimensional space. 
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The result is an infinite network of identical boxes (ensemble), so that the number of 
particles in every virtual copy is constant and any change is perpetuated an infinite number 
of times over each box. 
The conditions in which the system is simulated are controlled by the thermostat 
and the barostat algorithms that mimic a thermostatic bath and the isobaric conditions 
respectively. In the NVT canonical ensemble, the number of particles (N), volume (V) and 
temperature (T) are kept constant, allowing energy fluctuation. While in the NPT 
isothermal-isobaric ensemble volume and density can vary and pressure (P) is conserved, 
as well as the number of particles and the temperature. 
The actual production simulation starts after an equilibration/stabilisation step in 
which the system is minimised and relaxed to reach a stationary state and so as to remove 
initial unfavourable contacts between solvent and solute. The production time can last up 
to a 100 ns or more, depending on the complexity of the system and the purpose of the 
study. To test the stability of biomolecular aggregates, simple MDs ranging up to few ns of 
timespan length are reasonably adequate.117 The stability can be assessed by measuring 
the coordinate root mean squared deviation (RMSD) of the atoms trajectory, which 
measures the degree of fluctuation within the coordinates of a set of atoms across the 
whole production time. Clearly, a stable system will show little variations in the RMSD 
profile, whereas a particularly unstable system, in which the ligand may even leave the 
binding pocket, will generate a high variation in RMSD values. 
 
 
 1.2.6  MM-GB(PB)SA calculation 
 
Another relatively accurate way for estimating the free energy of the binding of 
small molecules to a biological target (ΔGbindsolv) is the calculation of Molecular Mechanics 
energies combined with the Generalised Born or Poisson-Boltzmann, and surface area 
continuum-solvation (MM-GBSA or MM-PBSA) methods. These methods can be used for 
rescoring molecular DBs in a SBVS. They are based on the average energy contribution of 
ensemble MD trajectories of the solvated ligand-protein complex.118,119 
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ΔGbindsolv is the difference in free energy of the solvated bound state (ligand-
receptor complex in solvent) and the solvated unbound states (free ligand and free 
receptor in solvent) (Equation 4). However, this calculation would be very computationally 
demanding and inaccurate to perform, due to the huge energy contribution coming from 
the large number of solvent-solvent interactions and fluctuations. In fact, these 
interactions are an order of magnitude larger than binding energy, causing additional noise 
to the calculation. 
 
 
Figure 4: Schematic illustration of the thermodynamic cycle used to calculate the binding free 
energy (ΔGbindsolv) associated with the chemical equilibrium between unbound receptor (R) and 
ligand (L) and their complex (RL), in their solvated states. ΔGbindsolv is decomposed as a sum of 
binding free energy in the vacuum (ΔGbindvac) and solvation free energy (ΔGsolv). 
 
 
To limit the complexity of the calculation, therefore, the interaction between ligand 
and receptor is considered as in the vacuum and corrected by adding the contribution of 
the solvation energy. As a result, ΔGbindsolv is decomposed according to the thermodynamic 
equilibrium depicted in Figure 4, and approximated as a sum of individual uncorrelated 
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terms: the changes upon binding free energy in the vacuum ΔGbindvac, and the free energies 
of solvation (ΔGsolv) of each state (i.e. the difference in free energy of the solvated and 
unsolvated states) (Equation 5). 
 
                                                           ΔGbindsolv = (GRL – GR – GL)solv                           Equation 4 
ΔGbindsolv = (GRL – GR – GL)vac + [(GRLsolv - GRLvac) - (GRsolv - GRvac) - (GLsolv - GLvac)] 
ΔGbindsolv = ΔGbindvac + [ΔGsolv(RL) - ΔGsolvR - ΔGsolvL] 
                                                              ΔGbindsolv = ΔGbindvac + ΔGsolv                          Equation 5 
  
This approach was originally developed in the AMBER software.120 Specifically, an 
ensemble average of vacuum binding free energy and solvation free energy is calculated 
from a given number of snapshots collected from the MD trajectories. In fact, the AMBER 
modules tleap and cpptraj create the required topology and trajectory data of the free 
ligand and free receptor, as well as the unsolvated states, by simply removing the 
appropriate atoms from the selected snapshots. With this approach, only a single 
production simulating the solvated receptor-ligand complex is required for the calculation 
(single trajectory approach). In less common cases, when the modelled system displays 
significant conformational changes and important protein rearrangements, like in an 
induced fit system, then three separated simulations of solvated unbound ligand, receptor 
and complex might be used (a three trajectories approach). The single trajectory 
approaches, however, often give more accurate results than those with three 
trajectories.121 
The binding free energy in the vacuum ΔGbindvac is approximated by the average of 
all internal molecular mechanic (MM) interaction energies determined from the MD force 
field (stretching, bending, torsions, van der Waals and electrostatic) between receptor and 
ligand. A conformational entropy variation term, multiplied by absolute temperature (TΔS), 
should be added to the MM interaction energy for a more accurate estimation of the 
binding free energy. Because of the high computational cost required for its determination, 
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however, and the additional uncertainty added by this calculation, most of the time, TΔS is 
neglected from the calculation (Equation 6).118,122,123 
The solvation term ΔGsolv is the sum of electrostatic and non-electrostatic term 
(Equation 7). The electrostatic solvation energy, which models the polar effects, is obtained 
by the Generalised Born (GB) or Poisson Boltzmann (PB) equation. Non-electrostatic 
contributions, which model the hydrophobic effects, are proportional to the surface area 
accessible to the solvent (SA). From here derives the MM-GBSA or MM-PBSA equation 
(Equation 8). 
 
 
                                                       ΔGbindvac = ΔEMM – TΔS ≈ ΔEMM                                     Equation 6 
                                             ΔGsolv = ΔGel + ΔGnon-el = ΔGGB/PB + ΔGSA                        Equation 7 
                                     ΔGbindsolv = ΔEMM + ΔGGB/PB + ΔGSA                    Equation 8 
 
 
In both the Generalised Born model and the linearized Poisson-Boltzamann 
equation, the solvent is regarded as an implicit continuous medium with a specific dielectric 
constant value (i.e. εwater = 80). This homogeneous medium solvation model, however, does 
not contain any information about water molecules in the binding site or their role in the 
ligand binding. In some systems, this lack of information can influence the result quite 
substantially, especially when water is pivotal for the ligand binding (e.g. water residue 
bridging through hydrogen bond) or when water is involved in transient interactions. 
Some efforts have been made to account for the contribution of structural water 
molecules in the MM-GBSA or MM-PBSA equation by explicitly including a hydration shell 
around the ligand. The Nwat-MMGBSA method, which was adopted in the present work, 
allows important water residues to be selected as part of the receptor, providing 
improvements in correlation with the biological data and thus increasing the prediction 
power.124–127 
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 2   Aim of the Research  
 
As outlined in Chapter 1, the metabolic dysfunction characterised by an upturn of 
the glycolytic rate and a downregulation of oxidative phosphorylation regardless of the 
levels of oxygen is a well-known phenomenon called the Warburg effect. Recent studies 
have highlighted the importance of this cellular metabolism reprogramming as the origin 
of the inflammation and pathological neovascularisation in atherosclerosis. In fact, various 
types of cells pivotally involved in the progression of atherosclerotic plaque display much 
the same glycolysis-driven metabolic profile. The result of this change is the fast production 
of ATP and bioprecursors, with a relentless high proliferation that leads to an improper 
immune response and plaque destabilisation. Targeting the Warburg effect via the 
inhibition of glycolysis represents an attractive therapeutic approach to delay the 
progression of atherosclerotic plaque or even, possibly, induce its regression. 
PFKFB dimeric bifunctional enzymes control the glycolytic flux through their 
Kase/Pase activities that regulate the level of F6P and F2,6P molecules. In fact, the latter 
allosterically activates the glycolytic enzyme PFK-1 and inhibits the gluconeogenic enzyme 
FBPase. Among the existing four PFKFB isoforms, the inducible ubiquitous form PFKFB3 
presents an unbalanced Kase vs. Pase activity ratio in favour of the Kase activity, resulting 
in a high level of F2,6P and a consequent acceleration of the glycolytic rate. 
From a clinical perspective, based on the substantial reported evidence suggesting 
the implication of PFKFB3 in the Warburg effect, this enzyme may serve as a very effective 
biological target. Specifically, inhibition of its prevailing kinase activity could reinstate the 
regular aerobic respiration, thereby restoring metabolism homeostasis and a normal 
glucose utilisation. This approach represents an innovative therapeutic strategy for the 
stabilisation of atherosclerotic plaque. 
To date, only a handful of small molecule inhibitors of the PFKFB3 kinase domain 
have been reported in the literature. Furthermore, the majority of these require further 
biological validation or optimisation, since they display relatively poor potency, poor 
isoform selectivity or “non-druggable” properties. Thus, there is a huge demand for novel 
ligands or a class of ligands with elevated affinity towards PFKFB3, capable of selectively 
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inhibiting its kinase activity. Moreover, a novel isoform specific inhibitor could serve as valid 
probe to pursue further understanding of the emerging biology of this interesting 
metabolic target, potentially removing doubts about presumed off-target modes of action. 
Two important classes of PFKFB3 inhibitors, developed by AstraZeneca and 
displaying an interesting profile and promising properties, have been co-crystallised with 
the protein. The availability of the 3D crystal structures of the PFKFB3-inhibitor complexes 
represents an excellent source of information, paving the way for the identification of the 
key interactions that are responsible for the molecular recognition and bioactivity. Indeed, 
the identification of drug-enzyme interactions is pivotal for finding new candidate 
inhibitors with greater target affinity and improved properties. 
In this scenario, computational tools, such as molecular modelling and VS, applied 
to the early stage of the drug discovery process, have demonstrated increasing reliability 
and prediction capacity for the identification of innovative biologically active molecules. 
Both ligand-based and structure-based virtual screening of chemical libraries considerably 
decrease the cost and the length of the hit identification process compared to the 
traditional expensive method of high-throughput screening. 
The main objectives of the present multidisciplinary project are therefore to: 
i. Use computational technologies to identify new compounds, or classes of 
compounds, capable of selectively inhibiting the kinase domain of PFKFB3; 
ii. Design and carry out the organic synthesis of the identified compounds; 
iii. Evaluate the biological activity of the selected compounds in vitro. 
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 3   AZI-Based Rational Design 
 3.1   Overview 
 
The phenoxy-indole and phenoxy-indazole series (AZI compounds) developed by 
the pharmaceutical company AstraZeneca, are a class of potent and selective kinase 
inhibitors of the PFKFB3 isoenzyme.68 At the beginning of this project, only a small number 
of reports on PFKFB3 kinase inhibitors had been presented in the literature, with the newly 
published AZI series being the ones showing the highest potency in both isolated enzymatic 
assays and cellular assays. As described above (paragraph 1.1.3.1), these compounds are 
ATP competitive ligands, since they non-covalently bind at the ATP binding site. The 
structure of these compounds has already been optimised through a structure-activity 
relationship (SAR) study that led to the identification of the phenoxy-indazole AZ33 
(compound 16, Table 1), as the most potent compound, showing a single-digit nM IC50 (half 
maximal inhibitory concentration).68 In addition, the isoform selectivity of these 
compounds has been assessed in vitro, with kinase assays performed on the isoforms 
PFKFB1 and PFKFB2. In addition, six crystallographic structures of PFKFB3 in complex with 
representative inhibitors of the AZI series (Table 1) have been elucidated and made 
available in the Protein Data Bank, as experimental evidence of their binding to the enzyme. 
From this early scenario, came the idea for this project to develop a virtual screen based 
on these compounds. 
The computational search was carried out taking advantage of the knowledge of 
the 3D structures of both the ligands and the receptor target, derived from the available X-
ray data of the complexes. A library containing over 1 million drug-like compounds, whose 
characteristics are described in paragraph 3.2 was explored. The workflow of this study 
involved a tiered screening where a ligand-based approach preceded a structure-based 
approach, therefore representing overall a hierarchical strategy procedure that can be 
divided into three levels of filtration, as depicted in Figure 5. 
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Table 1: Chemical structures and corresponding reported IC50 values of representative examples 
from the AZI class of ligands. Compounds 10-15 have been co-crystallised with the PFKFB3 
isoenzyme (PDB IDs are shown), while compound 16 (reported as AZ33, according to reference [68]), 
represents the most potent inhibitor of this series. 
 
 
 
Entry Compound Y R R1 R2 R3 
Reported 
IC50 
(µM)68  
5ajz 10 C CH2NH2 CN H H 2.01 
5ajv 11 C 
 
CN NH2 H 0.575 
5ajy 12 C CH2NH2 
 
H H 0.496 
5ajw 13 C CH2NH2 CN NH2 
 
0.104 
5ak0 14 C 
  
H Me 0.021 
5ajx 15 C 
 
CN H 
 
0.011 
AZ33 16 N 
 
CN H 
 
0.003 
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Figure 5: The overall computational strategy workflow of the tiered virtual screening that was based 
on the AZI compounds. 
 
 
In the first level, a 3D pharmacophore model featuring the ligand structural 
elements deemed to be essential for the kinase inhibition, was used for a preliminarily 
filtration of the search database (DB) (paragraph 3.3). In the second level, the resulting 
sieved subset of 400 molecules that satisfied the pharmacophore map was submitted to 
structure-based molecular docking using a monomeric model of PFKFB3 (paragraph 3.4). 
Both the pharmacophore filtration and docking method were validated using a collection 
of theoretically inactive ligands (decoys). The docking poses were refined with short 
Molecular Dynamic (MD) simulations, and a modified version of the MM-GBSA method 
(termed Nwat-MMGBSA) was used to calculate the binding free energy and to re-rank the 
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molecules accordingly (paragraph 3.5). Another aspect that was estimated in silico was the 
ligand selectivity over the other isoforms of the PFKFB family. For this purpose, the filtered 
library of compounds that satisfied the pharmacophore query were also re-submitted to 
molecular docking using monomeric models of PFKFB1, 2 and 4 isoforms. In the third level, 
twelve selected potential hits were re-evaluated for their binding affinity towards these 
isoforms, via Nwat-MMGBSA analysis of the respective MD trajectories. 
In conclusion, the final triage of the compounds was made basing on a combination 
of predicted receptor affinity and selectivity, synthetic feasibility and commercial 
availability (paragraph 3.6). The selected six chemically diverse small molecules, shown in 
Figure 14, formed the pool of first-generation candidates that were pursued in further 
experimental tests. 
 
 
 3.2   Molecular Databases 
 
 3.2.1  Search database 
 
The combination of two chemical libraries was explored. The first is an unpacked 
molecular database (DB), previously prepared by Contini’s research group;128 the second 
DB is a packed molecular DB provided within the software MOE.98 
The first library consists of a 3D conformational database of about 1 million 
compounds derived from the public library of commercially available compounds, the ZINC 
database.129 It contains chemically diverse small molecules covering of a wide part of the 
chemical space (redundancies were removed by filtration) and being suitable for future 
optimisation (i.e. the included molecules comply with the Oprea’s test for lead-likeness). 
The compounds in the library are clustered on a similarity basis (Tanimoto coefficient, Tc = 
0.8) and each cluster is represented by the molecule with the lowest molecular weight 
(MW). The DB also includes multi-conformational information for each small molecule 
previously generated using high-throughput fragment-based conformational search. 
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In addition, the DB supplied with MOE contains over 2000 biologically active 
molecules for a variety of targets. This library is specifically dedicated to pharmacophore 
searching applications and provides full conformational sampling, so that each molecule is 
packed with its associated multiple conformers. 
The molecular database obtained by merging the two libraries, constituted the 
search database for the present virtual screening. 
 
 
 3.2.2  Test databases preparation 
 
As explained in paragraph 1.2.1.2, in order to validate the VS method and assess its 
ability to discriminate between biologically active and inactive compounds, a suitable test 
DB, containing a set of biologically evaluated ligands, was required. Obviously, for the 
evaluation of VS methods, biological data must be available. Nonetheless, due to the lack 
of published negative reports about PFKFB3 non-binders, a framework of theoretically 
inactive ligands (decoys) had to be generated computationally so as to be able to test both 
the pharmacophore and docking method used herein. For this purpose, the online platform 
DUD•E (A Data of Useful Decoys: Enhanced) was employed.85,130 Decoys generally are 
hypothetical structures that have not yet been tested experimentally but that are unlikely 
to bind to a given target; thus they are highly likely to be inactive. In particular, the decoys 
are generated such that they resemble the active ligands in terms of their physicochemical 
properties but display dissimilar 2D topologies. 
Given a list of active ligands, the DUD•E server automatically generates a collection 
of decoys. The six co-crystallised AZI ligands, were used as the input ligand dataset. Each 
active ligand gave rise to 50 matched decoys, giving a total of 300 theoretically non-actives. 
The created list of compounds was processed to convert the 1D decoys into their 3D low 
energy conformers, with acceptable bond length and angles. In addition, hydrogen atoms 
were added, rebalancing strong acids and strong bases in their more probable protonation 
states in the aqueous environment, followed by a minimisation to find a low energy 
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conformation close to the starting geometry. Representative examples of decoys, 
compounds D1-6, are depicted in Figure 6. 
 
 
 
Figure 6: Chemical structures of six examples of decoys that were automatically generated through 
dissimilarity filter from the AZI chemical structures. 
 
The library obtained by merging the six crystallised AZI inhibitor 3D structures and 
the 300 decoys constituted the test-DB that was used for theoretical validation of the 
docking method (paragraph 3.4.1). 
In order to validate the pharmacophore model, whereas, an additional 3D 
conformational sampling of the decoys in the test database was needed. A tool provided 
by the software MOE was employed to divide the molecules into their fragments and 
compute the stochastic conformational search independently on each fragment before re-
assembling them in the database in their molecule conformations. 
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The library obtained by merging the AZI inhibitor 3D structures, preserved in their 
crystallographic bound conformations, and the conformational sampled decoys, 
constituted the 3D-conformational-test-DB that was used for theoretical validation of the 
pharmacophore model (paragraph 3.3.1). 
 
 
 3.3   Pharmacophore Model 
 
The pharmacophore model used in this work was designed basing on the AZI 
crystallised ligands, with the aid of the computational application ‘Pharmacophore 
Elucidator’ provided by MOE. This tool generates a collection of pharmacophore 
hypotheses from a given set of input ligand conformers, associated (if known) with their 
activity information. The methodology of the application involves the flexible alignment of 
the ligands (scored on the basis of their superimposability, i.e. their ‘Overlap’) and the 
determination of their shared chemical features. 
As outlined in paragraph 1.2.3, in general, to ensure quality and good 
discriminatory power within a pharmacophore model, it is recommended that the template 
ligands employed for its elucidation are highly potent, and possibly chemically diverse, 
inhibitors. As stated previously, when we started the research, the AZI ligands have been 
proven to be the most potent and selective PFKFB3 inhibitors, hence it was mandatory to 
use this series of compounds regardless of their chemical similarity. In fact, it should be 
mentioned that when the training set of active ligands displays a little diversity, such as 
within the AZI ligands, an intrinsic risk arising from using the ‘Pharmacophore Elucidator’ 
tool is that some identified pharmacophore features may be redundant. In particular, the 
initial ligand alignment of the application will clearly identify many common features and 
geometries, nonetheless not necessarily all of them might be connected to the ligand 
activity. On the other hand, however, trying to overlap inhibitors displaying high chemical 
diversity would be meaningless if they bind the receptor in completely different modes or 
even at alternative binding sites. As demonstrated from the crystal structures, AZI ligands 
bind PFKFB3 at its ATP binding site, whereas other reported compounds were either known 
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to bind at the F6P binding pocket58 or their binding site was never experimentally located 
and/or confirmed.63,65–67 Moreover, it should be also noted that other families of inhibitors 
have been disclosed61,62 and/or evaluated72 after the beginning of this project. Bearing 
these reasons in mind, it was reasonable to use only AZI ligands as a template for the 
pharmacophore design rather than including every PFKFB3 inhibitor present in the 
literature, since their inclusion would have misled the result of the search, potentially giving 
an inaccurate pharmacophore model. 
Nevertheless, the risk of redundancy due to the evident similarity within the crystal 
AZI ligands, could have been to some extent compensated by the availability of the atomic 
details of the ligand-receptor complex structures. In fact, the additional knowledge of the 
location and directionality of the interactions in the binding pocket constituted valuable 
information used for the pharmacophore design and especially its subsequent validation. 
In particular, as it will be described in the following paragraph 3.3.1, once the collection of 
pharmacophore hypotheses was obtained from the MOE elucidator tool, two consecutive 
approaches were adopted to choose the most representative query: 
i) a systematic assessment of the enrichment gained using each query model as a 
molecular filter of the 3D-conformational-test-DB; and; 
ii) a careful visual comparison of the most restrictive queries with the 
chemical/structural details of the X-ray protein-ligand complexes. 
As a result, the elucidation of the elucidation of the pharmacophore used for this study 
(Figure 7) can be considered to be not only ligand-based but also partially structure-based. 
 
 
 3.3.1  Pharmacophore Validation 
 
To select the most representative pharmacophore, the automatically generated set 
of query hypotheses with best superimposability were assessed by running the 
‘Pharmacophore Search’ filtering tool of the MOE software, followed by a visual inspection 
inside the binding site of PFKFB3. 
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The search algorithm of the ‘Pharmacophore Search’ aligns all the molecules of a 
given DB to a query, and outputs a filtered database of those ligands that matched the 
query as ‘Hits’. The dedicated 3D-conformational-test-DB of active/non-active ligands 
(paragraph 3.2.2) was used as the input database, and the search was thoroughly repeated 
for each one of the computed queries. A fulfilment of all features of each query was 
required for a compound conformation to pass the filter. Only those pharmacophore 
queries that reported no more than five decoys (false positive, FP ≤ 5) in the output 
database (Specificity ≥ 0.98, Equation 3), showing thereby a good enrichment, were 
subsequently reviewed. One restrictive pharmacophore model (Figure 7) retrieved only 
two decoys in addition to the six true ligands (Sensitivity = 1, Equation 2; Specificity = 0.99, 
Equation 3). 
A visual analysis reflecting on the structural details of the protein active site 
followed the enrichment assessment, so as to select only the query bearing features that 
explicitly mimicked real ligand-protein interactions that would most likely trigger the 
desired pharmacological effect. Query in Figure 7 showed consistency and 
complementarity with the ligand-protein interactions experimentally observed in the X-ray 
structures. Indeed, from the visual inspection, each pharmacophoric feature was situated 
in correspondence of interacting functional groups inside the pocket. 
On the other hand, we discarded other pharmacophoric hypotheses even though 
they gave good enrichment and high specificity in the decoys filtration, because their 
annotated features mimicked functional groups actually not involved in any interactions 
with the receptor, thus doubtfully related to activity or receptor recognition. For example, 
we dropped queries containing features corresponding to the cyano functional group at 
position-2 of the indole ring of some AZI compounds. Similarly, we discarded those queries 
with features mimicking the phenoxy portion of the AZI scaffold. In fact, as previously 
reported in the AZ paper68 and then confirmed by our inspection of the X-ray complexes, 
those moieties of the molecules do not appear to interact with any residue of the kinase 
pocket. 
Hence, eventually, the 5-features pharmacophore shown in Figure 7 was selected 
and used for the pharmacophore-based virtual screening (filtration) of the search database 
(paragraph 3.3.3). 
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 3.3.2  Pharmacophore Description 
 
Figure 7 illustrates the selected pharmacophore query, superimposed onto the 
aligned AZI ligands with the relative distances between features. Each feature of the 
pharmacophore map annotates the electronic and steric nature and location of specific 
functional groups that were expected to be mandatory for the binding. The features are 
represented by sphere specified as a location in space, a tolerance radius and the 
annotation type. The pharmacophore model selected for the present study comprises the 
following feature types: 
 
(a),(b) A hydrophobic centroid (Hyd) and an aromatic ring or a general π-system (Aro|PiR) 
required to mimic both the adenosine moiety of ADP/ATP and the indole/indazole 
ring of the AZI compounds. In the crystal structures, these fragments occupy a 
lipophilic cleft within the PFKFB3 kinase pocket and make an arene-H interaction 
with residues Val217 and Gly46 of the active site; 
(c) A projected location of the H-bond acceptor (Don2) to annotate the implicit 
direction of the H-bond (hydrogen bond) of the ligand with the backbone carbonyl 
oxygen of residue Leu238 of the active site; 
(d) A positively ionisable feature (Cat) for representing the basic group of the amine 
portion of the AZI that makes a solvent contact with a conserved water molecule of 
the crystal structures and a H-Bond with backbone carbonyl oxygen of residue 
Ile241; 
(e) A projected location of H-bond donor (Acc2) corresponding to the implicit direction 
of another H-bond with conserved water molecules bridging between the backbone 
amidic hydrogen of residue Val243. 
 
 
Chapter 3: AZI-Based Rational Design 
44 
 
Figure 7: Graphical representation of the validated pharmacophore model. (left) 3D overlay of the 
pharmacophore map (shown in coloured spheres) onto the aligned AZI inhibitors (shown in green 
sticks); (right) relative distances between features. The model consists of: a hydrophobic centroid 
(Hyd, average radius 1.4 Å); a general aromatic ring (Aro|PiR, average radius 1.4 Å); a projected 
location of H-bond acceptor (Don2, average radius 1.0 Å); a cationic ionisable heavy atom (Cat, 
average radius 1.4 Å); a projected location of H-bond donor (Acc2, average radius 1.0 Å).  
 
 
 3.3.3  Pharmacophore Filtration 
 
The validated pharmacophore model (Figure 7) was used for a preliminary filtration 
of the search DB (described in paragraph 3.2.1). For this purpose, the MOE 
‘Pharmacophore Search’ filtering tool was applied. The search algorithm aligns all the 
molecules of the DB to the given pharmacophore query using a rigid-body superimposition 
and then reports only those ligands that satisfy the query constraint. To guarantee 
specificity, as was done in the pharmacophore validation phase (paragraph 3.3.1), all the 
five features of the query were required to be matched at the same time for a compound 
conformation to pass the filter (‘systematic matching’ in MOE terminology). This operation 
allowed to narrow down the original search DB to 380 hit compounds fitting the 
pharmacophore map. 
Figure 8 shows 3D overlays of one representative conformation of compounds that 
matched the pharmacophore map and that were later selected for the experimental 
validation, 17-22 (2D chemical structures are shown in Figure 14). 
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Figure 8: Overlays of the pharmacophore with one representative matching conformation of 
compounds (from top-left to bottom-right corners) 17, 18, 19, 20, 21 and 22, examples of molecules 
that were retrieved in the filtered search database. 
 
All unique lowest energy conformations of every hit molecule were merged 
together, along with the six crystal ligands, to give a total of 386 ligands that were 
successively submitted to molecular docking for a SBVS. 
 
 
 
 
17 18
19
20
21 22
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 3.4   Molecular Docking 
 
The filtrated library of compounds fitting the pharmacophore map were submitted 
to molecular docking calculation. For comparison purposes, AZI crystallised ligands were 
also submitted with this set of compounds to the same protocol. 
In order to avoid misleading or limited information that might come by relying on a 
single PDB structure, cross-docking was also performed. Thus, all six structures extracted 
from crystals of PFKFB3 in complex with the AZI ligands, along with another available 
PFKFB3 crystal structure (PDB ID: 2I1V) were used to model a 3D monomeric structure of 
PFKFB3, for the purposes of the molecular docking calculation. 
Preliminary cleaning and correction of all PDB issues of every receptor structure was 
performed through common operations using MOE software. In particular, hydrogen 
atoms were added and adjusted to their optimised position, then uncertain ionisation 
states of polar atoms were fixed basing on physiological conditions. Furthermore, missing 
atomic data or ambiguous sequence identities were modelled or corrected. The system 
was then minimised according to the AMBER10:EHT131,132 force field and the Generalised 
Born implicit solvation model. 
In addition, the 3D models of PFKFB1, 2 and 4 were used for molecular docking in 
order to theoretically assess the potential isoforms selectivity of the ligands. 
 
The monomeric models of the isoforms PFKFB1, 2 and 4 have been prepared 
by Francesca Stanzione (Cambridge Crystallographic Data Centre), in respect 
of a collaborative work with our research group. 
 
Since no human crystallographic structures were available in the Protein Data Bank, 
the 3D structural models of the isoform PFKFB1, 2 and 4 have been built in silico by 
homology modelling, basing on their known amino acid sequences. The monomeric form 
of PFKFB3 extracted from the crystal structure (PDB ID: 5AJX) was used as the template for 
the construction of the isoform models, which was undertaken using the software 
Modeller.133 
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The docking program employed for the structure-based screening was PLANTS 
(Protein-Ligand ANT System).110,111 For this work the receptor was kept rigid (rigid docking), 
since we postulated that a potential new drug would bind to a reasonably similar protein 
conformation. This assumption was supported by evidence from previous studies 
suggesting that the bound state of the active pocket (which is itself rather rigid) causes no 
significant conformational changes to the enzyme.45 Moreover, when a comparison was 
performed by superimposing every available 3D holo form structure of PFKFB3 binding 
different ligands, only slight residue movements were evident, mostly situated in 
peripheral regions of the protein (i.e. the β-hairpin autoregulatory domain), far away from 
the binding site. Furthermore, as already mentioned in paragraph 1.2.4, because of its 
complexity, soft docking is quite computationally demanding and seldom performs better 
than rigid docking.104 
All tautomers, stereoisomers and ring conformations were generated using a fully 
automated tool and, after the docking process, only geometries with the lowest energy 
conformation were ranked and considered for a visual inspection. 
The docking method was validated using the test-DB described above (paragraph 
3.2.2) and the receptor model obtained from the 5AJX crystal structure. The ROC curve was 
generated and the corresponding area under the curve (AUC) and Enrichment Factor (EF) 
values were calculated (Figure 9). 
 
 
 3.4.1  Results and discussion  
 
The Enrichment Factor of test-DB molecular docking was calculated (EF, Equation 1) 
for the ligands ranked in the top 1 %, 10 % and 20 % score, obtaining, respectively: 37.5, 8.1 
and 4.9. This result means that by sampling the top 1  % (or 10 % or 20 %) of the ranked 
database, the probability of finding an active compound is 37.5 (or 8.1 or 4.9) times higher 
than the one associated with a random selection of 3 (or 30 or 60) molecules from the 
database. 
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Figure 9 shows the Receiver Operating Characteristic curve (ROC), which plots the 
true positive rate against the false positive rate. The value of the area under the curve 
(AUC) is 0.96, indicating that the docking method has good capacity to discriminate 
between true actives against the decoys. 
 
 
 
Figure 9: Enrichment assessment of the molecular docking protocol using the test-DB of active/non-
active ligands. The AUC relative to ROC curve plot (black line) is 0.96. The reference red line 
indicates no enrichment, corresponding to a random selection; The Enrichment Factor of 1  % top-
ranked ligands is 37.5; Enrichment Factor of 10 % top-ranked ligands is 8.1; Enrichment Factor of 20  
% top-ranked ligands is 4.9. 
 
 
 
Table 2: RMSD values associated with the deviation of the poses of AZI compounds 10, 11, 12, 13, 
14 and 15, predicted by molecular docking and the corresponding crystallographic poses. 
 
 
Compound 10 11 12 13 14 15 
RMSD 
value (Å) 
1.0 1.0 1.1 2.1 1.2 0.7 
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A visual inspection after every docking and cross-docking experiments showed that 
the AZI ligands were docked correctly. In fact, a good overlay was observed from the 
superimposition of docked and crystallised ligands (Figure 10). The root mean square 
deviations (RMSD) associated with the deviation between the docked and the crystal 
binding modes are reported in  
Table 2. Moreover, the overall trend of the docking scores of AZI ligands has good 
correspondence to the reported experimental activity data. 
Figure 11 depicts the docking poses of two representative examples of the 
compounds of the search DB that were later selected for the experimental validation, 
molecules 17 and 21 (2D chemical structures are shown in Figure 14). The xanthenone 
moiety of 17 is predicted to be tightly bound by an H-bond between the backbone amidic 
proton of the Asn163 and the carbonyl oxygen of the ligand, as well as through a network 
of π-interaction with the sidechain protons of the residue Val217. This arene-H interaction 
with Val217 is a conserved interaction that is also observed in the ADP-receptor crystal 
structure with the adenine ring of ADP. The sulphaguanidine tail of 17 is presumed to be 
stretched out towards the opening of the binding cavity, providing additional contacts with 
both backbone and sidechain acceptor residues of the enzyme through several H-bonds. 
Other ligands showed a binding mode strikingly close to the one observed in AZI 
crystal structures, almost perfectly fitting the AZI pharmacophore and making similar 
interactions. Docking binding mode of compound 21, is shown in Figure 11. The naphthyl 
ring of 21 overlays the lipophilic cleft, sitting coplanar to the superimposed indole portion 
of AZI 15. The central aromatic ring of 21, meanwhile, occupies the phenoxy moiety pocket 
of AZI compounds and displaces the water molecules which are seen when ADP binds. The 
amide group interacts via an H-bond with the backbone of Leu238, similar to what has been 
observed in the crystal structures of AZI. These key interactions are common binding 
features observed also in other docked ligand-receptor complexes of this study. 
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Figure 10: Comparison of the docking AZI ligands pose prediction (shown in green sticks) and the 
corresponding crystallographic poses (shown in orange sticks), by superimposition into the kinase 
catalytic domain of PFKFB3. From top-left to bottom-right corners: ligands 10, 11, 12, 13, 14 and 
15. Crystal structures are labelled with their PDB IDs. The natural ligand, ADP, is also in site in its 
crystallographic pose (shown in black sticks). 
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Figure 11: (left) Comparison by superimposition of the docking pose of ligand 17 (shown in green 
sticks) with the crystallographic pose of AZI 15 (shown in black sticks), into the kinase catalytic 
domain of PFKFB3 (PDB ID: 5AJX); (right) Comparison by superimposition of the docking pose of 
ligand 21 (shown in green sticks) with the crystallographic pose of AZI 15 (shown in black sticks), 
into the kinase catalytic domain of PFKFB3 (PDB ID: 5AJX). 
 
 
 
 3.5   Molecular Dynamic (MD) simulations and Nwat-
MMGBSA calculation 
 
After the docking process, compounds in complex with the receptor were subjected 
to molecular dynamic (MD) simulation. Among all the complexes generated through 
docking, those obtained using the 5AJX as the receptor model were arbitrarily chosen to 
be submitted to the MD simulations. Additionally, for comparison purposes, both docking-
generated and crystallographic complexes of the AZI ligands were simulated through an 
identical protocol. 
The aims of the MD simulation were to: i) carry out a refinement of the ligand poses 
generated by molecular docking and thereby assess the stability of the complexes ii) use 
the production trajectories to calculate binding affinities and re-score the ligands 
accordingly. 
Considering the high computational expenses demanded by MD screening, and also 
bearing in mind the purposes of the simulations, only a narrow time-span of 1 ns 
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production was simulated. Also, as it has been statistically assessed in previous studies, 
MDs production of 1 ns are considered sufficiently long for virtual screenings and rescoring 
purposes.117,125 The MD simulations were run according to the protocol reported by 
Maffucci et al.125,128 
The MD trajectories were analysed by evaluation of the root mean square deviation 
(RMSD) of i) the atoms of the ligands, ii) the backbone C-α of the receptor and iii) the 
backbone C-α of residues defining the kinase pocket, so as to measure the fluctuations 
during the simulation and to assess the system stability.  
The binding energies were estimated, from a specific number of collected frames 
of MD trajectories, through a proprietary version of the MM-GBSA method, namely the 
Nwat-MMGBSA method.124–126 As anticipated in paragraph 1.2.6, since the MM-GBSA (or 
MM-PBSA, if the Poisson Boltzmann equation is applied) calculation approximates the 
solvent to a continuum environment around the solute, it somehow underestimate the 
presence of eventually important water-mediated H-bond bridges between ligand and the 
protein. The Nwat-MMGBSA method developed by Maffucci et al.,124–126 however, 
ameliorates the solvation term of the MM-GBSA equation (Equation 7) by adding the 
effects of binding-site water molecules. In particular, Nwat-MMGBSA combines an 
established number of water molecules (Nwat) taken from the MD snapshots, with the GB 
(or PB) continuous solvation model. Consequently, explicit water residues are considered 
in the ligand affinity calculation as part of the receptor. The water molecules automatically 
selected for the calculation are those closest to the ligand throughout each frame of the 
MD simulation. Since they are located around the ligand, the explicit water molecules 
considered in this calculation are the ones that are most likely to be involved in the 
receptor-ligand interaction. 
It has been shown that this method provides better predictability than the classic 
MM-GBSA method with a negligible addition of computational cost.124–126 As previously 
stated by Maffucci et al., the extent of improvements achieved by adding explicit water can 
vary depending on the system, and in particular on the role of water in the ligand-receptor 
interaction.124–126 As a consequence, the optimal value of Nwat also varies with the system, 
but usually Nwat > 60 gave worse results, besides the additional computational cost. 
Nevertheless, it has been reported that an average of Nwat ≈ 30 can provide a good trade-
off.125 In the present work, to explore a broad range of possibilities, the calculation was 
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performed for each ligand in three different conditions, i.e. using 0, 30 and 60 number of 
waters in the hydration shell as part of the receptor (Nwat = 0, 30, 60). In order to assess 
the reproducibility of the protocol, molecular docking, MD simulation and Nwat-MMGBSA 
were performed in duplicate runs. 
In order to evaluate the correlation between the predicted values of the binding 
free energies (ΔGbind) and the reported experimental data for the inhibition activity of AZI 
ligands (-log10(IC50)), the Pearson’s coefficients (r2) were calculated for each of the three 
Nwat-MMGBSA calculations. In addition, since AZI ligands were simulated starting from 
both their crystallographic and their docked geometries, the two outcomes were 
compared: the ΔGbind corresponding to the MD simulation of the docked geometries of AZI 
complexes are hereinafter referred to as dock-Nwat-MMGBSA; while the ΔGbind 
corresponding to the MD simulation of the crystallographic geometries of AZI complexes 
are hereinafter referred to as crys-Nwat-MMGBSA (Figure 12 and Figure 13). 
In addition, in order to theoretically assess the isoform selectivity of the most 
promising ligands (12 compounds), 1 ns MD simulation, followed by Nwat-MMGBSA 
analysis, were also performed using 3D models of PFKFB1, 2 and 4 enzymes. 
 
 
 3.5.1  Results and discussion 
 
Correlations between calculated and experimental bioactivity data were evaluated 
by the Pearson’s coefficient r2, as reported in the plots in Figure 12 and Figure 13. Higher 
r2 were obtained when the crystallographic poses of the AZI ligands were used as the 
starting frame for the MD simulation (crys-Nwat-MMGBSA), in comparison to the 
corresponding dock-Nwat-MMGBSA correlation values (r2 of crys-Nwat-MMGBSA > r2 of 
dock-Nwat-MMGBSA, for each Nwat values). Overall, however, both results provided 
satisfactory reproduction of the experimental trend. 
The binding energies calculated with crys-Nwat-MMGBSA gave the best correlation 
(r2 = 0.89) picking zero (Nwat = 0) as the number of molecules in the explicit hydration shell 
(Figure 13). On the other hand, when performing the simulation of the poses of docking, 
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the best result (r2 = 0.61) was obtained with Nwat = 60 (Figure 12). The overall accordance 
between the predicted affinity and the experimental activity data supported the validity of 
the computational method, since satisfactory correlation values r2 were obtained for each 
calculation. 
 
 
Figure 12: Correlations between the experimental –log10(IC50) values68 and the calculated binding 
energies (ΔGbind) of AZI ligands (labelled according to their PDB IDs). ΔGbind were obtained from MD 
trajectories of the AZI ligands simulated for 1 ns in their docked poses (dock-Nwat-MMGBSA). The 
number of water residues (Nwat) explicitly accounted for in the calculation were: (from left to right) 
0, 30 and 60. 
 
 
Figure 13: Correlations between the experimental –log10(IC50) values68 and the calculated binding 
energies (ΔGbind) of AZI ligands (labelled according to their PDB IDs). ΔGbind were obtained from the 
MD trajectories of the AZI ligands simulated for 1 ns in their crystallised poses (crys-Nwat-
MMGBSA). The number of water residues (Nwat) explicitly accounted for in the calculation were: 
(from left to right) 0, 30 and 60. 
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 3.6    Selection of ligands  
 
In order to prioritise good candidate molecules to be experimentally evaluated in 
vitro for their bioactivity, all the docking results (seven calculations and one repeated run, 
with a total of eight docking scores for each compound) were combined with the calculated 
ΔGbind data (0, 30 and 60-MMGBSA per repeat run, with a total of six ΔGbind values for each 
compounds) and a consensus criterion of selection was adopted. This procedure made it 
possible to determine the extent of agreement between the results obtained from different 
calculation techniques and runs. This was also intended to balance any errors arising within 
each single calculation and thus to improve the probability of identifying ‘true’ ligands. 
The 30th percentile of the predicted affinity for the Nwat-MMGBSA calculations 
were imposed as thresholds to mark compounds as potential good candidates (where a 
potential good candidate has a predicted ΔGbind < threshold). The consensus approach was 
thus aimed at evaluating the frequency that a compound appears as potential good 
candidate. In particular, only ligands with Nwat-MMGBSA “full consensus” (i.e. ligands with 
ΔGbind < threshold in both the first and second run for each of the 0, 30 and 60-MMGBSA) 
were kept in a reduced DB, leaving a total of ten ligands. Also, five out of six AZI true active 
ligands showed “Nwa-MMGBSA full consensus”, which supported the validity of the 
method. 
Likewise, the 35th percentile was defined as the threshold for the docking scores 
calculated with PFKFB3 receptor. The choice of a slightly less restrictive threshold than the 
one assigned for Nwat-MMGBSA, was due to the intrinsic lower accuracy of docking 
calculation. Indeed, a docking score “full consensus” retained four out of six AZI true 
actives. 
From the set of ten “Nwat-MMGBSA-full consensus” ligands, four were 
subsequently excluded since they were suspected to be false positives, judging from the 
low consensus in the docking scores (i.e. the corresponding docking scores for the PFKFB3 
isoform did not reach the 35th-percentile threshold in at least three out of eight docking 
reiterations). The remaining six molecules were predicted to have high inhibitory activity, 
as characterised by the predicted binding free energy and docking score values. 
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It is worth noting that the initial strategy of selection was instead on the basis of a 
“partial consensus” with respect to the Nwat-MMGBSA calculations. Hence, at first, the 
rejection was applied in a relative rather than categorical way. Specifically, a predicted 
ΔGbind < threshold for at least four out of six ΔGbind values was required for a compound to 
be picked for further in vitro tests. This led to roughly 60 molecules being marked as 
potential active and selected for experimental assays. It was discovered, however, that 
unfortunately, only a very small number of molecules were still commercial, and the 
majority were either depleted or had been removed from the market. Therefore, a 
theoretical refinement of the accuracy of calculation, and a more restrictive selection 
scheme were needed, in order to limit the number of compounds considered worth 
synthesising and testing. In particular, a “full consensus” and further in silico evaluation of 
the ligands selectivity were required to reduce the number of candidates and so to alleviate 
the otherwise enormous synthetic work. The selectivity towards the other isoforms of the 
PFKFBs family was taken account of as follows. 
A penalty was assigned to non-selective ligands based on the scores obtained from 
molecular docking into either PFKFB1, PFKFB2 or PFKFB4 isoform models. In particular, 
ligands whose isoform docking score surpassed the 30th-percentile threshold were 
penalised as non-selective ligands. Another six ligands were subsequently reconsidered as 
potential candidates because resulted quite selective versus related isoforms (only one 
penalty), although still showing relatively good predicted potency (i.e. showing a “partial 
consensus” with at least five out of eight docking scores higher than the threshold and at 
least four out of six Nwat-MMGBSA ΔGbind values higher than the threshold). 
The twelve compounds retained in this way were submitted to 1 ns MD simulations 
using PFKFB1, PFKFB2 and PFKFB4 models as the receptor, and trajectories were analysed 
with the Nwat-MMGBSA method according to the same protocol (Nwat = 0, 30, 60). As a 
result, three ligands were excluded because they also showed high affinity towards PFKFB2 
and PFKFB4 (poor selectivity). Compounds that showed promising metrics were selected 
for the prospective follow-up tests. However, because of the high homology within the 
isoforms, it was not universally defined whether a compound would preferentially bind 
either one of them. 
Eventually, six chemically diverse compounds showing a convincing predicted 
affinity and selectivity profile, were selected. It should also be noted that the selection was 
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also partially influenced by the commercial availability and synthetic feasibility of the 
molecules. Hence, the final choice of candidates was driven by a trade-off between affinity 
and selectivity prediction, synthetic feasibility and commercial availability. The six picked 
compounds, shown in Figure 14 were either synthesised (compounds 17-20) or purchased 
(compounds 21 and 22) in order to test their affinity and biological activity towards the 
PFKFB3 enzyme in the wet lab.  
Paragraphs 5.1 - 5.4 describe the organic syntheses of these AZI-derived target 
molecules and, paragraph 6.1 sets out their biological evaluation. 
 
 
 
 
Figure 14: Chemical structures of the chemically diverse small molecules selected from the AZI-
based rational design as candidate PFKFB3 inhibitors. 
.
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 4   AZPP-Based Rational Design 
 4.1   Overview 
 
An alternative strategy for the identification of new PFKFB3 inhibitors was focussed 
on another class of ligands, the dihydropyrrolopyrimidinone series (AZPP), which were 
evaluated, after the beginning of this project, by St-Gallay et al..72 As described above 
(Paragraph 1.1.3.1), although exhibiting quite a low inhibitory activity (low µM 
concentration range of IC50, being about 10  to 1000-fold less potent than AZI ligands), these 
compounds display interesting lead-like properties and improvements to them might lead 
to an increase in potency and selectivity. Because of their low molecular weight (MW), 
average c logP < 4 and modifiable structure, these molecules bear the potential for further 
optimisation and their scaffold represents a promising starting point to build accurate 
structure-activity relationship studies (SAR). Moreover, the crystal structures of PFKFB3 
bound to four AZPP compounds (Table 3) are stored and freely available in the Protein Data 
Bank (PDB IDs: 4D4K, 4D4J, 4D4M, 4D4L). Despite the low resolution, it was observed from 
the X-ray structures that AZPPs bind at the PFKFB3 N-terminal domain into the ATP pocket 
of the kinase domain, thereby mimicking the adenosine moiety of ATP. In fact, the active 
core of this compounds is a fused heterocycle bearing a pyrrole and a pyrimidinone portion. 
Due to its structural resemblance to pyrimidines and purines, this isosteric scaffold has 
been the focus of significant interest in medicinal chemistry and a wide range of 
pharmacological applications have already reviewed,134 highlighting the remarkable 
potentiality of these compounds as candidate drugs. Moreover, their synthesis is relatively 
tractable, allowing the parallel preparation of several analogues using different starting 
materials that can be bought or prepared cheaply. 
Their optimisable properties and interesting profile prompted us to investigate this 
series of compounds further, embracing the possibility of exploring the chemical space 
around them. The new search plan was therefore founded on the synthetic opportunity 
associated with an exploitation/lead-optimisation process using the crystallised AZPP 
ligands as new probe compounds. 
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For this purpose, a new structure-based virtual screen was focussed on a dedicated 
chemical library, covering the more restricted chemical space around these compounds. 
Paragraph 4.2.1 describes the ligand optimisation for the rational design of AZPP 
derivatives that constituted the new library. 
The availability of X-ray structures again facilitated the ligand optimisation process, 
which was primarily aimed at improving the interaction and filling the pocket. In fact, from 
the crystal structures the ligand binding appears rather weak, mostly directed by van der 
Waals interactions. Also, a weak σ-hole interaction is showed when one of the two phenyl 
rings bears a halogen atom. As a consequence, two flipped binding modes are observed 
depending on the position of the halogen. Based on that, modifications to the AZPP 
structure were made by adding functional groups onto the phenyl rings in order to lock the 
ligands in a single binding mode. The library of analogues bearing the same heterocyclic 
active scaffold obtained in this way was then submitted to docking virtual screening with 
the dimeric model of PFKFB3 in order to prioritise the most promising compounds 
(paragraph 4.2.2). 
The AZPP analogues 29-32, along with the original AZPP compounds 23, 27 and 28 
shown in Figure 19 were selected for follow-up synthesis and biological testing with the 
recombinant PFKFB3 enzyme.  
In parallel to this structure-guided ligand optimisation strategy, a similarity search 
for scaffold hopping was carried out in order to identify new potential binders having 
physicochemical properties similar to the AZPP series but displaying chemically diverse 
structures. The molecule 24 (Table 3) was used as the query. A web server of the RPBS 
(Ressource Parisienne en Bioinformatique Structurale) web portal providing different small 
chemical banks to screen, was employed for the 3D similarity search (paragraph 4.3).135 
The hit molecules were docked inside the kinase domain of the dimeric model of PFKFB3, 
and the most promising compound 33 (Figure 20) was synthesised and tested. 
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Entry Compound X R 
Reported IC50 
(µM)72  
4d4k 23 H OMe 5.012 
4d4j 24 Br H 0.398 
4d4m 25 H Br 0.398 
4d4l 26 Cl H 0.631 
 
Table 3: Chemical structures and corresponding reported IC50 values72 of the four ligands of the 
AZPP series that have been co-crystallised with the PFKFB3 isoenzyme (PDB IDs are shown). 
 
 
 4.2   AZZPP Ligand Optimisation 
 
 4.2.1  Molecular Database Design 
 
A manual construction based on rational design/synthetic feasibility, combined 
with automatic generation of analogues, was aimed at building a focused chemical 
database. This allowed us to collate in a database a broad spectrum of synthesisable 
derivatives to be screened in order to investigate the chemical space surrounding the AZPP 
series. Molecules from the new library were drawn in a way that conserved much of the 
original active core, with small-scale structural changes. In particular, modifications were 
introduced mainly by replacing and/or functionalising, with a variety of substituents, the 
phenyl portions attached to the pyrrole moiety. Bioisosteric replacements were also made 
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at the structure whenever possible by switching groups with similar electrochemical 
properties and preserving the geometry. In addition, in order to satisfy synthetic 
accessibility needs, compounds amenable to be produced preferably through a divergent 
synthetic strategy (namely from a common key precursor), were also added in the library. 
The MOE ‘Database Viewer’ was used to build a 3D database of the set of molecules 
drawn from 2D Sketcher. In addition, the ‘MOE builder’ tool was employed to further 
modify the structures of the AZPP in situ, i.e. inside the kinase pocket, so as to check the 
goodness of fit. As mentioned, the goal of the optimisation was to increase the strength of 
the ligand-protein interaction, which for the AZPP series are mostly van der Waals rather 
than electrostatic or polar interaction. In particular, it was hypothesised that the 
functionalisation of the aromatic rings with judiciously positioned hydrogen bond donor 
(HBD) substituents, would offer more opportunities for hydrogen bonding to the backbone 
amide residue Leu238 and would increase binding site occupancy. Moreover, this 
modification would meet three out of five pharmacophore features of the previously used 
pharmacophore model. In particular, in addition to the Hyd, Aro|PiR features matching the 
central heterocyclic scaffold, the Don2 features would be also satisfied (Figure 15). 
 
 
Figure 15: Overlay of the pharmacophore with one representative conformation matching three 
out of five features of compound 32, an example of molecule that was included in the database of 
AZPP analogues. 
 
 
In addition, the ‘MedChem Transformations’ application of MOE software was 
employed to expedite the process of generating several analogues. To a given input 
32
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structure, known as an active ligand, the tool applies a set of transformation rules usually 
made in medicinal chemistry, through a match-and-replace algorithm. Then, the generated 
molecules were filtered upon their chemical attributes before being output in a 3D 
database. Each AZPP ligand extracted from the crystal structures (compounds 23 – 26) gave 
rise to 37 newly created analogues. The four output databases obtained in this way were 
merged together with the other manually constructed sub-set of analogues, to give a total 
of 654 compounds that were then submitted to docking calculation. 
 
 
 
 4.2.2  Molecular Docking 
 
Molecular docking of the constructed database of AZPP analogues was performed 
using the PLANTS program, without additional pre-processing, so that no new 
conformations were searched. Also in this case the receptor was kept rigid for the same 
reasons discussed in paragraph 3.4. For a more realistic receptor model, however, the 
head-to-head dimeric PFKFB3 structure (modelled using the crystal structure PDB ID: 2AXN) 
was used as the protein for the virtual screen. 
 
The dimeric model the PFKFB3 enzyme has been prepared by Xiao Hu, Early 
Stage Researcher of the Moglynet Project (University of Milan, Italy). 
 
The PFKFB3 endogenous substrates were kept in place during docking, so that the 
bisphosphatase catalytic domain contained F2,6P molecules (in of both chains of the 
dimer), while ATP and F6P occupied only one kinase pocket of the dimer. Docking was 
focussed on the whole empty kinase site, defined by both ATP and F6P pockets. With an 
approach similar to a blind docking, molecules from the database were evaluated exploring 
both pockets and, since only the most favourable mode was chosen, it was ultimately 
defined, in this way, which pocket each ligand would preferably bind. 
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For comparison purposes, with our library of analogues, the 21 published AZPP 
ligands (comprising the compounds 23 – 26) were also submitted to the same docking 
protocol. 
 
 
 4.2.3  Results and Discussion 
 
From a visual inspection of the docking poses, three AZPP ligands displayed a 180° 
flipped binding mode with respect to the crystallised poses (Figure 16). This observation 
was not totally unexpected, however, because, as anticipated in paragraph 4.1, the 
ambiguity in respect to the orientation of the AZPP compounds was already stated in the 
original AZ paper72 and also detailed in the validation report of the PDB files. Specifically, 
alternative ligand atom coordinates displaying lower occupancy from the electron density 
map have already been found in the X-ray structures, confusing the overall binding mode 
picture. 
On the other hand, the general position of the ligands was, however, reasonably 
well estimated by docking, since ligands nicely overlaid to the hydrophobic cleft of ATP, 
coplanar to the adenine portion. The RMSD associated with the deviation between the 
docked and the crystal binding modes of AZPP are reported in Table 4.  
Curiously, a few compounds were predicted to have propensity to bind at the F6P 
pocket rather than the ATP one, including compound 27 which experimentally proved to 
be the most potent among the AZPP analogues (Figure 17). 
The obtained docking results were compared with the reported experimental 
activity values of the AZPP; the plot at Figure 18 shows the correlation between reported 
pIC50 and docking scores. The attained correlation was quite low, meaning that even though 
docking posing was acceptably correct, the discrimination between fairly similar structures, 
such us this congeneric series, remained quite challenging during the scoring phase. 
Nonetheless, as already discussed in paragraph 1.2.4, several previous comparative studies 
have revealed rather poor accuracy in respect to docking scoring functions, as it is still a 
common limitation in this kind of calculation.136 
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Figure 16: Comparison of the docking AZPP ligands pose prediction (shown in cyan sticks) and the 
corresponding crystallographic poses (shown in yellow sticks), by superimposition into the kinase 
catalytic domain of PFKFB3. From top-left to bottom-right corners: ligands 23, 24, 25 and 26. Crystal 
structures are labelled according with their PDB IDs. The natural ligand, F6P, is also shown in its 
crystallographic pose (in black sticks). An approximation to the molecular solvent-excluded surface 
is shown coloured by atom colours (grey for carbon, red for oxygen, blue for nitrogen and cyan for 
H-bond hypotheses). 
 
 
 
 
Table 4: RMSD values associated with the deviation of the poses of AZPP compounds 23, 24, 25 and 
26, predicted by molecular docking and the corresponding crystallographic poses. 
 
Compound 23 24 25 26 
RMSD 
value (Å) 
1.9 6.5 6.5 6.6 
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Figure 17: Site view of ligand 27 (shown in yellow sticks) in its predicted binding mode and 
superimposed with both endogenous ligands, ATP and F6P (shown in black sticks), into the kinase 
catalytic domain of PFKFB3. An approximation to the molecular solvent-excluded surface is shown 
coloured by atom colours (grey for carbon, red for oxygen, blue for nitrogen and cyan for H-bond 
hypotheses). 
 
 
 
 
Figure 18: Correlation between reported –log10(IC50) of AZPP series72 and the docking score values. 
The crystallised AZPP ligands are labelled according to their PDB IDs. 
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Eventually, supplemented with qualitative docking calculations and principally 
guided by observation of interactions with the receptor, compounds 29-32 (Figure 19) were 
proposed to be empirically evaluated and thus synthesised. In order to compare activities, 
along with the selected compound, three compounds from the original collection, 
molecules 23, 27 and 28, were also synthesised and used as basis of comparison for the 
biological tests (Figure 19). 
Paragraph 5.5 describes the organic synthesis of these AZPP-derived target 
molecules and paragraph 6.1 their biological evaluation. 
 
 
Figure 19: Chemical structures of the synthesised and tested AZPP analogues. (top) Reported 
compounds 23, 27 and 28.72 (bottom) Compounds 29-32 are the molecules selected from the AZPP-
based ligands optimisation as candidate PFKFB3 inhibitors.  
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 4.3   Similarity Search and Molecular Docking 
 
The 3D similarity search around the AZPP series was carried out using the wwLigCSRre 
online facility.89 The server allows a specified conformational library of compounds to be 
mined and returns a subset of ranked hit structures matching a given query. In this case the 
query represents the 3D atom coordinates of an active ligand. The system molecular search 
is based on a 3D maximal common chemical patterns that takes into account both atomic 
nature and bond connectivity information. The alignment algorithm consists of an iterative 
and stochastic procedure for maximising the number of paired bonds with atomic 
compatibilities. The screened database of the present search was supplied with the server 
and consisted of a suitable chemically diverse library derived from the DrugBank source 
collection,137 containing synthesisable drug-like small molecules already stored with their 
conformational information. The 3D geometrical features of molecule 24 (Table 3), were 
used as the query ligand. Compounds from the library, were compared to the 3D structure 
of 24, and a maximum of 50 top-ranked matching ligands were retrieved. The obtained 
reduced database of hit compounds were then submitted to the molecular docking 
calculation into the kinase pocket using the PFKFB3 dimeric model described in paragraph 
4.2.2. 
 
 
 4.3.1  Results and Discussion 
 
After the similarity search mining was processed, the hit molecules were visually 
examined, comparing the selected 3D conformations by superimposition onto the query 
molecule 24. 
Figure 20 illustrates that the alignment of one hit molecule, compound 33, was 
reasonably correct. The dimethylthiazole moiety of 33 shows complementarity with the N-
aromatic ring attached to the pyrrole scaffold of 24, which, on the X-ray structure sits on 
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the cleft that hosts the ribose fragment of ATP. The pyrimidine and the p-
trifluoromethylphenyl substituent of 33 overlap the heterocyclic core and the p-halophenyl 
ring of 24, respectively.  
A visual analysis of the results of posing followed molecular docking, to assess the 
quality of the predicted binding modes. The most probable binding site for compound 33 
was predicted to be the binding channel occupied by phosphate groups when ADP/ATP is 
bound. In particular, the docked pose of 33 fits the cleft establishing contact interactions 
with hydrogen-bond-rich side chains. Moreover, the π-electron clouds of the planar 
aromatic groups of the molecule was predicted to engage with the hydrophobic side chain 
of Thr48 (Figure 21). 
 
  
Figure 20: (left) Superimposition of the similarity search hit, compound 33 (shown in cyan sticks), 
and the AZPP query, molecule 24 (shown in black sticks). (right) 2D chemical structures of the 
compounds 33 and 24. 
 
Also in this case, analysing the result of virtual screening and, from that, identifying 
the “right” compounds to take forward for further validation, represented a key challenge. 
As was done previously, we deemed it important to not underestimate synthetic feasibility 
and chemical reliability, in view of later stages of ligand validation. Among the other 
molecules, compound 33 showed the most convincing alignment with the AZPP 24 as well 
as a reasonable docking pose. Other molecules were instead discarded, even though 
showing good alignment and docking score, because either i) they were too similar to ATP, 
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ADP, purines and pyrimidines thus very likely unselective towards PFKFB3, or ii) because of 
their poor synthetic tractability. Therefore molecule 33 was chosen and synthesised for 
further biological studies. 
Paragraph 5.6 describes the organic synthesis of this target molecule and 
paragraph 6.1 its biological evaluation. 
 
 
 
  
Figure 21: Predicted binding mode by docking of compound 33 (shown in turquoise sticks), into the 
kinase catalytic domain. ATP is also shown in its crystallographic position (shown in white sticks). 
Hit molecule 33 was selected through the AZPP-based similarity search, and then synthesised for 
further biological evaluation. 
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 5   Organic Syntheses 
 
 5.1   Synthesis of TM1, compound 17 
 
The first target molecule (TM1), compound 17, was prepared through a multistep 
synthesis as illustrated below in Scheme 1, which is a refinement of previously published 
procedures.138–141 
The first step is a copper-mediated Ullmann’s condensation of the substituted 
chlorobenzoic acid and o-cresol 34, followed by cyclisation, resulting in the corresponding 
xanthone 36, through the carboxylic acid 35. 
 
 
Scheme 1: Optimised synthesis of TM1, compound 17. Reagents and conditions: (i) Cu2O, NaH (60 
% mineral oil), DMA, 150 °C, 4 h; (ii) conc. H2SO4, 100 °C, 3 h; (iii) NBS, benzoyl peroxide, CCl4, reflux, 
2 h; (iv) K2CO3(s), sulphaguanidine 38, DMF, r.t., 24 h. 
 
The Ullmann-type coupling usually occurs in rather harsh conditions such as high 
temperature and addition of strong base, especially with sterically hindered substrates, 
such as the compound 34; thus high-boiling polar solvents were necessary. In addition, the 
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rather strong air sensitivity of the phenol 34 required a nitrogen atmosphere. Very low 
yields with (mostly homocoupling) by-products were obtained when performing the 
reaction under microwave irradiation (mw), with caesium carbonate and dimethylglycine 
as the coordinating agent. Whereas the catalytic system Cu/CuI in the presence of pyridine 
and an inorganic base, in water, gave no-reaction. The best copper source used for 
catalysing the condensation step was found to be copper(I) oxide which could be used 
without any ligand, in the presence of NaH. Yet, because of its low solubility, the copper 
oxide was used in stoichiometric amounts (1 equivalent) in order to improve the yield. Also, 
utilisation of strong base could be avoided by using as starting materials the corresponding 
sodium salts of both chlorobenzoic acid and o-cresol. As has previously been well 
documented,142 the ortho-carboxylic group onto the aryl chloride makes the C2 more 
electrophilic, allowing good regioselectivity at this position. The crude material of the 
Ullman arylation, containing intermediate 35, could be used without purification for the 
following intramolecular Friedel Crafts acylation in concentrated sulphuric acid. 
Next, the free-radical bromination of the methyl group in carbon tetrachloride, using 
benzoyl peroxide (BPO) as a radical initiator and equimolar N-bromosuccinimide (NBS), 
gave the bromomethyl derivative 37 in relatively good yield, with only little formation of 
the dibrominated species. Last, the nucleophilic substitution of the benzylic bromide with 
the commercial sulphaguanidine 38 in basic conditions afforded the desired TM1, 
compound 17. 
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 5.2   Synthesis of TM2, compound 18 
 
The synthesis of the second target molecule (TM2), compound 18, is shown in 
Scheme 2. 
The dimethylformamide dimethyl acetal (DMFDMA) was used as the key building 
block for the preparation of the naphthyridine heterocycle.143–147 As reported in the 
literature, DMFDMA was used twice in the first and third step as a one-carbon synthon, 
and the enamine intermediates 40 and 42 did not need to be isolated for the following 
steps. Enaminedione 40 was directly reacted with freshly prepared sodium cyanocetamide 
in dry DMF at room temperature (23 °C) in a one-pot process. After acidification and work-
up, the substituted pyridinone 41 was obtained as a precipitate. 
The structure of the desired pyridinone 41 was confirmed by a combination of both 
HMBC and NOESY NMR analysis. A four-bond coupling between the aromatic proton and 
the methyl carbon in position-6 of the ring (W-coupling) was observed, moreover a 
diagnostic NOESY signal confirmed the spatial proximity between the methyl protons and 
the downfield N-H of the lactam. On the other hand, there was no evidence of coupling 
between N-H and the aromatic proton, excluding the hypothesis of having the isomer 45 
(Figure 22). Moreover, further confirmation was supported by the correspondence 
between the reported and obtained chemical shift data of the desired compound.146  
 
 
Figure 22: Chemical species related to the synthesis of compound 18. 
 
Next, adduct 42, obtained from the reaction of 41 with DMFDMA in DMF, was treated 
with an excess of ammonium acetate resulting in the desired napthyridine derivative 43. 
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Scheme 2: Optimised synthesis of TM2, compound 18. Reagent and conditions: (i) DMF, DMFDMA, 
r.t., 24 h; (ii) a) cyanocetamide, NaH (60 % mineral oil), r.t., 20 h; b) H2O/EtOH (1:1), conc. HCl, 24 h; 
(iii) DMF, DMFDMA, r.t., 48 h; (iv) NH4OAc, DMF, 125 °C, 24 h; (v) N-(3-aminopropyl)-N-
methylaniline 44, CsOHH2O cat, H2O, 145 °C, 24 h. 
 
 
Finally, target molecule TM2, 18 was obtained in good yield in a sole step, directly 
from the nitrile, by a CsOH-catalysed aminolysis in water with amine 44, in a sealed tube at 
high temperature.148 This reaction is a green alternative approach that conveniently 
allowed to avoid two troublesome steps: i) the hydrolysis of nitrile 43 to the corresponding 
carboxylic acid 46 (Figure 22), and ii) the following amidic coupling of napthytidine acid and 
the amine 44. Indeed, this latter two-step route in which the amide coupling was catalysed 
by HOBt and EDC∙HCl was unsuccessful since the purification of the substrate 46 was rather 
problematic. 
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Interestingly, along with the secondary carboxyamide 18, trace of the formylated 
adduct of amine 47 was also isolated from the crude mixture of the final aminolysis step 
(Figure 22). Further investigation by performing a control reaction in the same conditions, 
without nitrile 43 and introducing a catalytic amount of DMF, suggested that the 
formylation of the primary amine group of 44 occurred when trace of DMF were present 
in the reaction mixture. 
 
 
 5.3   Synthesis of TM3, compound 19 
 
Scheme 3 shows the optimised multistep synthesis of the third target molecule 
(TM3), compound 19. 
Attempts to obtain the intermediate 53 by reductive amination of the o-
pthalaldehyde with NaCNBH3 and monoprotected N-Boc-ethylenediamine 52 were 
unsuccessful, leading mostly to the corresponding diol and a series of undesired 
compounds. Thus, the isoindoline fragment of compound 53 was prepared from the 
commercially available dibromo-xylene and ethylenediamine 52 in presence of an organic 
base. The quaternary ammonium salt of TEA with bromide (adduct 48, Figure 23) was 
detected by mass spectrometry in the raw material. Even though 48 was easily removed by 
washing several times with water, the amount of the ammonium salt could be minimised 
by using a more hindered organic base, such as DIPEA. When two equivalents of bromide 
were used, after completion of the reaction, during concentration phase to remove solvent, 
the excess of bromide acted as a scavenger, trapping the product within the species 49 
(Figure 23). Hence, the optimised conditions consist of using an excess of amine 52 and 
DIPEA with respect to the bromide, which enabled to obtain 53 in good yield and no 
formation of the dialkylated xylylenediamine (adduct 50, Figure 23). 
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Figure 23: By-product obtained throughout the synthesis of compound 19. 
 
 
Deprotection of the amine was performed in standard acidic conditions with TFA, 
although ~ 30 % of the corresponding trifluoroacetamide of the amine 54 (adduct 51, Figure 
23), presumably formed during the basic work-up, was also detected and isolated from the 
crude mixture as a by-product. 
In the following step, the free amine 54 was reacted with 3-nitrobenzoyl chloride to 
obtain the carboxamide 55. The intrinsic basicity of the molecule 54 allowed the reaction 
to occur without the necessity of any base. On the contrary, unexpectedly, the addition of 
either TEA or DIPEA alongside DMAP (even in catalytic amount of the latter) was actually 
ineffective, meanwhile favouring the formation of unidentified by-products of competing 
side reactions. The nitro group of 55 was then reduced rather smoothly to aniline 56, either 
with Fe and acetic acid as the catalyst, or in the presence of nickel (II) chloride and sodium 
borohydride, obtaining good yields. Whereas other reduction conditions, such as Zn dust 
and ammonium chloride in methanol, did not afford the desired amino group. 
Finally, in the last step the 4-chloroquinaldine 57 underwent a SNAr reaction 
(Nucleophilic Aromatic Substitution) with 65 and a catalytic amount of concentrated HCl to 
afford TM3, 19. 
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Scheme 3: Optimised synthesis of TM3, compound 19. Reagent and conditions: (i) Boc2O, DCM, r.t. 
24 h; (ii) α,α’-Dibromo-o-xylene, DIPEA, CHCl3, r.t. overnight; (iii) a) TFA/DCM (40 % v/v), 0 °C, 2 h, 
b) NaOH aq. (vi) 3-nitrobezoyl chloride, THF, r.t., 8 h; (v) Fe, AcOH cat, EtOH, r.t., 24 h or NaBH4, 
NiCl26H2O, MeOH/EtOAc (20:1), r.t., 2 h; (vi) 4-chloroquinaldine 57, conc. HCl (cat), EtOH. 
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 5.4   Synthesis of TM4, compound 20 
 
The synthesis of target molecule TM4, compound 20 is shown in Scheme 4. Hasegawa 
et al. have already published an expeditious synthetic route for 20 where the 
benzimidazole ring is prepared by treating the dianiline 62 with the thiopseudourea 63.149 
We implemented the described pathway which starts from the commercially available 5-
chloro-2-nitroaniline and the N-protected 4-thioaniline 60. Instead of an acetyl group we 
opted to use tert-butyloxycarbonyl (Boc) as protecting group because of its more 
convenient removal conditions. The preparation of N-Boc-aminothiophenol was carried 
out in the presence of catalytic indium (III) chloride, in a good yield. Only a small amount of 
disulphide dimer as a by-product (compound 58, Figure 24), derived from the homo-
coupling of two thiol groups, was found and isolated from the reaction mixture.  
 
 
Figure 24: Disulphide by-product. 
 
The compound 60 was reacted with 5-chloro-2-nitroaniline in the presence of a 
base to provide the intermediate 61. Next, contrary to what has previously reported,149 in 
our hands, treating the nitro compound with sodium dithionite (Na2S2O4) did not give the 
expected aniline 62, with only starting material being recovered after work-up. 
Nevertheless, the reduction with the NaBH4/NiCl2 catalytic system afforded 62 in excellent 
yield. After cyclisation to benzo[d]imidazolyl methylcarbamate 64, via condensation with 
63, the Boc protecting group was removed in acidic conditions. The aniline 24 was then 
acylated with Boc-L-alanine through standard amidic coupling conditions, namely with 
HATU and DIPEA. Finally, deprotection of alanine gave the TM4 (Scheme 4). 
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Scheme 4: Optimised synthesis of TM4, compound 20. Reagent and conditions: (i) Boc2O, InCl3 cat., 
DCM, 35 °C. 2 h; (ii) 5-chloro-2-nitroaniline, ButOK, THF, reflux, overnight (iii) NiCl26H2O, NaBH4, 
MeOH/EtOAc (20:1), r.t., 2.5 h; (vi) 1,3-bis(methoxycarbonyl)-2-methyl-thiopseudourea 63, EtOH, 
reflux, overnight; (v) 4M HCl in dioxane, r.t. 24 h; (vi) Boc-L-Alanine, HATU, DIPEA, DCM, r.t. 4 h; (vii) 
4M HCl in dioxane, r.t. 24 h. 
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 5.5   Synthesis of AZPP series 
 
The synthesis of the dihydropyrrolopyrimidinone analogues was carried out as 
reported previously, through the formation of 2-amino-3-cyano-1,4-disubstituted pyrroles 
72a-e, followed by cyclocondensation with formic acid (Scheme 5).150–155 
 
 
Scheme 5: Synthesis of AZPP analogues. Reagent and conditions: (i) THF, 2 equivalents of aniline, 
20 °C, overnight or EtOH, NaHCO3(s), r.t. overnight; (ii) Malononitrile, EtONa (21 wt. % in EtOH), 85 
°C, overnight; (iii) HCOOH 85 %, reflux, overnight; (iv) CsOHH2O cat, NH4OH, H2O, 100°C, 8 h. 
 
 
26% - 45% 
over two steps 
30% - 88% 
 
24% - 76% 
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Several procedures for the preparation of the key α-aminoketone precursors 70 are 
described in the literature, and the vast majority starts from the commercially available 
substituted phenacyl bromides 67 and anilines 68 using different solvent and 
stoichiometric ratio.156–158 However, contrary to what is reported in some procedures, the 
reaction must be carried out thoroughly at room temperature, since the heat was found to 
facilitate the formation of the di-alkylated amine as a by-product. The optimal conditions 
consist of setting-up the reaction in EtOH with a 1:1:1 molar ratio of phenacyl bromide, 
aniline and NaHCO3. Furthermore, the α-aminoketones 70 were found quite unstable 
making it difficult its handling and isolation. Both acidity from silica gel and exposure to 
light degrade these intermediates. They thereby must be kept under an inert atmosphere 
and be immediately submitted to the following step. Particular care was required for the 
extremely unstable substrate 70a, and the highest yields were obtained by using THF as 
reaction solvent and adding two equivalents (one acting as a base) of the electron-rich p-
anisidine 67a. The product was then recovered after precipitation as a hydrobromide salt 
from THF and was reacted immediately through the following step. 
When compounds 70 were heated in the presence of equimolar amount of 
malononitrile and fresh EtONa, they underwent cyclisation to afford the substituted 
pyrroles 72, following a Knoevenagel condensation-type reaction, through the formation 
of adducts 71 (Scheme 5). The isolation of the intermediate 72a by flash chromatography 
was more troublesome due to its instability, thus purification by crystallisation was 
required instead, which was not beneficial for the yields. Compounds 72d and 72e, 
similarly, could not be isolated and were used immediately for the next step. For most of 
the substrates, the yields were actually affected by the reaction scale of starting materials. 
Finally, prolonged heating of 72 in formic acid gave the desired products. The reaction 
was believed to proceed through the corresponding 2-amino-3-carboxamidopyrroles 73, 
resulting from the hydrolysis of the nitrile group followed by condensation with formic acid, 
which causes the cyclisation to occur (Scheme 6). This mechanism was hypothesised after 
the detection by mass spectrometry of the α-amido amides 73 in the reaction mixtures of 
each substrate and it was also previously proposed in the literature.152,156  
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Scheme 6: (top) Supposed reaction mechanism for the formation of pyrimidinone heterocycle: 
hydrolysis of the nitrile group, followed by the condensation of formic acid and cyclisation;152,156 
(bottom) cyclocondensation of dinitrile compound 71e in boiling formic acid: only compound 30 
was afforded, whereas no trace of 32 was observed. 
 
In view of this supposed reaction mechanism of the pyrimidinone cycle, the synthesis 
of the primary amide 32 was, therefore, retro-synthetically designed as a one-pot process 
involving the hydrolysis in boiling formic acid of both pyrrolic and phenylic nitrile groups of 
71e, prior to the cyclisation. Unexpectedly, the nitrile group attached to the phenyl moiety, 
however, did not react, not even with a large excess of HCOOH(aq) and running the reaction 
at high temperature for several hours (Scheme 6). Hence, a different reaction mechanism 
may have been involved in this case. 
The obtained compound 30 was isolated, characterised and tested. Nitrile 30 was 
further reacted with NH4OH and catalytic CsOH to give the corresponding amide 32 by 
aminolysis. The overhydrolysis of the nitrile led to carboxylic acid 31 which was also 
isolated, characterised and biologically evaluated (Scheme 5). 
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 5.6    Synthesis of Similarity Search-Hit, compound 33 
 
For the preparation of similarity search hit, compound 33, the pyrimidine 
condensation method of Bredereck was applied, according to a convergent synthetic 
strategy (Scheme 7).159,160 
The chloroacetyl acetone 74 and the thioacetamide 75 were used as starting 
materials to build the 5-acetyl-thiazole intermediate 76, which was subsequently treated 
with DMFDMA. The obtained enaminone 77, was condensed with anilino guanidine 79 to 
give the desired pyrimidine 33. The anilino guanidine was derived from the corresponding 
para-trifluoromethyl aniline 68c by treatment of its nitrate salt with cyanamide (Scheme 
7). 
 
 
 
Scheme 7: Synthesis of the target molecule designed from AZPP through a similarity search, 
compound 33. Reagent and conditions: (i) Pyridine (Py), MeOH, r.t., overnight; (ii) DMFDMA, reflux, 
24 h; (iii) HNO3 (70 %), cyanamide 50 wt. % in H2O, 100 ˚C, overnight; (iv) NaOH, 2-methoxyethanol, 
125 ˚C, overnight. 
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 6   Biological Evaluation  
All biological experiments reported in this manuscript were carried out by Helena 
Macut, Early Stage Researcher of the Moglynet Project (University of Milan, 
Italy), in respect of a collaborative programme. 
 
 6.1   Kinase Assay 
 
The kinase assays of the compounds 17-20 (Figure 14), 23, 27-32 (Figure 19) and 33 
(Figure 20), were performed using the ADP-GloTM format161 according to literature 
protocol.68 The test method consists of a two-step process in which the kinase activity is 
quantified by the amount of ADP produced during the enzymatic kinase reaction, in 
presence of the ligand. In the first step, the enzyme and the substrates (ATP and F6P) are 
incubated with the ligand, and after 1 h (determined by PFKFB3 kinetics) a reagent, 
provided with the kit, is added to stop the reaction and deplete any unreacted ATP. In the 
second step, ADP is converted back to ATP and the newly synthesised ATP reacts with the 
luciferase/luciferin system producing a luminescence signal that is proportional to the ADP 
concentration. The generated light is measured by luminometer and it is directly correlated 
by a linear relationship with kinase activity. 
The assay was performed using human recombinant PFKFB3 that was produced and 
purified in-house. Synthesised AZ33, compound 16 (Table 1) was used as positive control 
since it proved to almost completely inhibit the kinase reaction. Compounds were screened 
at two different concentrations (100 µM and 10 µM). The corresponding residual activity 
(RA %), which compares the kinase activity of PFKFB3 in presence of the ligand with respect 
to the blank (i.e. in absence of ligand), was calculated. 
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 6.2   Results and Discussion  
 
 
Table 5 reports the residual activities of the compounds that were designed based 
on the AZI ligands (Chapter 3). Analysis of the RA % data obtained from this generation of 
candidate inhibitors revealed that unfortunately rather poor or no inhibition was observed 
for most of the ligands. 
Compound 20, amongst the others, however, showed a more significant signal 
change with respect to the blank signal, and gave a residual activity of 31.3  % and 60.5 %, at 
100 µM and 10 µM respectively. Looking at its chemical structure (Figure 14), it is the 
closest compound resembling the AZI ligands (for instance compared to AZI compound 11, 
Table 1). Indeed, it displays shape similarity and a comparable central hydrophobic scaffold 
formed by two aromatic portions connected with a heteroatom. The sulphur linker atom 
in 20, instead of the oxygen of the AZIs, might have increased the lipophilicity, however, 
the solubility was improved by the benzimidazole and the methyl carbamate moiety 
replacing the AZI indole. Moreover, although showed less potency compared to the low 
nM activity of some AZI ligands, inhibition activity of compound 20 was still within the 
active concentration range observed for the AZPP compounds. Compound 19 also revealed 
a relatively comparable inhibition, but with a concentration-independent behaviour, 
leading us to suppose that some kind of artefactual influences might have affected the 
result.  
Initially, we ascribed the surprisingly slight activating behaviour of compounds 21 
and 22 to a possible allosteric modulation. Indeed, as already mentioned, the PFKFB3 
enzyme has a distinctive dual nature, due to its two mutually contrasting activities. Besides, 
since they bind the same endogenous ligands (ATP/ADP and F6P/F2,6P), the 
bisphosphatase and the kinase domains of this enzyme intrinsically display similarities in 
their structural and physicochemical properties. As a consequence, since these evaluated 
molecules were designed to bind at the kinase domain, an indirect stimulatory effect on 
the enzymatic activity, through the binding at the bisphosphatase domain or other 
allosteric sites, cannot be excluded. Also, it has been observed previously that small 
molecules belonging to the same family of compounds can induce opposite effects towards 
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this enzyme, and only slight differences in their structures have proved to be discriminative 
characteristics for their biological effect.69 Taking our data from a relative perspective, 
however, it is also true that an allosteric activator would have showed a much higher 
increment of the activity, while compounds 21 and 22 only showed a two-fold activation 
which is probably too little effect, and thus negligible. 
 
 
Compound 
RA % 
(at 100 µM) 
RA % 
(at 10 µM) 
Reported IC50 (µM)68  
17 110.2  1.6 96.4  0.7 - 
18 100.4  3.3 59.4  3.9 - 
19 35.96  1.03 34.6  0.2 - 
20 31.3  1.1 60.5  2.8 - 
21 197.3  2.9 200.4  0.8 - 
22 286.4  5.4 107.8  6.3 - 
16 - 7.2  0.1 0.003 
 
Table 5: Kinase assay result of the compounds selected from the AZI-based virtual screening. 
Residual activity (RA %) is reported at 100 µM and 10 µM of ligand concentration). 
 
In some cases, the residual activity obtained at 100 µM was slightly higher than the 
corresponding value measured at 10 µM of inhibitor concentration. This could be an 
artefact due to the noise and a too low inhibition potency, or it may be due to possible 
interference by the compounds with the measurements. 
Table 6 reports the residual activity related to compounds designed basing on AZPP 
ligands (Chapter 4). The original AZPP ligands, compounds 23, 27 and 28, have a reported 
IC50 of 5.012 µM, 0.215 µM and 10.000 µM respectively,72 which is overall in agreement 
with the trend of our obtained residual activity results. After testing the close analogue of 
molecule 28, molecule 29, we found that modification of the trifluoromethyl group from 
meta position to para position of the phenyl ring, was not beneficial for potency, since 29 
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showed lower inhibition. The compound 30 was also tested as an organic salt, with 
trifluoroacetate (TFA) as counter-ion, in order to improve its solubility. This resulted, 
however, in a loss of activity of the salt form of 30 at 100 µM. 
The carboxylic acid and the primary amide derivatives 31 and 32 were designed 
specially to increase the poor hydrophilicity of the AZPP ligands and ensue additional polar 
interaction with the PFKFB3 enzyme, filling the kinase pocket. Unfortunately, however, the 
inhibition was shown to be comparable to the inhibition observed with the original AZPP 
compounds. Within this generation of candidates, compound 33, showing promising profile 
in silico, was synthesised and tested. Unexpectedly, however, this compound did not 
exhibit improved activity at the tested concentrations, since it reduced PFKFB3 kinase 
activity only partially (Table 6). 
 
Compound 
RA % 
(at 100 µM) 
RA % 
(at 10 µM) 
Reported IC50 
(µM)72 
23 9.31  0.01 23.1  0.75 5.012 
27 4.24  0.13 8.18  0.50 0.215 
28 30.2  0.06 30.3  0.73 10.000 
29 65.1  1.21 37.5  1.54 - 
30-TFA 40.2  1.29 40.4  0.26 - 
30 25.8  0.80 39.3  1.32 - 
31 55.7  1.0 61.7  1.37 - 
32-TFA 27.3  0.06 49.0  0.97 - 
33 73.4  0.16 67.7  1.89 - 
 
Table 6: Kinase assay result of the compounds selected from the APP-based virtual screenings. 
Residual activity (RA %) is reported at 100 µM and 10 µM of ligand concentration. 
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 7   Conclusion 
 
In summary, with this study we have presented our contribution to the challenging 
aim of identifying new potent and selective kinase inhibitors of the kinase domain of the 
PFKFB3 enzyme. Different tiered computational methods, such as both ligand-based and 
structure-based virtual screenings were applied to facilitate the process of the rational 
design of the prioritisation of promising compounds. Two classes of known active ligands, 
herein referred to as AZI68 and AZPP72 inhibitors, in combination with the 3D structure of 
the receptor, were used as a source of information for the development of molecular 
model used for virtual screenings, leading to two generations of new candidate inhibitors. 
Those selected compounds showing good predicted affinity towards the enzyme were 
synthesised, fully characterised and tested. Unfortunately, despite our consistent efforts 
and attempts, only low or no activity was detected within the tested compound 
concentrations.  
From the information presented in the literature at the onset of this project, we 
attempted to extract the best possible understandings to build a new model and develop 
virtual screenings (VS), also according with our resources available. It should be noted 
though, that despite the numerous positive studies, the discovery of new drugs or hit active 
molecules via VS is undeniably not a trivial task and unfortunately it is not always a 
successful process. It is known that these types of complex calculations inherently have a 
margin of error due to the approximations of parameters, besides the fact that other 
important aspects, such as the solubility in buffers, non-specific bindings, etc. cannot be 
simulated and predicted in VS. Thus, care must be taken with computational methods and 
VS results because the power of these tools primarily lies in the elimination of molecules 
that are unlikely to succeed, rather than the selection the “perfect” compounds. In fact, 
the effectiveness and impact of LBVS and SBVS are also very reliant on the actual number 
of compounds that are picked and tested. Pharmaceutical companies test thousands of hit 
molecules or continue to rely heavily on traditional high-throughput screening (HTS), since 
its efficacy still remains dominant in this field. 
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Given these considerations, it is worth remarking that unfortunately the vast majority 
of the hit molecules identified in our study, from the AZI-based rational design, were no 
more commercially available. This represented a big limitation since we necessarily had to 
take the risk of starting the inherently time-demanding organic syntheses before having 
the ready support of a biological validation of our computational model. In fact, the massive 
synthetic work, required for the individual preparation of the selected compounds, that 
besides are chemically different from one another, with no common precursors (Figure 14), 
delayed the important experimental feedback. As a consequence, the number of hit 
molecules that we were able to test, in a PhD project timespan, could not quite reach the 
sufficient percentage of compounds that needs to be tested to succeed in this type of 
campaign. 
However, with our piece of work we offer further insights in a molecular level into 
the facets of PFKFB3 ligand investigation. We provided a framework of our study on the 
structural and electronic characteristics of the ligand-protein interaction and we presented 
our set of observations used to build our model. Overall our results may still serve as an 
endorsement for future progress around the state-of-the-art of PFKFB3 ligand discovery. 
For instance, the presented pharmacophore model, which represents the crucial part of 
the screening cascade, can be refined in future studies. Modification of the tolerance radii 
of and the number of the matched features or the addition of volume and shape constraints 
for taking into account the steric allowance of the kinase pocket may represents a valuable 
step forward. We also speculate that optimisation of the pharmacophore model could be 
addressed to the inclusion of ligand occupancy in correspondence of the ribose cleft of ATP 
pocket. This part, matching with the N-substituent of the AZI ligand indole, in fact is 
reported to have an impact to the potency. For example, additional aromatic ring features 
could be imbedded in the model in order to offer more opportunities of π-stacking 
interactions with this portion of the protein which internal surface is defined by electron-
rich aromatic side chains. 
Moreover, even though no high-affinity ligands were identified, this work also 
provides additional information about the chemically diverse tested molecules that display 
interesting scaffolds and drug-like properties. In particular, with compound 20 at 100 µM, 
the kinase activity of PFKFB3 was inhibited by ~70 %, and ~40 % at 10 µM, with respect to 
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the blank, representing an encouraging result that might lead further investigations around 
this interesting core template. 
We then moved to the other class of more recently evaluated molecules, the AZPP 
derivatives, as a fresh starting point to carry out a ligand optimisation guided by a SAR 
study. In particular, we carried out a further investigation of their interesting properties, 
taking advantage of the breadth of feasible synthetic modifications. We built and explored 
a dedicated focused library of synthesisable and drug-like analogues. However, also in this 
case, the prediction of compound modifications that substantially enable improvements in 
inhibition potency is a complex task that is difficult to appreciate and, even more so to 
simulate on a computer. In fact, by molecular docking although we obtained reasonably 
good posing prediction, the discriminatory power between close analogues of a congeneric 
series of the same family of molecules was unavoidably rather weak. For this reason, the 
ligand selection was principally guided by the qualitative observation of the interactions 
with the receptor in the complex models, in order to fit the model. As such attempts to 
improve their affinity towards PFKFB3 and their solubility, by adding hydrogen bond donors 
and polar functional groups to best fit (even though only partially) the initial 
pharmacophore model, or by using compound salt forms were unfortunately ineffective 
(Figure 19), probably due to difficult desolvation before access the lipophilic pocket. Thus, 
the poor solubility of this generation of AZPP analogues in addition to the need for a new 
scaffold, induced us to undertake another concomitant strategy. As described, we 
performed a similarity search for scaffold hopping followed by molecular docking, taking 
advantage of the relatively limited computational time-scale required for these screening 
methods. The search led to a compound showing a more promising affinity towards the 
enzyme in silico, albeit it exhibited unfortunately only comparable low potency (Figure 20). 
However, in conclusion with this study we present relevant SAR outcomes and 
property indications associated with new derivatives of the known AZPP compounds. This 
little headway may guide follow-up studies as well as integrate the knowledge about this 
class of purine isosteres into the field of kinases inhibition.
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 8   Experimental  
Computational Study 
 
 8.1   AZI-Based computational part  
 
 8.1.1  Test Databases Preparation 
A benchmarking of theoretically non-actives was built through the Automated 
Decoy Generation Method provided by the online platform DUD•E (A Data of Useful 
Decoys: Enhanced).85,130 The six co-crystallised AZI ligands expressed as 1D SMILES strings 
(simplified molecular-input line entry-system)162 were used as input ligand dataset. Each 
active ligand gave rise to 50 matched decoys, giving a total of 300 theoretically non-actives. 
The obtained list of compounds was downloaded as 1D SMILES strings and then converted 
into 3D unique low energy conformers using the MOE ‘Database Viewer’ application. The 
3D structures of six crystallised AZI inhibitor were merged with the generated decoys in the 
DB. The ‘wash’ tool of MOE application was applied followed by an energy minimisation 
with ‘energy minimise’, with conjugate gradient method to RMS gradient 0.1 kcal/molÅ. 
Both ‘wash’ and ‘energy minimise’ were run with MMff94x force field163 and the 
Generalised Born implicit solvation model, to form the test-DB. 
 
 8.1.2  3D-Conformational Test Database Preparation 
A conformational sampling of the test-DB was performed using the ‘Conformation 
Import’ of MOE. Only decoys were selected into the Input dataset, in order to preserve the 
AZI ligands in their crystallographic bound conformations. The application was run with 
default settings, MMff94x force field and related parameters, Generalised Born implicit 
solvation model. A maximum of 15 conformations with the lowest energy were retained. 
Finally, the molecules were refined with MOE software by applying the upfront ‘wash’ and 
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‘minimisation’ preparation protocol in MMff94x force field and Generalised Born implicit 
solvation model, as described above (paragraph 8.1.1), giving the 3D-conformational-test-
DB. 
 
 8.1.3  Pharmacophore Elucidation 
A collection of pharmacophore queries was automatically generated through the 
‘Pharmacophore Elucidator’ tool provided by MOE software. The input set of template 
ligands contained the six co-crystallised AZI ligands, all given as active, since they were 
proven to be potent inhibitors. In order to maintain their crystallographic information, the 
3D conformations of the AZI ligands were kept untouched (‘As-is’, in MOE terminology) and 
no further conformational search was run. The annotation scheme ‘Unified’ was set for the 
assignment of the pharmacophore features, and 5 was set as maximum number of features 
per query. The program computed a collection of 121 query hypotheses. Only those queries 
displaying a good ligand alignment (Overlap score > 4.2) and matching each one of the six 
active compounds (Coverage = 6), giving a total of 80 queries, were taken into account for 
following validation. 
 
 8.1.4  Pharmacophore Filtration 
The ‘Pharmacophore Search’ filtering tool of MOE was used for the pharmacophore 
filtration. The ‘systematic matching’ of MOE was applied, by masking as ‘essential’ every 
features of each query. All conformations of the Hit molecules were retrieved in the output 
database by selecting ‘results: molecules’ in the Pharmacophore Search panel. 
All unique lowest energy conformations of every hit were merged together, along 
with the six crystal ligands, to give a total of 386 ligands. Before subjecting the ligands to 
molecular docking calculation, the molecules were refined with MOE software by applying 
the upfront ‘wash’ and ‘minimisation’ preparation protocol like described above 
(paragraph 8.1.1). 
For the validation of the pharmacophore query the 3D-conformational-test-DB was 
used as input dataset and ‘Pharmacophore Search’ was applied using same settings. 
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 8.1.5  Structures Preparation 
The computational models of monomeric PFKFB3 receptors were derived from 
crystal structures downloaded from the Protein Data Bank (PDB ID: 5AJX, 5AJY, 5AJZ, 5AJW, 
5AJV, 5AK0, 2I1V). All eventual co-crystallised non-standard residues and cofactors (such 
as ADP/ATP, F6P/F2,6P, phosphoric acid, phosphate ion or other bound substrates) were 
manually removed from the structure before docking. The ‘Structure Preparation’ of MOE 
was used to correct issues, whereas hydrogen were added with ‘Protonate 3D’ at pH = 7, T 
= 300 K and salinity = 0.1 M. Chain breaks and termini were appropriately capped with NME 
(N-methyl amide group) for the C-terminus, and ACE (acetyl group) for the N-terminus; 
missing atomic data or ambiguous sequence identities were modelled or corrected (e.g. 
replace selenomethionine by methionine). Following, an energy refinement of the system 
with AMBER10:EHT131,132 force field and the Generalised Born implicit solvation model was 
performed, keeping the backbone atoms and pocket residues (up to 8 Å from the ligand) 
constrained to original position. 
 
The following homology modelling description has been provided by Dr 
Francesca Stanzione (Cambridge Crystallographic Data Centre).  
 
The models of 3D monomeric structures of the isoform PFKFB1, 2 and 4  have been 
built in silico by homology modelling with Chimera graphical interface of MODELLER, basing 
on their known amino acid sequences (UniProt codes: P16118, O60825, Q16877).133 The 
monomeric form of PFKFB3 extracted from the crystal structure (downloaded from Protein 
Data Bank, PDB ID: 5AJX) was used as template. Before processing, the missing loops in the 
template structure were built using the loop/refinement tool of MODELLER. For each target 
sequence we created a new alignment with the template sequence based on the 
Needleman-Wunsch global alignment algorithm.164 The homology modelling, EM fitting 
were launched from Chimera and executed remotely via MODELLER. The system then 
calculated a set of plausible structures containing all non-hydrogen atoms. For each PFKFB 
isoform, 5 models were created and the model returning with the least restraints was 
selected for further analysis. Each model has been adapted to match the sequence length 
of the template. C- and N-termini were capped and limited energy minimization of the 
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retained isoforms models was performed in order to ensure absence of atomic clashes. The 
stereochemical quality was assessed using Ramachandran φ-ψ dihedral plot. Subsequently 
‘Protonate 3D’ of MOE was used to add hydrogen atoms. 
 
 8.1.6  Molecular Docking Protocol 
The calculations were performed on a multiprocessor HPC cluster (High Performance 
Computing provided by University of Milan), subdividing the task on a chosen number of 
processors for a PBS queuing system. Docking was focused in the ATP binding site, which 
3D coordinates were defined by a sphere of 13.5 Å radius, and centred on the centre of 
mass of the co-crystallised ligand. The protein structure was kept rigid. PLANTS program 
was used in a low search speed/high accuracy mode and ChemPLP was specified as scoring 
function. 
All ligands were automatically pre-processed by the SPORES software (Structure 
Protonation and Recognition System)165 to assign atom and bond type and to define 
stereoisomers for non-specified asymmetric centres. Alongside, all tautomers and ring 
conformations of the ligands were generated with the MOE software. After the posing 
process, the best ChemPLP score poses of each docked ligands of the database (i.e. the 
lowest energy geometry) was kept for further calculations. The outcome was re-scored 
according to scoring function values, resulting in a ranked database. 
For the validation of docking method, the test-DB of the active/non-active ligands 
was used. In addition, the R-script integrated in the virtual screening protocol, was used to 
automatically plot the ROC curve and calculate the corresponding AUC. 
 
 8.1.7  MD Simulations Protocol  
The simulations were carried out on a GPU workstation with the pmemd.cuda 
module of the Amber14 package.120 The initial geometry of the complexes for the MD 
simulations were obtained using the docked poses of the ligands and the receptor structure 
modelled from 5AJX PDB file. For AZI ligands, both docked and crystallographic poses were 
simulated in complex with the receptor. 
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The topological files and a set of initial coordinates were prepared for each complex 
using the tleap module of the AMBER package according with the ff14SB force field166 for 
the proteins, and gaff force field113 for the ligands. Each complex was inserted in an 
octahedral box in periodic boundary conditions (PBC). The system was solvated with the 
explicit TIP3P water model167 up to a distance of 10 Å from the solute and then was 
neutralized by replacing water molecules with an adequate number of Na+ or Cl- ions. In 
order to reach a stationary state and remove unwanted bad contacts or gaps between 
solvent and solute, the system was equilibrated and minimised with the steepest descent 
method. According to the reported protocol,126 in the first step (1000 cycles with the 
steepest descent algorithm and 5000 cycles with the conjugated gradient algorithm) the 
geometry of hydrogen atoms was optimised, followed by optimisation of ions and water 
residues. The water box was then equilibrated at 300 K, first in NVT ensemble for 45 ps, 
then in NPT ensemble for other 45 ps of simulation. In the following steps i) sidechains, 
waters and ions were minimised and ii) the whole system was minimised (2500 cycles with 
the steepest descent algorithm and 5000 cycles o with the conjugated gradient algorithm). 
Restraints of 10.0 kcal/mol and 5.0 kcal/mol were applied respectively on the receptor 
backbone and the ligand atoms. Then the system was progressively heated, from 0 to 300 
K, in six steps of 20 ps (ΔT = 50 K). During heating, the restraints of both backbone and 
ligand were gradually reduced to 5.0 kcal/mol and 0.5 kcal/mol respectively. The restraints 
were then maintained for 100 ps cycle of system equilibration in NVT ensemble and for 
other 100 ps cycle of equilibration in NPT ensemble. Then, followed three steps of 100 ps 
each of system equilibration in NPT ensemble, in which restraints were gradually 
decreased, to 2.0 kcal/mol for backbone and 0.2 kcal/mol for ligand. Final equilibration was 
reached in 1 ns of NPT ensemble, where restraints were gradually removed (first 500 ps 
with 1.0 kcal/mol and 0.1 kcal/mol restraints for backbone and ligand respectively, and 
then no restraints during last 500 ps of equilibration). After these steps, the unrestrained 
complex was simulated over 1 ns production in NPT ensemble at 300 K. The time-step used 
was 2 fs, with a total of 500’000 MD time-steps. To reduce computational complexity, the 
hydrogen motion was restrained with the SHAKE algorithm168 and an electrostatic cut-off 
of 8.0 Å was applied. 
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 8.1.8  Nwat-MMGBSA Protocol 
An ensemble of 100 snapshot equally spaced out were collected from the MD 
production runs for predicting the binding affinities through the Nwat-MMGBSA method. 
The Nwat-MMGBSA script was set up defining Nwat = 0, 30 and 60 explicit water molecules 
in the hydration shell. Molecular mechanics interaction energy and solvation free energy 
were calculated for all specified frames using the MMPBSA.py script of the AMBER 
package.120 For the solvation free energy calculations, the unsolvated topology and 
trajectory files of complex, receptor and ligand, were created according to the Nwat-
MMGBSA protocol.126 Specifically, the command ‘closest’ was implemented in cpptraj 
module to retain within the topology and trajectory files of both unsolvated receptor and 
complex, the selected number of water molecules surrounding the ligand, defined by the 
“Nwat” variable. In such way, the calculation of ΔGbindsolv explicitly takes into account, as 
part of the receptor, the hydration shell comprising the Nwat water residues (0, 30 and 60) 
that are the closest to the ligand in each frame of the MD simulation. 
 
 
 8.2   AZPP-Based computational part 
 
 8.2.1  AZPP Analogues Database Preparation 
The MOE ‘Database Viewer’ was used to convert the set of molecules, drawn from 
2D Sketcher and expressed as 1D SMILES strings, into 3D single low energy conformer 
database. MOE ‘Builder’ application was also used to implement and refine the structures. 
In addition, the ‘MedChem Transformations’ of MOE software was employed. The four 
AZPP ligands were extracted from the crystal structures, available in the Protein Data Bank 
(PDB IDs: 4D4K, 4D4J, 4D4M, 4D4L), and used as template input structures. The application 
was run with using default settings for technical parameters and filtering criteria, 
comprising: molecular weights lower than 450 Da, TPSA (topological polar surface area) in 
the range of 40 - 100 Å2 and absence of reactive groups. Each ligand gave rise to 37 newly 
created analogues collected in an output database. The 4 output databases were merged 
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together with the other unique sub-set of analogues manually constructed. Finally, the 
molecules were prepared for docking by applying the upfront ‘wash’ and ‘minimisation’ 
with MOE software, like described above (paragraph 8.1.1) 
 
 8.2.2  Similarity Search and Database Preparation 
The 3D similarity search was performed through the LigCSRre method provided by 
the online engine wwLigCSRre of the RPBS web portal.83,89,135 The three-dimensional mol2 
file of compound 24, extracted from crystal structure (PDB ID: 4D4J), was used as input 
ligand query. The search was performed over a dedicated 3D conformational library of 942 
drug-like small molecules derived from DrugBank source collection.137 A maximum of 50 
best-ranked ligands were retrieved in their matching conformation. After the mining 
process, the resulting list of aligned hits, expressed in 3D format (mol2 file), was 
downloaded and merged in a database using the ‘Database Viewer’ of MOE. After a visual 
inspection by superimposition onto the query, the molecules were refined by applying the 
‘wash’ and ‘minimisation’ preparation protocol with MOE software like described above 
(paragraph 8.1.1). 
 
 8.2.3  Molecular Docking Protocol 
The calculations were performed on a multiprocessor HPC cluster (High Performance 
Computing service provided by University of Aberdeen), subdividing the task on a chosen 
number of processors for a PBS queuing system. Molecular docking of the constructed 
database of AZPP analogues was performed using PLANTS software and the ChemPLP 
scoring function in a low speed/high accuracy mode. No new conformations of the ligands 
were generated before docking. 
 
The dimeric model the PFKFB3 enzyme has been prepared by Xiao Hu, Early 
Stage Researcher of the Moglynet Project (University of Milan, Italy). 
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The tandem model of PFKFB3 (extracted from crystal structure PDB ID: 2AXN) was 
used as the rigid receptor for the virtual screening. Docking was focussed on the whole 
empty kinase site which 3D coordinates were defined by the centre of mass of 
crystallographic ATP and F6P, and limited inside a sphere of 15.0 Å radius. The endogenous 
ligands were kept in situ inside the other binding sites of the dimer: F2,6P in the 
phosphatase domains; ATP and F6P in one of the two kinase domains. 
After the docking posing process, the best ChemPLP score poses of each docked 
ligands of the database (i.e. the lowest energy geometry) was kept for further calculations. 
The outcome was re-scored according to scoring function values, resulting in a ranked 
database. 
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Biology 
 
 
The following description has been provided by Helena Macut, Early Stage 
Researcher of the Moglynet Project (University of Milan, Italy). 
 
 
 8.3   Kinase Assay 
 
The Kinase assay was performed with ADP-GloTM Kinase assay purchased from 
Promega, 161 on a 384-well white plate, purchased from Greiner. The kinase base buffer 
containing 100 mM HEPES (pH 7.0), 400 mM KCl, 10 mM potassium phosphate (pH 7.0), 10 
mM MgCl2, 1 mM dithiothreitol, 0.2 mM Triton X100 was prepared prior to the assay. The 
recombinant PFKFB3 enzyme, expressed in Escherichia coli, was added to the base buffer 
immediately prior to starting the assay. Each well received 8 µL of enzyme diluted in the 
base buffer (final concentration in the assay was 150 nM). 
The tested compound was added to each well at 100 µM and at 10 µM (compounds 
were dissolved in kinase buffer, with max. 5  % DMSO). After 30 min incubation, each well 
received 8 µL of a mixture containing 100 µM ATP and 200 µM F6P. The reactions were left 
to incubate for 1 hour before the addition of 16 µL of ADP-GloTM Reagent that terminates 
the kinase reaction and depletes the remained ATP. After the second incubation of 50 
minutes at room temperature, 32 µL Kinase Detection Reagent was added. This reagent 
converts ADP to ATP and allows the newly synthesised ATP to be measured using a 
luciferase/luciferin reaction. After an additional hour, reaction mixtures were transferred 
to a Greiner white 384 well plate in triplicates (AZI-derivatives) or duplicates (AZPP-
derivatives), and Tecan Magellan spectrometer® with enhanced luminescence module was 
used to measure the luminescence signal generated in each well. The signal, expressed in 
RLU (relative light units), is proportional to the ADP concentration produced and is 
correlated with kinase activity. Since compounds showed low activity in comparison the 
blank, only residual activity was calculated. 
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 8.3.1.1  Sensitivity and linearity test 
 
Prior to compounds evaluation, a sensitivity and linearity test of the kinase assay 
were performed. Three ATP to ADP standard conversion curves were prepared at 1 mM, 
100 µM and 10 µM concentration of (ATP + ADP) standards (Figure 25), in 25 µL of reaction 
buffer. The reactions for standard curves were prepared in 96-well plate. The preparation 
of the 1 mM series of (ATP + ADP) standards in wells A1-12 is presented in Table 7. The 
wells B1-12 and C1-12 received 90 µL of the kinase reaction buffer. The 100 µM series was 
prepared by transferring 10 µL of the sample in well A1 to well B1, well A2 to B2, etc. The 
10 µM series was prepared by transferring 10 µL of the sample in well B1 to well C1, well 
B2 to C2, etc. 
 
 
Well number A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
1 mM ADP (µL) 100 80 60 40 20 10 5 4 3 2 1 0 
1 mM ATP (µL) 0 20 40 60 80 90 95 96 97 98 99 100 
Table 7 : Preparation of the 1 mM series of (ATP + ADP) standards. 
 
25 µL of standard from each well were transferred into separate wells of the new 
assay plate, and 25 µL of ADP-GloTM Reagent were added to each well. After 40 min 
incubation at room temperature, 50 µL of Kinase Detection Reagent were added to each 
well. Luminescence was measured after additional 1 h incubation at room temperature and 
standard curves were generated. A linear relationship was confirmed between the 
luminescent signal and the amount of ADP in the reaction buffer for all three (ATP + ADP) 
concentration series tested. 
 
 
Figure 25: 1 mM, 100 µM and 10 µM standard curves.
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Chemistry 
 
General methods 
 
Dry solvents were obtained from commercial sources and used without further 
purification. Reactions performed in dry solvents were carried out under nitrogen 
atmosphere. NaH was used as a 60 % dispersion in mineral oil. Reactions were monitored 
by thin-layer chromatography (TLC), unless otherwise noted. TLCs, included those used for 
purification, were performed on Merck silica gel glass plates (60 F254). Visualisation was 
accomplished by UV light (254 nm) and/or staining with a ceric ammonium molybdate, 
KMnO4 or ninidrine solution. Flash chromatography was performed using Silica gel (60 Å, 
particle size 40–63 μm) purchased from Merck. 1H NMR and 13C NMR spectra were 
recorded on a Bruker AVANCE III 400 NMR spectrometer and calibrated using residual 
undeuterated solvent as internal reference. 19F NMR spectra were recorded on a Bruker 
AVANCE III 400 NMR spectrometer and were referenced to CFCl3. 13C NMR spectra were 
recorded with complete proton decoupling. Chemical shifts (δ) are reported in parts per 
million (ppm) and coupling constants (J) are given in Hertz (Hz). The following abbreviations 
are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet 
of doublet, ddd = doublet of doublet of doublet, m = multiplet, bs = broad signal. When 
necessary, resonances were assigned using two-dimensional experiments (COSY, HMBC 
and HSQC). Mass Analyses (MS) were performed using Agilent 1200 HPLC system coupled 
to Agilent G6120 single quadrupole detector equipped with an electrospray ionisation (ESI) 
source in direct infusion modality. ESI-MS spectra were recorded in positive mode unless 
otherwise noted. RP- (reverse phase)-HPLC-MS analyses were performed with an Agilent 
1200 HPLC system equipped with a DAD and an ESI-MS detector. HPLC conditions for 
analytical analyses: Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 4.6 mm (L × ID) 
injected volume 10 μL, flow rate 1 mL/min, unless otherwise specified. HPLC preparative 
purification were performed using a Agilent 1260 HPLC system equipped with DAD detector 
with reverse phase, Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 21.2 mm (L × ID), 
flow rate 20 mL/min. 
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 8.4   Target Molecule 1 
 
 8.4.1  4-Chloro-2-phenoxybenzoic acid (35)  
 
 
 
 
To a round bottom flask containing the carboxylic acid (300 mg, 1.6 mmol) and o-
cresol 34 (340 mg, 3.1 mmol) dissolved in DMA (3 mL), 2.5 equivalents of NaH (60  % in 
mineral oil), were added at 0 °C. The mixture was stirred for 20 minutes under nitrogen 
atmosphere at r.t., then Cu2O (224.6 mg, 1.6 mmol) was added and the temperature was 
increased to 150 °C. After 4 h, the mixture was diluted with EtOAc, neutralized with a 
solution of HCl 1N and washed three times with water. In order to remove the excess of 
unreacted o-cresol, a saturated solution of NaHCO3 (pH 8) was added to the organic phase. 
The basic aqueous layer containing the sodium salt of 35 was separated and then acidified 
to pH 3 with an aqueous solution of HCl 2N and extracted with DCM (3 x 10 mL). The organic 
phase was dried over Na2SO4, filtered and the DCM was removed under reduced pressure, 
to obtain 320 mg of reaction crude containing 35 that was immediately used for the 
following step, without further purification. MS (ESI, m/z): C14H12ClO3+ [M+H]+ calc.: 263.05, 
found: 263.0 [M+H]+, 285.0 [M+Na]+, 547.1 [2M+Na]+. 1H NMR (400 MHz, CDCl3) δ 8.16 (d, 
J = 8.5 Hz, 1H, aromat.), 7.38 – 7.22 (m, 3H, aromat.), 7.16 (dd, J = 8.5, 1.9 Hz, 1H, aromat.), 
7.05 (dd, J = 7.8, 1.3 Hz, 1H, aromat.), 6.63 (d, J = 1.9 Hz, 1H, aromat.), 2.23 (s, 3H, CH3). 13C 
NMR (101 MHz, CDCl3) δ 165.0, 158.0, 151.4, 141.0, 134.9, 132.5, 130.6, 128.2, 126.9, 
123.7, 121.4, 116.9, 115.9, 16.2. The 1H and 13C NMR data matched with the data reported 
in the literature.139,140 
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 8.4.2  3-chloro-5-methyl-9H-xanthen-9-one (36) 
 
 
An ice-cooled conc. H2SO4 (98 % w/v, 8 mL) was added dropwise at 0 °C to the crude 
mixture containing acid 35. The reaction mixture was gradually heated up to 100 °C and 
stirred for 3 h. The reaction was stopped, diluted with water and cooled down to r.t., then 
the pH was adjusted to 9 by carefully adding a 2N solution of NaOH at 0 °C. Finally, the 
product was extracted with DCM (3 x 10 mL) and dried giving 36 as a white solid (242 mg, 
55 % yield over two steps). TLC Rf = 0.5 (solvent system: n-Hex/EtOAc, 10:1). MS (ESI, m/z): 
C14H10ClO2+ [M+H]+ calc.: 245.04, found: 245.0. 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.5 
Hz, 1H, aromat.), 8.15 (d, J = 8.0 Hz, 1H, aromat.), 7.61 – 7.49 (m, 2H, aromat.), 7.33 (dd, J 
= 8.5, 1.9 Hz, 1H, aromat.), 7.31 – 7.25 (m, 1H, aromat.), 2.53 (s, 3H, CH3). 13C NMR (101 
MHz, CDCl3) δ 176.8, 156.3, 154.5, 140.8, 136.1, 128.2, 127.4, 124.9, 124.4, 123.9, 121.7, 
120.3, 118.2, 15.8. The 1H and 13C NMR data matched with the data reported in the 
literature.139 
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 8.4.3  5-(bromomethyl)-3-chloro-9H-xanthen-9-one (37)  
 
 
A mixture of 36 (50 mg, 0.2 mmol), NBS (41 mg, 0.3 mmol) and BPO (75  % remainder 
water) in CCl4 was refluxed for 2 h. After cooling down to r.t. the solvent was removed under 
reduced pressure and the crude mixture was purified by isocratic flash chromatography 
(solvent system: n-Hex/EtOAc, 4:1) to afford 37 as a white solid (50 mg, 76 % yield). MS (ESI, 
m/z): C14H9BrClO2+ [M+H]+ calc.: 322.95 found: [M+H]+ 322.9. 1H NMR (400 MHz, CDCl3) δ 
8.31 (dd, J = 8.0, 1.7 Hz, 1H, aromat.), 8.28 (d, J = 8.5 Hz, 1H, aromat.), 7.79 (dd, J = 7.4, 1.7 
Hz, 1H, aromat.), 7.65 (d, J = 1.9 Hz, 1H, aromat.), 7.42 – 7.35 (m, 2H, aromat.), 4.80 (s, 2H, 
CH2). 13C NMR (101 MHz, CDCl3) δ 176.1, 156.0, 153.8, 141.3, 136.2, 128.3, 127.7, 127.1, 
125.4, 124.3, 122.4, 120.4, 118.3, 26.3. The 1H and 13C NMR data matched with the data 
reported in the literature.139 
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 8.4.4  N-carbamimidoyl-4-(((6-chloro-9-oxo-9H-xanthen-4-yl) 
methyl)amino)benzenesulfonamide (17)  
 
 
 
To a solution of 37 (55 mg, 0.17 mmol) in dry DMF (1.5 mL), the suphaguanidine 38 
(38.4 mg, 0.18 mmol) and K2CO3 (24 mg, 0.17 mmol) were added at room temperature. 
After stirring for 24 h, the mixture was diluted with EtOAc and washed three times with 
water (3 x 10 mL). The organic phase was dried over Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude mixture was purified by gradient elution flash 
chromatography (solvent system: DCM/MeOH, gradient: from 0  % to 3 % of MeOH) to 
afford 17 as a white solid (31 mg, 40 % yield). Analytical RP-HPLC: Phenomenex Gemini C18 
column, 5 μm, 110 Å, 250 × 4.60 mm (L × ID) (solvent system: H2O/ACN, gradient: from 40 
% to 80 % of ACN in 15 min, flow: 1 mL/min; tR = 9.4 min). MS (ESI, m/z): C21H18ClN4O4S+ 
[M+H]+ calc.: 457.07, found: 457.1 [M+H]+, 479.1 [M+Na]+, 495.0 [M+K]+, 913.2 [2M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 8.19 (d, J = 8.6 Hz, 1H, aromat.), 8.08 (dd, J = 7.9, 1.6 Hz, 1H, 
aromat.), 8.00 (d, J = 1.9 Hz, 1H, aromat.), 7.80 (dd, J = 7.3, 1.6 Hz, 1H, aromat.), 7.55 (dd, J 
= 8.6, 1.9 Hz, 1H, aromat.), 7.49 – 7.39 (m, 3H, aromat.), 6.99 (t, J = 6.2 Hz, 1H, NH), 6.66 (d, 
J = 8.8 Hz, 2H, aromat.), 6.62 – 6.44 (bs, 4H, guanid.), 4.69 (d, J = 6.2 Hz, 2H, CH2). 13C NMR 
(101 MHz, DMSO-d6) δ 175.4, 157.8, 155.7, 153.6, 150.4, 139.7, 133.9, 131.4, 128.5, 127.8, 
127.2, 124.9, 124.6, 124.2, 121.2, 119.9, 118.5, 111.0, 40.6. The 1H and 13C NMR data 
matched with the data reported in the literature.138 
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 8.5   Target Molecule 2 
 
 8.5.1  5-Acetyl-6-methyl-2-oxo-1,2-dihydropyridine-3-
carbonitrile (41) 
 
A mixture of acetylacetone 39 (100 mg, 1mmol) and N,N’-dimethylformamide 
dimethyl acetal (DMFDMA; 133 µL, 1 mmol) in dry DMF was stirred at r.t under nitrogen 
atmosphere for 24 h. The resulting yellow mixture, containing the adduct dimetylamino 
pentane dione 40 was used immediately for the following step. TLC Rf = 0.4 (solvent system: 
DCM/MeOH, 10:1) MS (ESI, m/z): C8H14NO2+ [M+H]+ calc.: 156.10, found: 156.1 [M+H]+, 
178.1 [M+Na]+. In another flask, a mixture of NaH (60 % in mineral oil) (80 mg, 2 mmol) and 
cyanocetamide (84 mg, 1 mmol) in dry DMF was stirred at r.t. under nitrogen atmosphere 
for 10 minutes. The adduct 40 from the first flask was added to the mixture and it was 
allowed to react at r.t. for 20 h. 5 mL of H2O/EtOH (1:1) were added followed by 
concentrated HCl (37 %) to adjust the pH to 3. After 24 h the acidic solution was diluted 
with H2O and was extracted with EtOAc (3 x 8 mL). The organic phase was washed several 
times with H2O dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. The product was isolated by crystallisation from EtOH to obtain 175 mg of 41 (98 
% yield) as a white solid. The 1H NMR data matched with the data reported in the literature. 
MS (ESI, m/z): C9H9N2O2+ [M+H]+ calc.: 177.07, found: 177.1 [M+H]+, 199.1 [M+Na]+. 1H 
NMR (400 MHz, CDCl3) δ 12.36 (bs, 1H, NH), 8.33 (s, 1H, aromat.), 2.81 (s, 3H, CH3), 2.52 (s, 
3H, COCH3). 1H NMR (400 MHz, Acetone-d6) δ 11.62 (bs, 1H, NH), 8.60 (s, 1H, aromat.), 2.72 
(s, 3H, CH3), 2.54 (s, 3H, COCH3). 1H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H, NH), 8.65 (s, 
1H, aromat.), 2.55 (s, 3H, CH3), 2.45 (s, 3H, COCH3). 13C NMR (101 MHz, Acetone-d6) δ 
195.16, 160.23, 159.29, 150.43, 116.45, 116.08, 101.30, 28.97, 20.70. 13C NMR (101 MHz, 
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DMSO-d6) δ 195.0, 159.7, 158.6, 149.8, 115.9, 115.3, 99.1, 28.9, 19.9. The 1H and 13C NMR 
data matched with the data reported in the literature.146  
 
 
 
 8.5.2   (E,Z)-5-Acetyl-6-(2-(dimethylamino)vinyl)-2-oxo-1,2-
dihydropyridine-3-carbonitrile (42) 
 
A mixture containing the pyridinone 41 (250 mg, 1.4 mmol) and DMFDMA (207 µL, 
1.6 mmol) in DMF was stirred under nitrogen atmosphere at r.t. over-weekend. After 
dilution with MeOH, a bright yellow solid precipitated from the mixture. The solid was 
filtrate, washed with acetone, dried over Na2SO4, filtered and used immediately for the 
following step. MS (ESI, m/z): C12H14N3O2+ [M+H]+ calc.: 232.11, found : [M+H]+ 232.1, 
[M+Na]+ 254.1. 1H NMR (400 MHz, DMSO-d6) δ 11.37 (bs, 1H, NH), 8.33 (s, 1H, aromat.), 
8.22 (d, J = 13.2 Hz, 1H, aromat.), 6.63 (d, J = 13.2 Hz, 1H, aromat.), 3.04 (bs, 6H, N(CH3)2), 
2.38 (s, 3H, CH3). The 1H and 13C NMR data matched with the data reported in the 
literature.145 
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 8.5.3  5-Methyl-2-oxo-1,6-naphthyridine-3-carbonitrile (43) 
 
Four equivalents of NH4OAc (438 mg, 5.6 mmol) were added to a solution of 
enamine 42 (320 mg, 1.4 mmol) in DMF. The mixture was gradually heated in an oil bath to 
125 °C for 24 h. After cooling down to r.t., the brown cake mixture was washed several 
times with H20 and extracted with Et2O. The organic phase was dried over Na2SO4, filtered 
and the Et2O was removed under reduced pressure to obtain 147 mg of 43, a white solid 
(79 % yield over two steps). The 1H NMR data matched with the data reported in the 
literature. Analytical RP-HPLC (solvent system: H2O/ACN, gradient: from 3 % to 10 % of ACN 
in 10 min, flow: 1 mL/min; tR = 8.3). C10H8N3O+ [M+H]+ calc.: 186.07, found: [M+H]+ 186.1, 
[M+Na]+ 208.2, [M+K]+ 224.0. 1H NMR (400 MHz, MeOD) δ 8.89 (s, 1H, aromat.), 8.40 (d, J 
= 6.0 Hz, 1H, aromat.), 7.16 (d, J = 6.0 Hz, 1H), 2.80 (s, 3H, CH3). 1H NMR (400 MHz, DMSO-
d6) δ 12.57 (bs, 1H, NH), 8.98 (s, 1H, aromat.), 8.42 (d, J = 5.8 Hz, 1H, aromat.), 7.10 (d, J = 
5.8 Hz, 1H, aromat.), 2.72 (s, 3H, CH3). 13C NMR (101 MHz, DMSO-d6) δ 159.2, 158.7, 150.8, 
147.5, 145.1, 115.5, 112.5, 108.6, 106.6, 21.5. The 1H and 13C NMR data matched with the 
data reported in the literature.145 
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 8.5.4  5-Methyl-N-(3-(methyl(phenyl)amino)propyl)-2-oxo-1,6-
naphthyridine-3-carboxamide (18) 
 
 
A mixture of nitrile 43 (100 mg, 0.5 mmol), N-(3-aminopropyl)-N-methylaniline 44 
(105 mg, 0.6 mmol) and CsOH·H2O (8.1 mg, 0.05 mmol) in H2O (0.5 mL) was sealed in a 
Schlenk tube under nitrogen atmosphere and gradually heated up to 145 °C. After 24 h the 
reaction mixture was diluted with water and extracted three times with DCM and once with 
EtOAc. The organic phases were collected and dried over Na2SO4, filtered and, after 
removing the solvent, the resulting crude was purified by gradient elution flash 
chromatography (solvent system: DCM/EtOH, from 0% to 5% of EtOH) to give 18 (86 mg, 
45% yield) as pale-yellow solid. Analytical RP-HPLC (solvent A: H2O + 0.1% TFA, solvent B: 
ACN + 0.1% TFA, gradient: from 10% to 50% of B in 10 min flow: 1 mL/min; tR = 6.5 min). 
MS (ESI, m/z): C20H23N4O2+ [M+H]+ calc.: 351.18, found: 176.2 [M+2H]2+, 351.2 [M+H]+, 373.1 
[M+Na]+, 389.1 [M+K]+.1H NMR (400 MHz, CDCl3) δ 10.62 (s, 1H, NH), 9.52 (t, J = 5.5 Hz, 1H, 
NH), 9.21 (s, 1H, aromat.), 8.47 (d, J = 5.8 Hz, 1H, aromat.), 7.24 – 7.17 (m, 2H, aromat.), 
7.00 (d, J = 5.8 Hz, 1H, aromat.), 6.77 – 6.70 (m, 2H, aromat.), 6.70 – 6.64 (m, 1H, aromat.), 
3.62 – 3.50 (m, 2H, CH2), 3.51 – 3.41 (m, 2H, CH2), 2.96 (s, 3H, CH3), 2.90 (s, 3H, CH3), 2.02 
– 1.90 (m, 2H, CH2). 13C NMR (101 MHz, CDCl3) δ 163.1, 162.8, 160.5, 150.3, 149.3, 143.9, 
142.5, 129.4, 122.8, 116.6, 114.3, 112.6, 108.1, 50.6, 38.7, 37.9, 27.0, 22.1. 
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 8.6   Target Molecule 3 
 
 8.6.1  tert-Butyl (2-aminoethyl)carbamate (52) 
 
 
A solution of di-tert-butyl dicarbonate, Boc2O (1 g, 4.6 mmol) in DCM was added, 
through a dropping funnel, over 1 h, to a solution of ethylenediamine (6 equivalents 2 mL, 
27.5 mmol) pre-dissolved in DCM while maintaining vigorous stirring. The mixture was 
stirred at r.t. for 24 h, then, after concentration, the resulting oil was taken into aqueous 
solution of NaHCO3 (5% w/v) and extracted three times with DCM (3 x 20 mL). The organic 
phase was dried over Na2SO4 and the DCM was removed under reduced pressure to afford 
725 g of 52 in quantitative yield. MS (ESI, m/z): C7H17N2O2+ [M+H]+ calc.: 161.13, found: 
161.1. 1H NMR (400 MHz, CDCl3) δ 5.34 (bs, 1H, NH), 3.13 – 2.87 (m, J = 43.3 Hz, 2H, CH2), 
2.70 – 2.53 (m, 2H, CH2), 1.28 (s, 9H, OC(CH3)3). The 1H and 13C NMR data matched with the 
data reported in the literature.169 
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 8.6.2  tert-Butyl (2-(isoindolin-2-yl)ethyl)carbamate (53) 
 
 
 
To a solution of α,α’-Dibromo-o-xylene (104.3 mg, 0.39 mmol) in CHCl3 (2 mL), a 
solution of DIPEA (172 µL) in CHCl3 (1 mL) was added dropwise at 0 °C followed by another 
solution of N-Boc ethylenediamine 16 (95 mg, 0.59 mmol) in CHCl3 (1 mL). The resulting 
mixture was stirred at r.t. overnight. When bromine was no longer detected by TLC, the 
reaction was stopped, and the solvent was removed under reduced pressure. The crude 
was washed three times with water and extracted with EtOAc. The organic phase was dried 
over Na2SO4 and the EtOAc was removed under reduced pressure to afford 100 mg of crude 
that was used without purification for the next step. TLC Rf = 0.3 (solvent system: n-
Hex/EtOAc 1:1). MS (ESI, m/z): C15H23N2O2+ [M+H]+ calc.: 263.18, found: 263.2. 1H NMR 
(MeOD, 400 MHz): δ = 7.23 (m, 4H, aromat.), 3.97 (s, 4H, benzylic), 3.29 (m, 2H, CH2), 2.85 
(m, 2H, CH2), 1.46 (s, 9H, OC(CH3)3); 1H NMR (CDCl3, 400 MHz): δ = 7.22 (s, 1H, aromat.), 
5.15 (bs, 1H, NH), 3.97 (s, 4H, benzylic), 3.34 (m, 2H, CH2), 2.89 (m, 2H, CH2), 1.46 (s, 9H, 
OC(CH3)3).13C NMR (101 MHz, MeOD) δ = 158.4, 140.6, 128.1, 123.3, 80.1, 60.0, 56.4, 40.2, 
28.8. 
  
Chapter 8: Experimental – Chemistry 
 
116 
 8.6.3  2-(Isoindolin-2-yl)ethan-1-amine (54) 
 
 
 
 
Compound 53 (80 mg, 0.3 mmol) was treated with a solution of TFA in DCM (40% 
v/v), at 0 °C, for 2 h. The solvent was removed by bubbling nitrogen and stripping with DCM 
several times. 8 mL of aqueous solution of HCl 1N was added and the mixture was 
lyophilised. The resulting crude was treated with a 1N solution of NaOH then extracted with 
DCM to remove the counter ion and give the free amine of 54 (45 mg, 94% yield). MS (ESI, 
m/z): C10H15N2+ [M+H]+ calc.: 163.12 found: 163.1. 1H NMR (400 MHz, MeOD) δ 7.21 (qd, J 
= 6.7, 4.3 Hz, 4H, aromat.), 3.99 (s, 4H, benzylic), 3.12 – 3.04 (m, 2H, CH2), 3.03 – 2.94 (m, 
2H, CH2). The 1H and 13C NMR data matched with the data reported in the literature.170 
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 8.6.4  N-(2-(Isoindolin-2-yl)ethyl)-3-nitrobenzamide (55) 
 
 
The amine 54 (40 mg, 0.14 mmol) was dissolved in THF at 0 °C then 3-nitrobenzoyl 
chloride (50 mg, 0.3 mmol) was added to the solution and the reaction was warmed up to 
r.t. and stirred for 8 h. The reaction was quenched with a saturated aqueous solution of 
NaHCO3 and extracted with EtOAc. The crude material was purified by isocratic flash 
chromatography (solvent system: DCM/MeOH, 9.5:0.5) to give 55 (30 mg, 68 % yield). TLC 
Rf = 0.3 (solvent system DCM/MeOH 9.5:0.5). MS (ESI, m/z): C17H18N3O3+ [M+H]+ calc.: 
312.13, found: 312.2. 1H NMR (400 MHz, MeOD) δ 8.74 (t, J = 2.0 Hz, 1H, aromat.), 8.37 
(ddd, J = 8.0, 2.0, 1.0 Hz, 1H, aromat.), 8.28 – 8.21 (m, 1H, aromat.), 7.71 (t, J = 8.0 Hz, 1H, 
aromat), 7.27 – 7.16 (m, 4H, aromat.), 4.02 (s, 4H, benzylic), 3.67 (t, J = 6.6 Hz, 2H, CH2), 
3.02 (t, J = 6.6 Hz, 2H, CH2). 13C NMR (101 MHz, MeOD) δ 167.7, 149.7, 140.6, 137.3, 134.4, 
130.9, 128.2, 126.9, 123.3, 123.3, 59.9, 55.8, 39.8. 
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 8.6.5  3-Amino-N-(2-(isoindolin-2-yl)ethyl)benzamide (56) 
 
 
 
 
 
METHOD A 
The nitro-compound 55 (30 mg, 0.1 mmol) was dissolved in EtOH (1.5 mL) and AcOH (0.5 
mL) was added at 0 °C, followed by Fe (80 mg, 1.4 mmol). The reaction was warmed up to 
r.t. and vigorously stirred for 24 h. After dilution with EtOAc, the mixture was washed three 
times with water and three time with an aqueous solution of NaHCO3 (5 % w/v). The organic 
phase was dried over Na2SO4, filtered and the reaction crude was purified by gradient 
elution flash chromatography (solvent system: DCM/MeOH, from 0 % to 10 % of MeOH) to 
afford the aniline 56 (20 mg, 71 % yield).  
 
METHOD B 
The nitro-compound 55 (100 mg, 0.32 mmol) was dissolved in MeOH/EtOAc (20:1), then 
NiCl2·H2O (125.8 mg, 0.64 mmol) was added to the solution. The mixture was stirred for 20 
min then NaBH4 (73 mg, 1.9 mmol) was added at 0 °C. The reaction was warmed up to r.t. 
and stirred for 1 h, then quenched with a saturated aqueous solution of NH4Cl and 
extracted three times with EtOAc (3 x 20 mL). The organic layer was dried over Na2SO4, 
filtered and the solvent was removed under reduced pressure to give the aniline 56 (80 mg, 
90 % of yield). MS (ESI, m/z): C17H20N3O+ [M+H]+ calc.: 282.16, found: 141.6 [M+2H]2+, 282.1 
[M+H]+, 304.1 [M+Na]+, 585.3 [2M+Na]+. 1H NMR (400 MHz, MeOD) δ 7.26 – 7.19 (m, 4H, 
aromatic.), 7.18 – 7.08 (m, 3H, aromatic.), 6.84 (ddd, J = 8.0, 2.2, 1.2 Hz, 1H, aromatic), 4.01 
(s, 4H, benzylic), 3.60 (t, J = 6.8 Hz, 2H, CH2), 2.98 (t, J = 6.8 Hz, 2H, CH2). 13C NMR (101 MHz, 
MeOD) δ 170.9, 149.4, 140.6, 136.5, 130.2, 128.1, 123.3, 119.3, 117.3, 114.9, 60.0, 55.9, 
39.6.  
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 8.6.6  N-(2-(Isoindolin-2-yl)ethyl)-3-((2-methylquinolin-4-
yl)amino)benzamide (19) 
 
 
 
To a solution of 56 (30 mg, 0.1 mmol) and 4-chloroquinaldine 57 (36 mg, 0.2 mmol) 
in EtOH, 300 µL of concentrated HCl (37  %) were added. The mixture was refluxed under 
nitrogen atmosphere for 3 h. The mixture was allowed to cool down to r.t. and, after 
removal of the solvent under reduced pressure, the residue was basified with a saturated 
solution of NaHCO3 aq. and extracted three times with EtOAc (3 x 15 mL). The organic phase 
was dried over Na2SO4, filtered and, after removing the solvent under reduced pressure, 
the product was purified by preparative RP-HPLC (solvent A = H2O + 0.1 % TFA, solvent B = 
ACN + 0.1 % TFA, gradient from 15 % B to 40 % B in 10 min; flow 20 mL/min; tR: 8.8 min) to 
give 19 (30 mg, 65 % yield). Analytical RP-HPLC (solvent A: H2O + 0.1 % of TFA, solvent B: 
ACN + 0.1 % of TFA, gradient: from 15 % to 40 % of B in 10 min, flow: 1 mL/min, tR = 9.2 min). 
MS (ESI, m/z): C27H27N4O+ [M+H]+ calc.: 423.22, found: 212.2 [M+2H]2+, 423.2 [M+H]+, 445.2 
[M+Na]+. 1H NMR (400 MHz, MeOD) δ 8.53 (d, J = 8.1 Hz, 1H, aromat.), 8.05 – 7.64 (m, 7H, 
aromat.), 7.41 (s, 4H, aromat.), 6.75 (s, 1H, aromat.), 4.86 (s, 4H, benzylic) 3.90 (t, J = 5.7 
Hz, 2H, CH2), 3.73 (t, J = 5.7 Hz, 2H, CH2), 2.62 (s, 3H, CH3). 13C NMR (101 MHz, MeOD) δ 
169.8, 156.8, 156.3, 140.0, 139.0, 136.9, 135.2, 134.9, 131.6, 130.2, 130.2, 128.3, 127.6, 
126.0, 123.9, 123.9, 120.8, 117.8, 101.5, 60.2, 55.8, 37.4, 20.3. 
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 8.7   Target Molecule 4 
 
 8.7.1  tert-Butil 4-mercaptophenylcabamate (60) 
 
 
 
4-aminotiophenol 59 (200 mg, 1.6) was added to a solution of Boc2O (349 mg) and 
catalytic amount (10 %) of InCl3 (35.4 mg, 0.16 mmol) in DCM at r.t under nitrogen 
atmosphere. The yellow mixture was stirred at 35 °C for 2 h. The thick yellow oily mixture 
was then diluted with EtOAc and washed three times with H2O. The organic layer was dried 
over Na2SO4, filtered and solvents were removed under reduced pressure. The crude 
mixture was purified by isocratic flash chromatography (solvent system: n-Hex/EtOAc, 8:1) 
to obtain 263 mg (1.16 mmol, 73 % yield) of 60 as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.29 – 7.19 (m, 4H, aromat.), 6.62 (s, 1H, NH), 3.40 (s, 1H, SH), 1.51 (s, 9H, OC(CH3)3). 13C 
NMR (101 MHz, CDCl3) δ 152.5, 138.4, 131.1, 131.0, 130.8, 118.9, 80.9, 28.3. The 1H and 
13C NMR data matched with the data reported in the literature.171 
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 8.7.2  tert-Butyl (4-((3-amino-4-nitrophenyl)amino)-
phenyl)carbamate (61) 
 
 
 
To a mixture of Boc-protected aniline 60 (260 mg, 1.15 mmol) and ButOK (142.5 mg, 
1.27 mmol) in THF, 5-chloro-2-nitroaniline (368 mg, 1.27 mmol) was added at r.t. under 
nitrogen atmosphere. The red mixture was refluxed overnight. When the reaction was 
shown to be complete by TLC, it was stopped and cooled down to r.t.. After removal of the 
solvent, the reaction crude was purified by isocratic flash chromatography (solvent system 
n-Hex/EtOAc, 8:1) to obtain 61 as a yellow solid (382 mg, 92 % yield). TLC Rf = 0.35 (solvent 
system n-Hex/EtOAc, 8:1). MS (ESI, m/z): C17H20N3O4S+ [M+H]+ calc.: 362.11, found: 362.1. 
1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 9.1 Hz, 1H, aromat.), 7.47 (m, 4H, aromat.), 6.61 (bs, 
1H, NH), 6.39 (dd, J = 9.1, 2.0 Hz, 1H, aromat.), 6.26 (d, J = 2.0 Hz, 1H, aromat.), 6.01 (bs, 
2H, NH2), 1.54 (s, 9H, OC(CH3)3). 13C NMR (101 MHz, CDCl3) δ 152.6, 150.5, 145.0, 140.2, 
136.6, 129.9, 126.7, 122.9, 119.6, 115.1, 113.6, 81.4, 28.4. 
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 8.7.3  tert-Butyl (4-((3,4-diaminophenyl)amino) 
phenyl)carbamate (62) 
 
 
Compound 61 (180 mg, 0.5 mmol) was dissolved in MeOH/EtOAc (20:1), then 
NiCl2·H2O (237 mg, 1 mmol) was added to the solution. The mixture was stirred for 20 min 
then NaBH4 (113.17 mg, 3 mmol) was added portion-wise at 0 °C. The reaction was warmed 
up to r.t. and stirred for 2.5 h, then quenched with aq. NH4Cl and extracted with EtOAc. The 
organic layer was dried over Na2SO4, filtered and, after removing the solvent under reduced 
pressure, the crude was purified by gradient elution flash chromatography (solvent system: 
n-Hex/EtOAc, from 3.5:6.5 to 3:7) to give 62 (156 mg, 94 % yield). TLC Rf = 0.5 (solvent 
system: n-Hex/EtOAc, 3:7). MS (ESI, m/z): C17H22N3O2S+ [M+H]+ calc.: 332.14, found: 332.0 
[M+H]+, 354.1 [M+Na]+, 663.3 [2M+H]+, 685.2 [2M+Na]+. 1H NMR (400 MHz, MeOD) δ 7.26 
(d, J = 8.7 Hz, 2H, aromat.), 7.10 – 7.04 (m, 2H, aromat.), 6.78 (dd, J = 1.7, 0.5 Hz, 1H, 
aromat.), 6.67 (dd, J = 2.1, 1.1 Hz, 2H, aromat.), 1.50 (s, 9H, OC(CH3)3). 1H NMR (400 MHz, 
CDCl3) δ 7.24 – 7.14 (m, 3H, aromat.), 6.83 – 6.50 (m, 4H, aromat.), 3.42 (s, 4H, NH), 1.50 
(s, 9H, OC(CH3)3). 13C NMR (101 MHz, MeOD) δ 155.1, 138.4, 136.6, 136.5, 133.8, 130.4, 
125.8, 123.9, 122.0, 120.3, 117.7, 80.9, 28.6. 
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 8.7.4  tert-Butyl (4-((2-((methoxycarbonyl)amino)-1H-
enzo[d]imidazol-5-yl)amino)phenyl)carbamate (64) 
 
 
 
 
The dianiline 62 (156 mg, 0.47 mmol) was dissolved in EtOH, then 1,3-
bis(methoxycarbonyl)-2-methyl-thiopseudourea 63 (102 mg, 0.49 mmol) was added. The 
mixture was stirred at reflux temperature overnight. After cooling down to r.t., the product 
64 was isolated as brown precipitate by filtration and it was used without further 
purification for the following step (136 mg, 70 % yield). MS (ESI) C20H23N4O4S+ [M+H]+ calc. 
415.14 found 415.1 [M+H]+, 829.2 [2M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.62 (bs, 2H, 
NHC(NH)), 9.42 (bs, 1H, NH), 7.46 – 7.32 (m, 4H, aromat.), 7.24 – 7.15 (m, 2H, aromat.), 
7.07 (dd, J = 8.2, 1.8 Hz, 1H, aromat.), 3.74 (s, 3H, OCH3), 1.46 (s, 9H, OC(CH3)3). 13C NMR 
(101 MHz, DMSO-d6) δ 154.7, 152.7, 148.0, 138.7, 131.1, 128.8, 126.4, 124.6, 118.9, 79.2, 
52.5, 28.1. 
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 8.7.5  Methyl (5-((4-aminophenyl)amino)-1H-
benzo[d]imidazol-2-yl)carbamate (65) 
 
 
Compound 64 (100 mg, 0.24 mmol) was dissolved in a 4M solution of HCl in 1,4-
dioxane (4 mL) at 0 °C. The mixture was warmed up to r.t. and stirred for 24 h. The solvent 
was removed under reduced pressure and the resulting 65 was immediately used for the 
next step (160 mg, quantitative yield). MS (ESI, m/z): C15H15N4O2S+ [M+H]+ calc.: 315.09, 
found: 315.1. 1H NMR (400 MHz, MeOD) δ 7.73 (s, 1H, aromat.), 7.67 (d, J = 8.2 Hz, 1H, 
aromat.), 7.53 (d, J = 8.2 Hz, 1H, aromat.), 7.40 (dd, J = 17.7, 8.3 Hz, 4H, aromat.), 3.97 (s, 
3H, OCH3). 13C NMR (101 MHz, MeOD) δ 154.0, 146.3, 139.6, 132.1, 131.9, 131.1, 131.1, 
130.8, 130.3, 125.2, 118.2, 115.2, 54.8. The 1H and 13C NMR data matched with the data 
reported in the literature.149 
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 8.7.6  Methyl (S)-(5-((4-(2-((tert-butoxycarbonyl)amino)-
propanamido)phenyl)amino)-1H-benzo[d]imidazol-2-
yl)carbamate (66) 
 
 
Boc-L-Alanine (14 mg, 0.1 mmol) was dissolved in DCM then HATU (56 mg, 0.2 
mmol) and DIPEA (40 µL, 0.3 mmol) were added to the solution at r.t.. The reaction mixture 
was stirred for 20 min, then the aniline 65 (24 mg, 0.1 mmol) was added. After 4 h an 1N 
aqueous solution of HCl was added and the mixture was extracted with EtOAc. The crude 
material was purified by preparative RP-HPLC (solvent A = H2O + 0.1 % TFA, solvent B = ACN 
+ 0.1 % TFA, gradient from 40 % to 80 % of B in 15 min; flow 20 mL/min; tR: 7.2 min) to give 
66•TFA (24 mg, 40 % yield). Analytical RP-HPLC (solvent A: H2O + 0.1 % of TFA, solvent B: 
ACN + 0.1 % of TFA, gradient: from 40 % to 80 % of B in 15 min, flow: 1 mL/min, tR = 7.6 min). 
MS (ESI, m/z): C23H28N5O5S+ [M+H]+ calc.: 486.18, found: 486.2 [M+H]+, 971.4 [2M+H]+, 
993.3 [2M+Na]+. 1H NMR (400 MHz, DMSO-d6) δ 11.70 (bs, 2H, NHC(NH)), 9.99 (s, 1H, NH), 
7.56 (d, J = 8.7 Hz, 2H, aromat.), 7.44 – 7.34 (m, 1H, aromat.), 7.20 (d, J = 8.7 Hz, 2H, 
aromat.), 7.12 – 6.95 (m, 2H, aromat.), 4.09 (m, 1H, CH), 3.75 (s, 3H, OCH3), 1.37 (s, 9H, 
OC(CH3)3), 1.25 – 1.22 (m, 3H, CH3). 1H NMR (400 MHz, MeOD) δ 7.53 – 7.37 (m, 4H, 
aromat.), 7.24 – 7.16 (m, 3H, aromat.), 4.23 – 4.10 (m, 1H, CH), 3.84 (s, 3H, OCH3), 1.44 (s, 
9H, OC(CH3)3), 1.36 (d, J = 7.1 Hz, 3H, CH3).13C NMR (101 MHz, DMSO-d6) δ 171.9, 155.2, 
148.1, 137.9, 130.4, 125.7, 125.1, 119.9, 78.0, 52.5, 50.4, 28.2, 17.9. 
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 8.7.7  Methyl (5-((4-aminophenyl)amino)-1H-
benzo[d]imidazol-2-yl)carbamate (20) 
 
 
Compound 66 (100 mg, 0.24 mmol) was dissolved in a 4M solution of HCl in 1,4-
dioxane (4 mL) at 0 °C. The mixture was warmed up to r.t. and stirred for 24 h. The solvent 
was removed under reduced pressure to give 20 (100 mg, quantitative yield). Preparative 
RP-HPLC (solvent A = H2O + 0.1 % TFA, solvent B = ACN + 0.1 % TFA, gradient from 15 % to 
60 % B in 10 min; flow 20 mL/min; tR: 7.2 min). Analytical RP-HPLC (solvent A: H2O + 0.1 % 
of TFA, solvent B: ACN + 0.1 % of TFA, gradient: from 15 % to 60 % of B in 10 min, flow: 1 
mL/min, tR = 7.9 min). MS (ESI, m/z): C18H20N5O3S+ [M+H]+ calc.: 386.13, found: 386.2 
[M+H]+, 408.0 [M+Na]+, 771.3 [2M+H]+, 793.3 [2M+Na]+. 1H NMR (400 MHz, MeOD) δ 7.61 
– 7.53 (m, 2H, aromat.), 7.54 – 7.44 (m, 2H, aromat.), 7.35– 7.29 (m, 3H, aromat.), 4.04 (q, 
J = 7.1 Hz, 1H, CH), 3.91 (s, 3H, OCH3), 1.58 (d, J = 7.1 Hz, 3H, CH3). 13C NMR (101 MHz, 
MeOD) δ 169.3, 154.5, 139.0, 134.2, 133.6, 132.0, 128.3, 122.0, 116.0, 114.8, 54.5, 50.9, 
17.6. The 1H and 13C NMR data matched with the data reported in the literature.149 
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 8.8   AZPP series 
 
 8.8.1  General procedure for preparation of α-
aminoacetophenone 
 
 
METHOD A 
α-Bromoacetophenone 67 (1-3 mmol) in dry THF (1,5-3 mL) was added dropwise to 
a flame-dried and nitrogen-purged flask containing a solution of aniline 68 (2 equivalents) 
in dry THF. The mixture was stirred overnight at 20 °C, under N2. The excess of aniline was 
removed as insoluble salts by filtration and the resulting supernatant was dried under 
reduced pressure and immediately used for the following step, without further purification. 
 
 
METHOD B 
To a solution of aniline 68 in dry EtOH, 1 equivalent of α-bromoacetophenone 67 
was added portion wise followed by 1 equivalent of NaHCO3(s). The mixture was stirred at 
room temperature overnight in nitrogen atmosphere. The precipitate formed from the 
reaction was collected by filtration and immediately used for the following step, without 
further purification. 
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 8.8.1.1  2-((4-Methoxyphenyl)amino)-1-phenylethan-1-one (70a) 
 
Prepared according to METHOD A. Quantitative yield. 1H NMR (400 MHz, CDCl3) δ 
8.07 – 7.98 (m, 2H, aromat.), 7.67 – 7.58 (m, 1H, aromat.), 7.57 – 7.47 (m, 2H, aromat.), 
6.83 (d, J = 9.0 Hz, 2H, aromat.), 6.71 (d, J = 9.0 Hz, 2H, aromat.), 4.61 (s, 2H, CH2), 3.76 (s, 
3H, OCH3). The 1H and 13C NMR data matched with the data reported in the literature.153 
 
 8.8.1.2  1-(4-Methoxyphenyl)-2-((2-methoxyphenyl)amino)ethan-1-one 
(70b) 
 
Prepared according to METHOD B. Quantitative yield. MS (ESI, m/z): C16H18NO3+ 
[M+H]+ calc.: 272.13, found: [M+H]+ 272.1. 1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 9.3, 2.4 
Hz, 2H, aromat.), 6.98 (dd, J = 9.3, 2.4 Hz, 2H, aromat.), 6.90 (td, J = 7.7, 1.4 Hz, 1H, aromat.), 
6.82 (dd, J = 7.7, 1.3 Hz, 1H, aromat.), 6.72 (td, J = 7.7, 1.3 Hz, 1H, aromat.), 6.61 (dd, J = 
7.7, 1.4 Hz, 1H, aromat.), 4,57 (s, 2H, CH2), 3.90 (s, 3H, OCH3), 3.88 (s, 3H, OCH3). 13C NMR 
(101 MHz, CDCl3) δ 193.6, 164.0, 147.3, 137.5, 130.1, 128.2, 121.2, 117.0, 114.1, 110.2, 
109.7, 55.6, 55.6, 49.9. 
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 8.8.1.3  1-Phenyl-2-((3-(trifluoromethyl)phenyl)amino)ethan-1-one (70c) 
 
 
Prepared according to METHOD B. Quantitative yield. TLC Rf = 0.5 (solvent system: 
DCM/MeOH, 10:1).MS (ESI, m/z): C15H13F3NO+ [M+H]+ calc.: 280.09, found: [M+H]+ 280.1. 
1H NMR (400 MHz, CDCl3) δ 8.09 – 8.01 (m, 2H, aromat.), 7.69 – 7.61 (m, 1H, aromat.), 7.59 
– 7.50 (m, 2H, aromat.), 7.31 (t, J = 7.8 Hz, 1H, aromat.), 6.99 (d, J = 7.6 Hz, 1H, aromat.), 
6.94 – 6.78 (m, 2H, aromat.), 5.18 (bs, 1H), 4.64 (d, J = 4.2 Hz, 2H, CH2). 13C NMR (101 MHz, 
CDCl3) δ 194.4, 147.2, 134.7, 134.1, 131.7 (q, J = 31.9 Hz), 129.7, 128.99, 127.8, 124.3 (d, J 
= 272.3 Hz), 116.4, 114.2 (q, J = 3.8 Hz), 108.8 (q, J = 3.9 Hz), 50.0. The 1H and 13C NMR data 
matched with the data reported in the literature.172 
 
 
 8.8.1.4  1-Phenyl-2-((4-(trifluoromethyl)phenyl)amino)ethan-1-one (70d) 
 
 
Prepared according to METHOD B, quantitative yield. MS (ESI, m/z): C15H13F3NO+ 
[M+H]+ calc.: 280.09, found: [M+H]+  280.1. 1H NMR (400 MHz, CDCl3) δ 8.09 – 7.98 (m, 2H, 
aromat.), 7.69 – 7.61 (m, 1H, aromat.), 7.58 – 7.50 (m, 2H, aromat.), 7.46 (d, J = 8.4 Hz, 2H, 
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aromat.), 6.72 (d, J = 8.4 Hz, 2H, aromat.), 4.64 (d, J = 4.3 Hz, 2H, CH2). 13C NMR (101 MHz, 
CDCl3) δ, 194.3, 149.5, 134.8, 134.3, 129.1, 127.9, 126.9 (q, J = 3.3 Hz), 126.2 (q, J = 296.6 
Hz), 119.5 (q, J = 32.6 Hz), 114.3, 112.3, 49.7. The 1H and 13C NMR data matched with the 
data reported in the literature.173 
 
 
 8.8.1.5  4-(Phenylglycyl)benzonitrile (70e) 
 
 
 
Prepared according to METHOD B, quantitative yield. TLC Rf = 0.5 (solvent system: 
n-Hex/EtOAc, 7:3).MS (ESI, m/z): C15H13N2O+ [M+H]+ calc.: 237.10, found: [M+H]+ 237.1. 1H 
NMR (400 MHz, CDCl3) δ 8.12 (d, J = 8.2 Hz, 2H, aromat.), 7.83 (d, J = 8.2 Hz, 2H, aromat.), 
7.26 – 7.20 (m, 2H, aromat.), 6.79 (t, J = 7.3 Hz, 1H, aromat.), 6.72 (d, J = 8.3 Hz, 2H, 
aromat.), 4.65 (s, 2H, CH2). 13C NMR (101 MHz, CDCl3) δ 194.2, 146.8, 138.0, 132.9, 129.6, 
128.4, 118.4, 117.8, 117.3, 113.2, 51.0.  
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 8.8.2  General procedure for preparation of 2-Amino-3-cyan-
1,4-disubstituted pyrroles 
 
To a solution of (1 -3 mmol) α-aminoacetophenone 70 in dry EtOH and the 1 
equivalent of malononitrile was added followed by a 21 wt.  % solution of EtONa in EtOH (1 
equivalent). The mixture was gradually heated up to 85 °C for 3 h. The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography or 
crystallisation from EtOH. 
 
 
 8.8.2.1  2-Amino-1-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-3-carbonitrile 
(72a) 
 
Purified by crystallisation from EtOH. White crystal, 43 % yield over two steps. MS 
(ESI, m/z): C19H18N3O2+ [M+H]+ calc.: 290.13, found: [M+H]+ 290.1. 1H NMR (400 MHz, CDCl3) 
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δ 7.67 – 7.60 (m, 2H, aromat), 7.41 – 7.34 (m, 2H, aromat.), 7.35 – 7.30 (m, 2H, aromat.), 
7.28 – 7.23 (m, 1H, aromat.), 7.06 – 6.99 (m, 2H, aromat.), 6.49 (s, 1H, aromat.), 4.16 (bs, 
2H, NH2), 3.86 (s, 3H, OCH3). 13C NMR (101 MHz, CDCl3) δ 159.76, 146.68, 133.20, 129.45, 
128.89, 126.99, 126.96, 125.99, 123.63, 117.79, 115.25, 113.19, 72.80, 55.75. The 1H and 
13C NMR data matched with the data reported in the literature.153 
 
 
 8.8.2.2  2-Amino-1-(2-methoxyphenyl)-4-(4-methoxyphenyl)-1H-pyrrole-3-
carbonitrile (72b) 
 
 
 
Purified by gradient elution flash chromatography (solvent system: n-Hex/EtOAc, 
from 3:2 to 2:3). Pale yellow solid, 35 % yield over two steps. MS (ESI, m/z): C19H18N3O2+ 
[M+H]+ calc.: 320.14, found: [M+H]+ 320.1. 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.7 Hz, 
2H, aromat.), 7.46 – 7.39 (m, 1H, aromat.), 7.30 (d, J = 7.9 Hz, 1H, aromat.), 7.08 (t, J = 7.8 
Hz, 2H, aromat.), 6.92 (d, J = 8.7 Hz, 2H, aromat.), 6.41 (s, 1H, aromat.), 4.22 (bs, 2H, NH2), 
3.87 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). 13C NMR (101 MHz, CDCl3) δ 158.6, 154.0, 147.4, 
130.3, 128.3, 127.1, 125.9, 125.7, 123.4, 121.5, 118.1, 114.2, 113.0, 112.64, 6.12, 55.3. 
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 8.8.2.3  2-Amino-4-phenyl-1-(3-(trifluoromethyl)phenyl)-1H-pyrrole-3-
carbonitrile (72c) 
 
 
Purified by gradient elution flash chromatography (solvent system: n-Hex/DCM, 
from 2:3 to 3:7). 34 % yield over two steps. Analytical RP-HPLC (solvent A: H2O, solvent B: 
ACN + 0.1 % TFA, gradient: from 20 % to 80 % of B in 20 min flow: 1 mL/min; tR = 22.25 min). 
MS (ESI, m/z): C18H13F3N3+ [M+H]+ calc.: 328.11, found: [M+H]+.1H NMR (400 MHz, CDCl3) δ 
7.78 – 7.60 (m, 6H, aromat.), 7.40 (t, J = 7.6 Hz, 2H, aromat.), 7.32 – 7.27 (m, 1H, aromat.), 
6.57 (s, 1H, aromat.), 4.15 (bs, 2H, NH2). 13C NMR (101 MHz, CDCl3) δ 146.0, 137.6, 132.7, 
131.0, 129.0, 128.6, 127.4, 126.2, 125.4 (q, J = 3.6 Hz), 124.9, 122.4 (q, J = 3.9 Hz,), 117.1, 
112.7, 29.8. 
 
 
 8.8.2.4  2-Amino-4-phenyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-
carbonitrile (72d) 
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The crude material was immediately used for the following step. MS (ESI, m/z): C18H13F3N3+ 
[M+H]+ calc.: 328.11, found: [M+H]+ 328.1. 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H, 
aromat.), 7.69 – 7.57 (m, 4H, aromat.), 7.35 – 7.45 (m, 2H, aromat.), 7.29 (t, J = 8.7 Hz, 1H, 
aromat.), 6.57 (s, 1H, aromat.), 4.20 (bs, 2H, NH2). 
 
 
 8.8.2.5  2-Amino-4-(4-cyanphenyl)-1-phenyl-1H-pyrrole-3-carbonitrile (72e) 
 
 
Purified by gradient elution flash chromatography (solvent system: n-Hex/EtOAc, 
from 7:3 to 1:1) to obtain 74 mg of 72e with 26 % yield over two steps. MS (ESI, m/z): 
C18H13N4+ [M+H]+ calc.: 285.11, found: [M+H]+ 285.1. 1H NMR (400 MHz, CDCl3) δ 7.77 – 
7.70 (m, 2H, aromat.), 7.68 – 7.62 (m, 2H, aromat.), 7.59 – 7.53 (m, 2H, aromat.), 7.52 – 
7.46 (m, 1H, aromat.), 7.45 – 7.40 (m, 2H, aromat.), 6.64 (s, 1H, aromat.), 4.27 (bs, 2H, NH2). 
13C NMR (101 MHz, CDCl3) δ 147.1, 137.8, 136.4, 132.8, 130.4, 129.9, 129.2, 126.2, 125.5, 
122.1, 120.1, 119.2, 119.0, 117.2, 114.4, 110.1. 
.  
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 8.8.3  General procedure for preparation of 5,7-disubstituted-
7H-pyrrolo[2,3-d]pyrimidin-4(3H)-ones 
 
 
 
A mixture of (1-3 mmol) 2-Amino-3-cyan-1,4-disubstituted pyrrole and a large 
excess (20 equivalents) of formic acid 85  % (v/v) was refluxed in a sealed Schlenk tube 
overnight. The reaction mixture was then allowed to cool down to r.t., ice-cooled water 
was added, and the precipitate was filtered and crystallised. 
 
 
 8.8.3.1  7-(4-Methoxyphenyl)-5-phenyl-3,7-dihydro-4H-pyrrolo[2,3-
d]pyrimidin-4-one (23) 
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Amber solid. Purified by precipitation in water then crystallisation, 46 %. MS (ESI, 
m/z): C19H16N3O2+ [M+H]+ calc.: 318.12, found: [M+H]+ 318.1, [M+Na]+ 340.1, [M+K]+ 356.0, 
[2M+Na]+ 657.2. Analytical RP-HPLC: Phenomenex Jupiter C18 column, 5 μm, 300 Å, 150 × 
4.6 mm (L × ID) (solvent A: H2O, solvent B: ACN + 0.1 % TFA, gradient: from 30 % to 80 % of 
B in 15 min, flow: 1 mL/min; tR = 9.5 min). 1H NMR (400 MHz, CDCl3) δ 12.42 (bs, 1H, NH), 
793 – 7.94 (m, 3H, aromat.), 7.51 (d, J = 8.9 Hz, 2H, aromat.), 7.43 (t, J = 7.5 Hz, 2H, aromat.), 
7.34 – 7.29 (m, 1H, aromat.), 7.06 (d, J = 8.9 Hz, 2H, aromat.), 3.87 (s, 3H, OCH3). 13C NMR 
(101 MHz, CDCl3) δ 165.8, 161.2, 159.2, 148.8, 143.23 133.3, 130.3, 128.7, 128.5, 127.1, 
126.4, 122.4, 121.8, 114.8, 106.2, 55.7. The 1H and 13C NMR data matched with the data 
reported in the literature.153 
 
 
 
 8.8.3.2  7-(2-Methoxyphenyl)-5-(4-methoxyphenyl)-3,7-dihydro-4H-
pyrrolo[2,3-d]pyrimidin-4-one (27) 
 
 
Pale yellow solid. Purified by gradient elution flash chromatography (solvent system: n-
Hex/EtOAc, from 3.5:6.5 to 1:4), 30  % yield. Preparative RP-HPLC (solvent A: H2O + 0.1 % 
TFA, solvent B: ACN + 0.1 % TFA; gradient: from 40 % to 88 % of B in 8 min, flow: 20 mL/min; 
tR = 7.4 min). Analytical RP-HPLC (solvent A: H2O, solvent B: ACN + 0.1 % TFA; gradient: from 
40 % to 100 % of B in 10 min, flow: 1 mL/min; tR = 7.6 min). MS (ESI, m/z): C20H18N3O3+ [M+H]+ 
calc.: 348.13, found: [M+H]+ 348.1, [M+Na]+ 370.1, [M+K]+ 386.0, [2M+Na]+ 717.3. 1H NMR 
(400 MHz, CDCl3) δ 11.05 (bs, 1H, NH), 7.85 (s, 1H, aromat.), 7.81 (d, J = 8.2 Hz, 2H, aromat.), 
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7.49 – 7.40 (m, 2H, aromat.), 7.15 (s, 1H, aromat.), 7.14 – 7.07 (m, 2H, aromat.), 6.96 (d, J 
= 8.0 Hz, 2H, aromat.), 3.84 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). 1H NMR (400 MHz, DMSO-d6) 
δ 11.98 (d, J = 3.0 Hz, 1H, NH), 7.93 – 7.87 (m, 2H, aromat.), 7.83 (d, J = 3.0 Hz, 1H, aromat.), 
7.51 – 7.44 (m, 1H, aromat.), 7.45 – 7.40 (m, 2H, aromat.), 7.27 – 7.22 (m, 1H, aromat.), 
7.09 (td, J = 7.6, 1.0 Hz, 1H, aromat.), 6.95 – 6.90 (m, 2H, aromat.), 3.78 (s, 3H, OCH3), 3.76 
(s, 3H, OCH3). 1H NMR (400 MHz, Acetone-d6) δ 10.80 (s, 1H), 8.03 – 7.97 (m, 2H), 7.86 (s, 
1H), 7.52 – 7.44 (m, 2H), 7.33 (s, 1H), 7.25 (dd, J = 8.8, 1.2 Hz, 1H), 7.11 (td, J = 7.6, 1.2 Hz, 
1H), 6.95 – 6.89 (m, 2H), 3.82 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). 13C NMR (101 MHz, Acetone-
d6) δ 55.5, 56.3, 106.4, 113.3, 114.2, 121.2, 121.5, 122.9, 127.2, 127.4, 129.9, 130.4, 144.3, 
150.1, 155.8, 159.4, 159.4. 13C NMR (101 MHz, DMSO-d6) δ 158.6, 157.9, 154.4, 148.9, 
143.9, 129.8, 129.3, 128.9, 126.0, 125.6, 122.4, 120.4, 119.6, 113.5, 112.6, 104.8, 55.8, 55.0. 
13C NMR (101 MHz, CDCl3) δ 55.5, 56.0, 112.5, 113.9, 121.0, 121.1, 123.3, 125.8, 126.0, 
128.9, 130.2, 142.7, 149.3, 154.34, 158.9, 160.7. 
 
 8.8.3.3  5-Phenyl-7-(3-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-
d]pyrimidin-4-one (28) 
 
 
Pale yellow solid. Purified by precipitation in water then crystallisation, 48 % of yield. 
MS (ESI, m/z): C19H13F3N3O+ [M+H]+ calc.: 356.10, found: [M+H]+ 356.1, [M+Na]+ 378.0, 
[M+K]+ 394.0. Analytical RP-HPLC (solvent A: H2O, solvent B: ACN + 0.1 % TFA, gradient: from 
50 % to 90 % of B in 20 min, flow: 1 mL/min; tR = 11.8 min). 1H NMR (400 MHz, CDCl3) δ 11.33 
(bs, 1H, NH), 8.00 – 7.84 (m, 5H, aromat.), 7.74 – 7.67 (m, 2H, aromat.), 7.45 (t, J = 7.6 Hz, 
2H, aromat.), 7.40 – 7.31 (m, 2H, aromat.); 19F NMR (376 MHz, CDCl3) δ -62.67; 13C NMR 
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(101 MHz, CDCl3) δ 160.8, 148.8, 143.4, 137.9, 132.7, 132.2 (q, J = 32.7 Hz), 130.3, 128.9, 
128.6, 128.1, 127.5, 124.5 (q, J = 3.6 Hz), 123.7 (q, J = 272.6 Hz), 123.1, 121.8 (q, J = 3.8 Hz), 
121.6, 107.0. 
 
 8.8.3.4  5-Phenyl-7-(4-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-
d]pyrimidin-4-one (29) 
 
 
Purified by precipitation in water then preparative RP-HPLC, 23% of yield (over 
compound 70). Preparative RP-HPLC (solvent A = H2O + 0.1 % TFA, solvent B = ACN + 0.1 % 
TFA, gradient from 55 % to 100 % B in 15 min; flow 20 mL/min; tR: 8.8 min). MS (ESI, m/z): 
C19H13F3N3O+ [M+H]+ calc.: 356.10, found: [M+H]+ 356.1, [M+Na]+ 378.0, [M+K]+ 394.0. 
Analytical RP-HPLC (solvent A: H2O + 0.1 % TFA, solvent B: ACN + 0.1 % TFA, gradient: from 
55 % to 100 % of B in 10 min, flow: 1 mL/min; tR = 9.0 min). 1H NMR (400 MHz, MeOD) δ 8.01 
(d, J = 8.4 Hz, 2H, aromat.), 7.97 (s, 1H, aromat.), 7.88 (dd, J = 13.2, 5.0 Hz, 4H, aromat.), 
7.65 (s, 1H, aromat.), 7.38 (dd, J = 10.4, 4.7 Hz, 2H, aromat.), 7.29 (dd, J = 10.5, 4.3 Hz, 1H, 
aromat.); 19F NMR (376 MHz, MeOD) δ -63.92; 13C NMR (101 MHz, MeOD) δ 150.1, 145.2, 
142.0, 134.4, 130.2, 129.9, 129.8, 129.1, 127.9, δ 127.5 (q, J = 3.9 Hz), 126.1, 124.1, 122.6. 
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 8.8.3.5  4-(4-Oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)benzonitrile (30) 
 
 
Pale yellow solid. Purified by precipitation in water and preparative RP-HPLC, 88 % 
yield. MS (ESI, m/z): C19H13N4O+ [M+H]+ calc.: 313.11, found: 313.1 [M+H]+, 647.2 [2M+Na]+, 
663.3 [2M+K]+.b Analytical RP-HPLC (solvent A: H2O + 0.1 % of TFA, solvent B: ACN + 0.1 % 
of TFA, gradient: from 50  % to 95 % of B in 15 min, flow: 1 mL/min, tR = 7.2 min). Preparative 
RP-HPLC (solvent A: H2O + 0.1 % TFA solvent B: ACN + 0.1 % TFA; gradient: from 30 % to 90  
% of B in 10 min, flow: 20 mL/min; tR = 9.20 min).1H NMR (400 MHz, DMSO-d6) δ 12.29 (d, 
J = 3.2 Hz, 1H, NH), 8.36 – 8.24 (m, 2H, aromat.), 8.09 (s, 1H, aromat.), 8.01 (d, J = 3.2 Hz, 
1H, aromat.), 7.90 – 7.80 (m, 2H, aromat.), 7.82 – 7.72 (m, 2H, aromat.), 7.62 – 7.52 (m, 2H, 
aromat.), 7.50 – 7.41 (m, 1H, aromat.). 13C NMR (101 MHz, DMSO-d6) δ 158.6, 148.6, 144.9, 
138.3, 136.9, 132.0, 129.2, 128.7, 127.5, 124.7, 123.7, 119.3, 119.0, 108.4, 106.0. 
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 8.8.4  4-(4-Oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)benzoic acid (31) 
 
 
A mixture of nitrile (262 mg, 0.84 mmol), NH4OH (3.0 mL) and CsOH·H2O (12.58 mg, 
0.08 mmol) in H2O (0.5 mL) was sealed in a Schlenk tube under nitrogen atmosphere and 
gradually heated up to 100 °C. After 8h, the reaction mixture was cooled down to r.t., 
diluted with water EtOAc. The two phases were separated. The basic aqueous layer was 
acidified with a solution of HCl 1N (pH 3) end extracted with DCM and EtOAc giving 31 as 
pale yellow solid. The organic layer was dried over Na2SO4, filtered and the solvent was 
removed under reduced pressure, giving a mixture of the compounds, 31 and 32 in ratio 
24 % - 76 %. The two compounds were separated by preparative RP-HPLC (solvent A: H2O + 
0.1 % TFA solvent B: ACN + 0.1 % TFA; gradient: from 30 % to 90 % of B in 10 min, flow: 20 
mL/min; tR = 7.20 min). MS (ESI, m/z): C19H14N3O3+ [M+H]+ calc.: 332.10, found: 332.1 
[M+H]+, 663.3 [2M+H]+, 685.2 [2M+Na]+. Analytical RP-HPLC (solvent A: H2O+ 0.1 % TFA, 
solvent B: ACN + 0.1 % TFA, gradient: from 30 % to 90 % of B in 10 min, flow: 1 mL/min; tR = 
7.6 min). 1H NMR (400 MHz, DMSO-d6) δ 12.82 (bs, 1H, OH), 12.23 (d, J = 3.7 Hz, 1H, NH), 
8.25 – 8.09 (m, 2H, aromatic.), 8.00 (d, J = 3.8 Hz, 1H, aromatic.), 7.99 (s, 1H, aromatic.), 
7.97 – 7.89 (m, 2H, aromatic.), 7.83 – 7.73 (m, 2H, aromatic.), 7.64 – 7.50 (m, 2H, aromatic.), 
7.44 (tt, J = 7.4, 1.1 Hz, 1H, aromatic.). 13C NMR (101 MHz, DMSO-d6) δ 157.6, 148.8, 138.6, 
135.0, 128.2, 127.3, 119.5, 119.4, 118.6, 118.4, 117.7, 115.0, 113.3, 110.0, 96.3. 
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 8.8.5  4-(4-Oxo-7-phenyl-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)benzamide (32) 
 
Pale yellow solid. Purified by Preparative RP-HPLC (solvent A: H2O + 0.1 % TFA solvent 
B: ACN + 0.1 % TFA; gradient: from 30 % to 90 % of B in 10 min, flow: 20 mL/min; tR = 5.90 
min). MS (ESI, m/z): C19H15N4O2+ [M+H]+ calc.: 331.12, found: 331.1 [M+H]+, 353. [M+Na]+, 
369.0 [M+K]+, 661.3 [2M+H]+, 683.3 [2M+Na]+. Analytical RP-HPLC (solvent A: H2O+ 0.1 % 
TFA, solvent B: ACN + 0.1 % TFA, gradient: from 30 % to 90 % of B in 10 min, flow: 1 mL/min; 
tR = 6.3 min). 1H NMR (400 MHz, DMSO-d6) δ 12.20 (d, J = 3.3 Hz, 1H, NH), 8.12 (d, J = 8.5 
Hz, 2H, aromatic.), 8.02 – 7.93 (m, 3H, aromatic.), 7.88 (d, J = 8.5 Hz, 2H, aromatic.), 7.81 – 
7.75 (m, 2H, aromatic.), 7.62 – 7.52 (m, 2H, aromatic.), 7.47 – 7.40 (m, 1H, aromatic.), 7.31 
(bs, 1H). 13C NMR (101 MHz, DMSO-d6) δ 167.8, 158.56, 148.2, 144.6, 137.1, 136.3, 131.8, 
129.2, 127.8, 127.3, 124.7, 122.6, 119.9, 106.1. 
  
Chapter 8: Experimental – Chemistry 
 
142 
 8.9   Similarity Search-Hit  
 
 8.9.1  1-(2,4-Dimethylthiazol-5-yl)ethan-1-one (76) 
 
 
150 µL of 3-chloro-2,4-pentadionewere 74 were added dropwise to a precooled 
solution (at 0 °C) of thioacetamide 75 (100 mg, 1.33 mmol) in MeOH (1 mL) and 40 µL of 
pyridine (Py) and the reaction was stirred overnight at r.t.. After dilution with EtOAc, the 
mixture was washed three times with water and with aqueous solution of HCl 1N. The 
organic phases were dried over Na2SO4, filtered and the solvent was removed under 
reduced pressure, to obtain 76 in quantitative yield. Analytical RP-HPLC (solvent A: H2O, 
solvent B: ACN + 0.1 % of TFA, gradient: from 10 % to 70 % of B in 15 min, tR = 9.38 min). MS 
(ESI, m/z): C7H10NOS+ [M+H]+ calc.: 156.05, found: 156. 1H NMR (400 MHz, CDCl3) δ 2.69 (s, 
3H, CH3), 2.68 (s, 3H, CH3), 2.50 (s, 3H, CH3). The 1H and 13C NMR data matched with the 
data reported in the literature.174 
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 8.9.2   (E,Z)-3-(Dimethylamino)-1-(2,4-dimethylthiazol-5-
yl)prop-2-en-1-one (77) 
 
 
 
A solution of ketone 76 (318 µL, 2.6 mmol) in DMFDMA (660 µL, 5 mmol) was refluxed 
under nitrogen atmosphere for 24 h. After cooling down to r.t., the mixture was diluted 
with Et2O (30 mL) and basified with an aqueous solution of NaOH 1N (10 mL). The ethereal 
layer was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. 
The crude mixture was purified by gradient elution flash chromatography (solvent system: 
n-Hex/EtOAc, from 2:3 to 1:4) to afford 400 mg of a yellow solid (73 % yield). Analytical RP-
HPLC (solvent A: H2O, solvent B: ACN + 0.1 % of TFA, gradient: from 10 % to 70 % of B in 15 
min, tR = 7.49 min). MS (ESI, m/z): C10H15N2OS+ [M+H]+ calc.: 211.09, found: 211. 1H NMR 
(400 MHz, CDCl3) δ 7.65 (d, J = 12.2 Hz, 1H, CH), 5.30 (d, J = 12.2 Hz, 1H, CH), 3.07 (s, 3H, 
NCH3), 2.83 (s, 3H, NCH3), 2.63 (s, 3H, CH3), 2.59 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 
181.3, 165.6, 154.7, 153.6, 133.1, 95.0, 45.07, 37.3, 19.3, 17.8. The 1H and 13C NMR data 
matched with the data reported in the literature.159 
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 8.9.3  1-(4-Trifluoromethyl)phenyl)guanidine (79) 
 
 
To an ice-cooled mixture solution of the 4-(trifluoromethyl)aniline 68c (313 µL, 2.5 
mmol) in EtOH (1 mL), a 70 % aqueous solution of HNO3 (180 µL) was added at 0 °C 
dropwise. The cyanamide 50 wt. % in H2O (500 µL, 13 mmol) was added and the mixture 
was gradually heated up to 100 °C overnight under nitrogen atmosphere. The mixture was 
diluted with Et2O and basified with a solution of NaOH 1N. The ethereal phase was 
separated, the aqueous layer was extracted three time with EtOAc. The combined organic 
phases were dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure, to obtain a crude mixture containing 79 that was immediately used for the 
following step. Analytical RP-HPLC (solvent A: H2O, solvent B: ACN + 0.1 % of TFA, gradient: 
from 10 % to 100 % of B in 10 min, tR = 6.83 min). TLC (solvent system: EtOAc/Hexane 3:7, 
Rf = 0.3) MS (ESI, m/z): C8H9F3N3+ [M+H]+ calc.: 204.07, found: 204.1. 1H NMR (400 MHz, 
CDCl3) δ 7.44 (d, J = 8.3 Hz, 2H, aromat.), 6.93 (d, J = 8.2 Hz, 2H, aromat.), 4.98 (bs, 4H, 
guanidine). The 1H and 13C NMR data matched with the data reported in the literature.159 
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 8.9.4   [4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-(4-
trifluoromethylphenyl)amine (33) 
 
 
 
A mixture of enaminone 77 (450 mg, 2.13 mmol), the 4-trifluoromethyl guanidine 79 
(896 mg, 4.41 mmol) and NaOH (80 mg, 2 mmol) in 2-methoxyethanol was heated up to 
125 °C under nitrogen atmosphere. The mixture was stirred overnight and then, after 
cooling down to r.t., the solvent was evaporated under reduced pressure and the residue 
was purified by isocratic flash chromatography (solvent system: n-Hex/EtOAc 1:1) to obtain 
355 mg of 33 (47 % of yield). Analytical RP-HPLC (solvent A: H2O, solvent B: ACN + 0.1 % of 
TFA, gradient: from 10 % to 100 % of B in 10 min, tR = 11.91 min). MS (ESI, m/z): C16H14F3N4S+ 
[M+H]+ calc.: 351.09, found: 351.1.1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 5.3 Hz, 1H, 
aromat.), 7.78 (d, J = 8.5 Hz, 2H, aromat.), 7.60 (d, J = 8.5 Hz, 2H, aromat.), 7.42 (bs, 1H, 
NH), 7.02 (d, J = 5.3 Hz, 1H, aromat.), 2.72 (s, 3H, CH3), 2.71 (s, 3H, CH3); 19F NMR (376 MHz, 
CDCl3) δ -61.77;  13C NMR (101 MHz, CDCl3) δ 167.4, 159.5, 159.3, 158.7, 152.8, 142.6, 
131.2, 126.3 (q, J = 3.8 Hz), 124.5 (q, J = 271.3 Hz), 124.2 (q, J = 32.7 Hz), 118.5, 109.8, 19.6, 
18.4. 
 
References 
146 
 
 
 
REFERENCES 
 
 
  
References 
147 
 
(1)  Ruparelia, N.; Chai, J. T.; Fisher, E. A.; Choudhury, R. P. Inflammatory 
Processes in Cardiovascular Disease: A Route to Targeted Therapies. Nat Rev Cardiol 
2016, advance online publication. https://doi.org/10.1038/nrcardio.2016.185. 
(2)  Davies, M. J.; Thomas, A. C. Plaque Fissuring--the Cause of Acute Myocardial 
Infarction, Sudden Ischaemic Death, and Crescendo Angina. Heart 1985, 53 (4), 363–
373. https://doi.org/10.1136/hrt.53.4.363. 
(3)  Wang, J. C.; Bennett, M. Aging and Atherosclerosis. Circulation Research 2012, 
111 (2), 245–259. https://doi.org/10.1161/CIRCRESAHA.111.261388. 
(4)  Ross, R. Atherosclerosis — An Inflammatory Disease. New England Journal of 
Medicine 1999, 340 (2), 115–126. https://doi.org/10.1056/NEJM199901143400207. 
(5)  Bentzon, J. F.; Otsuka, F.; Virmani, R.; Falk, E. Mechanisms of Plaque 
Formation and Rupture. Circulation Research 2014, 114 (12), 1852–1866. 
https://doi.org/10.1161/CIRCRESAHA.114.302721. 
(6)  Chiong, M.; Morales, P. E.; Torres, G.; Gutiérrez, T.; García, L.; Ibacache, M.; 
Michea, L. Influence of Glucose Metabolism on Vascular Smooth Muscle Cell 
Proliferation. Vasa 2013, 42 (1), 8–16. https://doi.org/10.1024/0301-1526/a000243. 
(7)  Ylä-Herttuala, S.; Bentzon, J. F.; Daemen, M.; Falk, E.; Garcia-Garcia, H. M.; 
Herrmann, J.; Hoefer, I.; Jukema, J. W.; Krams, R.; Kwak, B. R.; et al. Stabilisation of 
Atherosclerotic Plaques: Position Paper of the European Society of Cardiology (ESC) 
Working Group on Atherosclerosis and Vascular Biology. Thrombosis and 
Haemostasis 2011, 106 (07), 1–19. https://doi.org/10.1160/TH10-12-0784. 
(8)  Otsuka, F.; Sakakura, K.; Yahagi, K.; Joner, M.; Virmani, R. Has Our 
Understanding of Calcification in Human Coronary Atherosclerosis Progressed? 
Arteriosclerosis, Thrombosis, and Vascular Biology 2014, 34 (4), 724–736. 
https://doi.org/10.1161/ATVBAHA.113.302642. 
(9)  Finn, A. V.; Jain, R. K. Coronary Plaque Neovascularization and Hemorrhage: A 
Potential Target for Plaque Stabilization. JACC: Cardiovascular Imaging 2010, 3 (1), 
41–44. https://doi.org/10.1016/j.jcmg.2009.11.001. 
(10)  Virmani, R.; Kolodgie, F. D.; Burke, A. P.; Farb, A.; Schwartz, S. M. Lessons From 
Sudden Coronary Death. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20 
(5), 1262–1275. https://doi.org/10.1161/01.ATV.20.5.1262. 
(11)  Van der Donckt, C.; Van Herck, J. L.; Schrijvers, D. M.; Vanhoutte, G.; Verhoye, 
M.; Blockx, I.; Van Der Linden, A.; Bauters, D.; Lijnen, H. R.; Sluimer, J. C.; et al. Elastin 
Fragmentation in Atherosclerotic Mice Leads to Intraplaque Neovascularization, 
Plaque Rupture, Myocardial Infarction, Stroke, and Sudden Death. Eur. Heart J. 2015, 
36 (17), 1049–1058. https://doi.org/10.1093/eurheartj/ehu041. This is an Open 
Access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which 
permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
References 
148 
(12)  Moreno, P. R. Vulnerable Plaque: Definition, Diagnosis, and Treatment. 
Cardiology Clinics 2010, 28 (1), 1–30. https://doi.org/10.1016/j.ccl.2009.09.008. 
(13)  Alsheikh-Ali, A. A. The Vulnerable Atherosclerotic Plaque: Scope of the 
Literature. Annals of Internal Medicine 2010, 153 (6), 387. 
https://doi.org/10.7326/0003-4819-153-6-201009210-00272. 
(14)  Bennett, M. R.; Evan, G. I.; Schwartz, S. M. Apoptosis of Human Vascular 
Smooth Muscle Cells Derived from Normal Vessels and Coronary Atherosclerotic 
Plaques. Journal of Clinical Investigation 1995, 95 (5), 2266–2274. 
https://doi.org/10.1172/JCI117917. 
(15)  Virmani, R.; Kolodgie, F. D.; Burke, A. P.; Finn, A. V.; Gold, H. K.; Tulenko, T. N.; 
Wrenn, S. P.; Narula, J. Atherosclerotic Plaque Progression and Vulnerability to 
Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25 (10), 2054–
2061. https://doi.org/10.1161/01.ATV.0000178991.71605.18. 
(16)  Carmeliet, P. Angiogenesis in Health and Disease. Nat. Med. 2003, 9 (6), 653–
660. https://doi.org/10.1038/nm0603-653. 
(17)  Kaartinen, M.; Penttilä, A.; Kovanen, P. T. Mast Cells Accompany Microvessels 
in Human Coronary Atheromas: Implications for Intimal Neovascularization and 
Hemorrhage. Atherosclerosis 1996, 123 (1), 123–131. https://doi.org/10.1016/0021-
9150(95)05794-3. 
(18)  Herrmann, J.; Lerman, L. O.; Mukhopadhyay, D.; Napoli, C.; Lerman, A. 
Angiogenesis in Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 
2006, 26 (9), 1948–1957. https://doi.org/10.1161/01.ATV.0000233387.90257.9b. 
(19)  Davies, M. J.; Thomas, A. Thrombosis and Acute Coronary-Artery Lesions in 
Sudden Cardiac Ischemic Death. New England Journal of Medicine 1984, 310 (18), 
1137–1140. https://doi.org/10.1056/NEJM198405033101801. 
(20)  Schaar, J. Terminology for High-Risk and Vulnerable Coronary Artery Plaques. 
European Heart Journal 2004, 25 (12), 1077–1082. 
https://doi.org/10.1016/j.ehj.2004.01.002. 
(21)  O’Neill, L. A. J.; Hardie, D. G. Metabolism of Inflammation Limited by AMPK 
and Pseudo-Starvation. Nature 2013, 493 (7432), 346–355. 
https://doi.org/10.1038/nature11862. 
(22)  Palsson-McDermott, E. M.; O’Neill, L. A. J. The Warburg Effect Then and Now: 
From Cancer to Inflammatory Diseases. BioEssays 2013, 35 (11), 965–973. 
https://doi.org/10.1002/bies.201300084. 
(23)  Garedew, A.; Henderson, S. O.; Moncada, S. Activated Macrophages Utilize 
Glycolytic ATP to Maintain Mitochondrial Membrane Potential and Prevent Apoptotic 
Cell Death. Cell Death & Differentiation 2010, 17 (10), 1540–1550. 
https://doi.org/10.1038/cdd.2010.27. 
(24)  Jiang, H.; Shi, H.; Sun, M.; Wang, Y.; Meng, Q.; Guo, P.; Cao, Y.; Chen, J.; Gao, 
X.; Li, E.; et al. PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial 
Component of Innate Antiviral Defense. The Journal of Immunology 2016, 197 (7), 
References 
149 
2880–2890. https://doi.org/10.4049/jimmunol.1600474. 
(25)  Nishizawa, T.; Kanter, J. E.; Kramer, F.; Barnhart, S.; Shen, X.; Vivekanandan-
Giri, A.; Wall, V. Z.; Kowitz, J.; Devaraj, S.; O’Brien, K. D.; et al. Testing the Role of 
Myeloid Cell Glucose Flux in Inflammation and Atherosclerosis. Cell Reports 2014, 7 
(2), 356–365. https://doi.org/10.1016/j.celrep.2014.03.028. 
(26)  Tawakol, A.; Singh, P.; Mojena, M.; Pimentel-Santillana, M.; Emami, H.; 
MacNabb, M.; Rudd, J. H. F.; Narula, J.; Enriquez, J. A.; Través, P. G.; et al. HIF-1α and 
PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and 
Anerobic Metabolism in Atherosclerotic MacrophagesSignificance. Arteriosclerosis, 
Thrombosis, and Vascular Biology 2015, 35 (6), 1463–1471. 
https://doi.org/10.1161/ATVBAHA.115.305551. 
(27)  Pircher, A.; Treps, L.; Bodrug, N.; Carmeliet, P. Endothelial Cell Metabolism: A 
Novel Player in Atherosclerosis? Basic Principles and Therapeutic Opportunities. 
Atherosclerosis 2016, 253, 247–257. 
https://doi.org/10.1016/j.atherosclerosis.2016.08.011. 
(28)  Schoors, S.; De Bock, K.; Cantelmo, A. R.; Georgiadou, M.; Ghesquière, B.; 
Cauwenberghs, S.; Kuchnio, A.; Wong, B. W.; Quaegebeur, A.; Goveia, J.; et al. Partial 
and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological 
Angiogenesis. Cell Metabolism 2014, 19 (1), 37–48. 
https://doi.org/10.1016/j.cmet.2013.11.008. 
(29)  De Bock, K.; Georgiadou, M.; Schoors, S.; Kuchnio, A.; Wong, B. W.; Cantelmo, 
A. R.; Quaegebeur, A.; Ghesquière, B.; Cauwenberghs, S.; Eelen, G.; et al. Role of 
PFKFB3-Driven Glycolysis in Vessel Sprouting. Cell 2013, 154 (3), 651–663. 
https://doi.org/10.1016/j.cell.2013.06.037. 
(30)  Xu, Y.; An, X.; Guo, X.; Habtetsion, T. G.; Wang, Y.; Xu, X.; Kandala, S.; Li, Q.; Li, 
H.; Zhang, C.; et al. Endothelial 6-Phosphofructo-2-Kinase (PFKFB3) Plays a Critical 
Role in Angiogenesis. Arterioscler Thromb Vasc Biol 2014, 34 (6), 1231–1239. 
https://doi.org/10.1161/ATVBAHA.113.303041. 
(31)  De Bock, K.; Georgiadou, M.; Carmeliet, P. Role of Endothelial Cell Metabolism 
in Vessel Sprouting. Cell Metabolism 2013, 18 (5), 634–647. 
https://doi.org/10.1016/j.cmet.2013.08.001. 
(32)  Wang Yong; Xu Yiming; Yan Siyuan; Liu Zhiping; Zhou Yaqi; Zeng Xianqiu; Huo 
Yuqing. Abstract 719: PFKFB3 Mediated Glycolysis in Vascular Smooth Muscle Cells Is 
Essential for Arterial Neointima Formation. Arteriosclerosis, Thrombosis, and 
Vascular Biology 2015, 35 (suppl_1), A719–A719. 
https://doi.org/10.1161/atvb.35.suppl_1.719. 
(33)  Werle, M.; Kreuzer, J.; Höfele, J.; Elsässer, A.; Ackermann, C.; Katus, H. A.; 
Vogt, A. M. Metabolic Control Analysis of the Warburg-Effect in Proliferating Vascular 
Smooth Muscle Cells. J Biomed Sci 2005, 12 (5), 827–834. 
https://doi.org/10.1007/s11373-005-9010-5. 
(34)  Docherty, C. K.; Carswell, A.; Friel, E.; Mercer, J. R. Impaired Mitochondrial 
Respiration in Human Carotid Plaque Atherosclerosis: A Potential Role for Pink1 in 
References 
150 
Vascular Smooth Muscle Cell Energetics. Atherosclerosis 2018, 268, 1–11. 
https://doi.org/10.1016/j.atherosclerosis.2017.11.009. 
(35)  Folco, E. J.; Sheikine, Y.; Rocha, V. Z.; Christen, T.; Shvartz, E.; Sukhova, G. K.; 
Di Carli, M. F.; Libby, P. Hypoxia But Not Inflammation Augments Glucose Uptake in 
Human Macrophages: Implications for Imaging Atherosclerosis With 18Fluorine-
Labeled 2-Deoxy-D-Glucose Positron Emission Tomography. Journal of the American 
College of Cardiology 2011, 58 (6), 603–614. 
https://doi.org/10.1016/j.jacc.2011.03.044. 
(36)  Warburg, O. On the Origin of Cancer Cells. Science 1956, 123 (3191), 309–314. 
https://doi.org/10.1126/science.123.3191.309. 
(37)  Abdel-Haleem, A. M.; Lewis, N. E.; Jamshidi, N.; Mineta, K.; Gao, X.; Gojobori, 
T. The Emerging Facets of Non-Cancerous Warburg Effect. Frontiers in Endocrinology 
2017, 8. https://doi.org/10.3389/fendo.2017.00279. 
(38)  Chen, Z.; Liu, M.; Li, L.; Chen, L. Involvement of the Warburg Effect in Non-
Tumor Diseases Processes. Journal of Cellular Physiology 2018, 233 (4), 2839–2849. 
https://doi.org/10.1002/jcp.25998. 
(39)  Chesney, J.; Mitchell, R.; Benigni, F.; Bacher, M.; Spiegel, L.; Al-Abed, Y.; Han, 
J. H.; Metz, C.; Bucala, R. An Inducible Gene Product for 6-Phosphofructo-2-Kinase 
with an AU-Rich Instability Element: Role in Tumor Cell Glycolysis and the Warburg 
Effect. Proc Natl Acad Sci U S A 1999, 96 (6), 3047–3052. 
(40)  Ros, S.; Schulze, A. Balancing Glycolytic Flux: The Role of 6-Phosphofructo-2-
Kinase/Fructose 2,6-Bisphosphatases in Cancer Metabolism. Cancer Metab 2013, 1, 
8. https://doi.org/10.1186/2049-3002-1-8. 
(41)  Chesney, J. 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase and 
Tumor Cell Glycolysis: Current Opinion in Clinical Nutrition and Metabolic Care 2006, 
9 (5), 535–539. https://doi.org/10.1097/01.mco.0000241661.15514.fb. 
(42)  Schoors, S.; Cantelmo, A. R.; Georgiadou, M.; Stapor, P.; Wang, X.; 
Quaegebeur, A.; Cauwenberghs, S.; Wong, B. W.; Bifari, F.; Decimo, I.; et al. 
Incomplete and Transitory Decrease of Glycolysis. Cell Cycle 2014, 13 (1), 16–22. 
https://doi.org/10.4161/cc.27519. 
(43)  Pilkis, S. J.; Claus, T. H.; Kurland, I. J.; Lange, A. J. 6-Phosphofructo-2-
Kinase/Fructose-2,6-Bisphosphatase: A Metabolic Signaling Enzyme. Annu. Rev. 
Biochem. 1995, 64, 799–835. 
https://doi.org/10.1146/annurev.bi.64.070195.004055. 
(44)  Kim, S.-G.; Manes, N. P.; El-Maghrabi, M. R.; Lee, Y.-H. Crystal Structure of the 
Hypoxia-Inducible Form of 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 
(PFKFB3) A POSSIBLE NEW TARGET FOR CANCER THERAPY. J. Biol. Chem. 2006, 281 
(5), 2939–2944. https://doi.org/10.1074/jbc.M511019200. 
(45)  Kim, S.-G.; Cavalier, M.; El-Maghrabi, M. R.; Lee, Y.-H. A Direct Substrate–
Substrate Interaction Found in the Kinase Domain of the Bifunctional Enzyme, 6-
Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase. Journal of Molecular Biology 
References 
151 
2007, 370 (1), 14–26. https://doi.org/10.1016/j.jmb.2007.03.038. 
(46)  Cavalier, M. C.; Kim, S.-G.; Neau, D.; Lee, Y.-H. Molecular Basis of the Fructose-
2,6-Bisphosphatase Reaction of PFKFB3: Transition State and the C-Terminal 
Function. Proteins 2012, 80 (4), 1143–1153. https://doi.org/10.1002/prot.24015. 
(47)  Minchenko, A.; Leshchinsky, I.; Opentanova, I.; Sang, N.; Srinivas, V.; 
Armstead, V.; Caro, J. Hypoxia-Inducible Factor-1-Mediated Expression of the 6-
Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Gene ITS POSSIBLE 
ROLE IN THE WARBURG EFFECT. J. Biol. Chem. 2002, 277 (8), 6183–6187. 
https://doi.org/10.1074/jbc.M110978200. 
(48)  Obach, M.; Navarro-Sabaté, À.; Caro, J.; Kong, X.; Duran, J.; Gómez, M.; 
Perales, J. C.; Ventura, F.; Rosa, J. L.; Bartrons, R. 6-Phosphofructo-2-Kinase (Pfkfb3) 
Gene Promoter Contains Hypoxia-Inducible Factor-1 Binding Sites Necessary for 
Transactivation in Response to Hypoxia. J. Biol. Chem. 2004, 279 (51), 53562–53570. 
https://doi.org/10.1074/jbc.M406096200. 
(49)  Okar, D. A.; Lange, A. J. Fructose-2,6-Bisphosphate and Control of 
Carbohydrate Metabolism in Eukaryotes. Biofactors 1999, 10 (1), 1–14. 
(50)  Okar, D. A.; Lange, A. J.; Manzano, À.; Navarro-Sabatè, A.; Riera, L.; Bartrons, 
R. PFK-2/FBPase-2: Maker and Breaker of the Essential Biofactor Fructose-2,6-
Bisphosphate. Trends in Biochemical Sciences 2001, 26 (1), 30–35. 
https://doi.org/10.1016/S0968-0004(00)01699-6. 
(51)  El-Maghrabi, M. R.; Noto, F.; Wu, N.; Manes, N. 6-Phosphofructo-2-
Kinase/Fructose-2,6-Bisphosphatase: Suiting Structure to Need, in a Family of Tissue-
Specific Enzymes. Curr Opin Clin Nutr Metab Care 2001, 4 (5), 411–418. 
(52)  Rider, M. H.; Bertrand, L.; Vertommen, D.; Michels, P. A.; Rousseau, G. G.; 
Hue, L. 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase: Head-to-Head with 
a Bifunctional Enzyme That Controls Glycolysis. Biochemical Journal 2004, 381 (3), 
561–579. https://doi.org/10.1042/BJ20040752. 
(53)  Sakakibara, R.; Kato, M.; Okamura, N.; Nakagawa, T.; Komada, Y.; Tominaga, 
N.; Shimojo, M.; Fukasawa, M. Characterization of a Human Placental Fructose-6-
Phosphate, 2-Kinase/Fructose-2,6-Bisphosphatase. J. Biochem. 1997, 122 (1), 122–
128. 
(54)  Atsumi, T.; Chesney, J.; Metz, C.; Leng, L.; Donnelly, S.; Makita, Z.; Mitchell, R.; 
Bucala, R. High Expression of Inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-
Bisphosphatase (IPFK-2; PFKFB3) in Human Cancers. Cancer Res. 2002, 62 (20), 5881–
5887. 
(55)  Marsin, A.-S.; Bouzin, C.; Bertrand, L.; Hue, L. The Stimulation of Glycolysis by 
Hypoxia in Activated Monocytes Is Mediated by AMP-Activated Protein Kinase and 
Inducible 6-Phosphofructo-2-Kinase. J. Biol. Chem. 2002, 277 (34), 30778–30783. 
https://doi.org/10.1074/jbc.M205213200. 
(56)  Manes, N. P.; El-Maghrabi, M. R. The Kinase Activity of Human Brain 6-
Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase Is Regulated via Inhibition by 
References 
152 
Phosphoenolpyruvate. Archives of Biochemistry and Biophysics 2005, 438 (2), 125–
136. https://doi.org/10.1016/j.abb.2005.04.011. 
(57)  Hirata, T.; Watanabe, M.; Miura, S.; Ijichi, K.; Fukasawa, M.; Sakakibara, R. 
Inhibition of Tumor Cell Growth by A Specific 6-Phosphofructo-2-Kinase Inhibitor, N-
Bromoacetylethanolamine Phosphate, and Its Analogues. Bioscience, Biotechnology, 
and Biochemistry 2000, 64 (10), 2047–2052. https://doi.org/10.1271/bbb.64.2047. 
(58)  Seo, M.; Kim, J.-D.; Neau, D.; Sehgal, I.; Lee, Y.-H. Structure-Based 
Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer 
Therapeutic Agents Targeting the Warburg Effect. PLoS ONE 2011, 6 (9), e24179. 
https://doi.org/10.1371/journal.pone.0024179. 
(59)  Crochet, R. B.; Cavalier, M. C.; Seo, M.; Kim, J.-D.; Yim, Y.-S.; Park, S.-J.; Lee, Y.-
H. Investigating Combinatorial Approaches in Virtual Screening on PFKFB3: A Case 
Study for Small Molecule Kinases. Anal Biochem 2011, 418 (1), 143–148. 
https://doi.org/10.1016/j.ab.2011.06.035. 
(60)  Brooke, D. G.; van Dam, E. M.; Watts, C. K. W.; Khoury, A.; Dziadek, M. A.; 
Brooks, H.; Graham, L.-J. K.; Flanagan, J. U.; Denny, W. A. Targeting the Warburg 
Effect in Cancer; Relationships for 2-Arylpyridazinones as Inhibitors of the Key 
Glycolytic Enzyme 6-Phosphofructo-2-Kinase/2,6-Bisphosphatase 3 (PFKFB3). Bioorg. 
Med. Chem. 2014, 22 (3), 1029–1039. https://doi.org/10.1016/j.bmc.2013.12.041. 
(61)  Gustafsson, N. M. S.; Färnegårdh, K.; Bonagas, N.; Ninou, A. H.; Groth, P.; 
Wiita, E.; Jönsson, M.; Hallberg, K.; Lehto, J.; Pennisi, R.; et al. Targeting PFKFB3 
Radiosensitizes Cancer Cells and Suppresses Homologous Recombination. Nature 
Communications 2018, 9 (1), 3872. https://doi.org/10.1038/s41467-018-06287-x. 
(62)  Boutard, N.; Białas, A.; Sabiniarz, A.; Guzik, P.; Banaszak, K.; Biela, A.; Bień, M.; 
Buda, A.; Bugaj, B.; Cieluch, E.; et al. Discovery and Structure-Activity Relationships of 
N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors. ChemMedChem 
2018. https://doi.org/10.1002/cmdc.201800569. 
(63)  Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M. A.; 
Arumugam, S.; Dean, W. L.; Eaton, J.; et al. Small-Molecule Inhibition of 6-
Phosphofructo-2-Kinase Activity Suppresses Glycolytic Flux and Tumor Growth. Mol. 
Cancer Ther. 2008, 7 (1), 110–120. https://doi.org/10.1158/1535-7163.MCT-07-
0482. 
(64)  Clem, B. F.; O’Neal, J.; Tapolsky, G.; Clem, A. L.; Imbert-Fernandez, Y.; Kerr, D. 
A.; Klarer, A. C.; Redman, R.; Miller, D. M.; Trent, J. O.; et al. Targeting 6-
Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. Mol. 
Cancer Ther. 2013, 12 (8), 1461–1470. https://doi.org/10.1158/1535-7163.MCT-13-
0097. 
(65)  Chand, P.; Chesney, J. A.; Clem, B. F.; Tapolsky, G. H.; Telang, S.; Trent, J. O. 
Small Molecule Inhibitors of Pfkfb3 and Glycolytic Flux and Their Methods of Use as 
Anti-Cancer Therapeutics. WO2011103557A1, August 25, 2011. 
(66)  Zhu, W.; Ye, L.; Zhang, J.; Yu, P.; Wang, H.; Ye, Z.; Tian, J. PFK15, a Small 
Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits 
References 
153 
Invasion in Gastric Cancer. PLoS One 2016, 11 (9). 
https://doi.org/10.1371/journal.pone.0163768. 
(67)  Redman, R. A.; Pohlmann, P. R.; Kurman, M. R.; Tapolsky, G.; Chesney, J. A. A 
Phase I, Dose-Escalation, Multi-Center Study of PFK-158 in Patients with Advanced 
Solid Malignancies Explores a First-in-Man Inhbibitor of Glycolysis. JCO 2015, 33 
(15_suppl), TPS2606–TPS2606. 
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2606. 
(68)  Boyd, S.; Brookfield, J. L.; Critchlow, S. E.; Cumming, I. A.; Curtis, N. J.; 
Debreczeni, J.; Degorce, S. L.; Donald, C.; Evans, N. J.; Groombridge, S.; et al. 
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase 
PFKFB3. J. Med. Chem. 2015, 58 (8), 3611–3625. 
https://doi.org/10.1021/acs.jmedchem.5b00352. 
(69)  Pyrkov, T. V.; Sevostyanova, I. A.; Schmalhausen, E. V.; Shkoporov, A. N.; 
Vinnik, A. A.; Muronetz, V. I.; Severin, F. F.; Fedichev, P. O. Structure-Based Design of 
Small-Molecule Ligands of Phosphofructokinase-2 Activating or Inhibiting Glycolysis. 
ChemMedChem 2013, 8 (8), 1322–1329. https://doi.org/10.1002/cmdc.201300154. 
(70)  Angbrant, J.; Homan, E.; LUNDBÄCK, T.; Martinsson, J.; Sari, M.; JÖNSSON, M.; 
FÄRNEGÅRDH, K.; Hallberg, K. Bisarylsulfonamides Useful as Kinase Inhibitors in the 
Treatment of Inflammation and Cancer. WO2011161201A1, December 29, 2011. 
(71)  Aay, N.; Bajjalieh, W.; Huang, P.; Kabigting, L.; Kearney, P.; Marlowe, C. K.; 
Moon, K.; Nuss, J. M.; TAMBO-ONG, A.; Tesfai, Z.; et al. Inhibitors of Inducible Form 
of 6-Phosphofructose-2-Kinase. WO2012149528A1, November 1, 2012. 
(72)  St-Gallay, S. A.; Bennett, N.; Critchlow, S. E.; Curtis, N.; Davies, G.; Debreczeni, 
J.; Evans, N.; Hardern, I.; Holdgate, G.; Jones, N. P.; et al. A High-Throughput Screening 
Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors. SLAS Discov 
2018, 23 (1), 11–22. https://doi.org/10.1177/2472555217732289. 
(73)  Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual Screening—an Overview. 
Drug Discovery Today 1998, 3 (4), 160–178. https://doi.org/10.1016/S1359-
6446(97)01163-X. 
(74)  Yu, W.; MacKerell, A. D. Computer-Aided Drug Design Methods. Methods Mol 
Biol 2017, 1520, 85–106. https://doi.org/10.1007/978-1-4939-6634-9_5. 
(75)  Lavecchia, A.; Di Giovanni, C. Virtual Screening Strategies in Drug Discovery: A 
Critical Review. Curr. Med. Chem. 2013, 20 (23), 2839–2860. 
(76)  Kirkpatrick, P.; Ellis, C. Chemical Space. Nature 2004, 432, 823. 
https://doi.org/10.1038/432823a. 
(77)  Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
Computational Approaches to Estimate Solubility and Permeability in Drug Discovery 
and Development Settings1PII of Original Article: S0169-409X(96)00423-1. The 
Article Was Originally Published in Advanced Drug Delivery Reviews 23 (1997) 3–25.1. 
Advanced Drug Delivery Reviews 2001, 46 (1), 3–26. https://doi.org/10.1016/S0169-
409X(00)00129-0. 
References 
154 
(78)  Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A “rule of Three” for Fragment-
Based Lead Discovery? Drug Discov. Today 2003, 8 (19), 876–877. 
(79)  Hann, M. M.; Oprea, T. I. Pursuing the Leadlikeness Concept in Pharmaceutical 
Research. Curr Opin Chem Biol 2004, 8 (3), 255–263. 
https://doi.org/10.1016/j.cbpa.2004.04.003. 
(80)  Oprea, T. I. Property Distribution of Drug-Related Chemical Databases. J. 
Comput. Aided Mol. Des. 2000, 14 (3), 251–264. 
(81)  Maggiora, G.; Vogt, M.; Stumpfe, D.; Bajorath, J. Molecular Similarity in 
Medicinal Chemistry. J. Med. Chem. 2014, 57 (8), 3186–3204. 
https://doi.org/10.1021/jm401411z. 
(82)  Böhm, H.-J.; Flohr, A.; Stahl, M. Scaffold Hopping. Drug Discovery Today: 
Technologies 2004, 1 (3), 217–224. https://doi.org/10.1016/j.ddtec.2004.10.009. 
(83)  Quintus, F.; Sperandio, O.; Grynberg, J.; Petitjean, M.; Tuffery, P. Ligand 
Scaffold Hopping Combining 3D Maximal Substructure Search and Molecular 
Similarity. BMC Bioinformatics 2009, 10, 245. https://doi.org/10.1186/1471-2105-10-
245. 
(84)  Andreas Bender, J.-L. F. Handbook of Chemoinformatics Algorithms 
https://www.crcpress.com/Handbook-of-Chemoinformatics-Algorithms/Faulon-
Bender/p/book/9781420082920. 
(85)  Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of Useful 
Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J. 
Med. Chem. 2012, 55 (14), 6582–6594. https://doi.org/10.1021/jm300687e. 
(86)  Thimm, M.; Goede, A.; Hougardy, S.; Preissner, R. Comparison of 2D Similarity 
and 3D Superposition. Application to Searching a Conformational Drug Database. 
Journal of Chemical Information and Computer Sciences 2004, 44 (5), 1816–1822. 
https://doi.org/10.1021/ci049920h. 
(87)  Bauer, R. A.; Bourne, P. E.; Formella, A.; Frömmel, C.; Gille, C.; Goede, A.; 
Guerler, A.; Hoppe, A.; Knapp, E.-W.; Pöschel, T.; et al. Superimposé: A 3D Structural 
Superposition Server. Nucleic Acids Res 2008, 36 (Web Server issue), W47–W54. 
https://doi.org/10.1093/nar/gkn285. 
(88)  Rush, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A Shape-Based 3-D Scaffold 
Hopping Method and Its Application to a Bacterial Protein-Protein Interaction. J. Med. 
Chem. 2005, 48 (5), 1489–1495. https://doi.org/10.1021/jm040163o. 
(89)  Sperandio, O.; Petitjean, M.; Tuffery, P. WwLigCSRre: A 3D Ligand-Based 
Server for Hit Identification and Optimization. Nucleic Acids Res. 2009, 37 (Web 
Server issue), W504-509. https://doi.org/10.1093/nar/gkp324. 
(90)  Petitjean, M. Interactive Maximal Common 3D Substructure Searching with 
the Combined SDM/RMS Algorithm. Computers & Chemistry 1998, 22 (6), 463–465. 
https://doi.org/10.1016/S0097-8485(98)00017-5. 
(91)  Wermuth, C. G.; Ganellin, C. R.; Lindberg, P.; Mitscher, L. A. Glossary of Terms 
References 
155 
Used in Medicinal Chemistry (IUPAC Recommendations 1998). Pure and Applied 
Chemistry 1998, 70 (5), 1129–1143. https://doi.org/10.1351/pac199870051129. 
(92)  Langer, T.; Wolber, G. Pharmacophore Definition and 3D Searches. Drug 
Discovery Today: Technologies 2004, 1 (3), 203–207. 
https://doi.org/10.1016/j.ddtec.2004.11.015. 
(93)  Strategies for 3D Pharmacophore-Based Virtual Screening. Drug Discov Today 
Technol 2010, 7 (4), e203-270. https://doi.org/10.1016/j.ddtec.2010.11.004. 
(94)  Greene, J.; Kahn, S.; Savoj, H.; Sprague, P.; Teig, S. Chemical Function Queries 
for 3D Database Search. J. Chem. Inf. Comput. Sci. 1994, 34 (6), 1297–1308. 
https://doi.org/10.1021/ci00022a012. 
(95)  Kurogi, Y.; Güner, O. F. Pharmacophore Modeling and Three-Dimensional 
Database Searching for Drug Design Using Catalyst. Curr. Med. Chem. 2001, 8 (9), 
1035–1055. 
(96)  Seidel, T.; Bryant, S. D.; Ibis, G.; Poli, G.; Langer, T. 3D Pharmacophore 
Modeling Techniques in Computer-Aided Molecular Design Using LigandScout. In 
Tutorials in Chemoinformatics; Varnek, A., Ed.; John Wiley & Sons, Ltd: Chichester, 
UK, 2017; pp 279–309. https://doi.org/10.1002/9781119161110.ch20. 
(97)  Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. 
A. PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model 
Development, and 3D Database Screening: 1. Methodology and Preliminary Results. 
J. Comput. Aided Mol. Des. 2006, 20 (10–11), 647–671. 
https://doi.org/10.1007/s10822-006-9087-6. 
(98)  Molecular Operating Environment (MOE), 2013.08; Chemical Computing 
Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 
2018 https://www.chemcomp.com/announcements/2015-12-21.htm. 
(99)  Hurst, T. Flexible 3D Searching: The Directed Tweak Technique. J. Chem. Inf. 
Comput. Sci. 1994, 34 (1), 190–196. https://doi.org/10.1021/ci00017a025. 
(100)  RCSB PDB: Homepage https://www.rcsb.org/. 
(101)  Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. Molecular Docking: A Powerful 
Approach for Structure-Based Drug Discovery. Curr Comput Aided Drug Des 2011, 7 
(2), 146–157. 
(102)  Miller, M. D.; Kearsley, S. K.; Underwood, D. J.; Sheridan, R. P. FLOG: A System 
to Select “quasi-Flexible” Ligands Complementary to a Receptor of Known Three-
Dimensional Structure. J. Comput. Aided Mol. Des. 1994, 8 (2), 153–174. 
(103)  Korb, O.; Stützle, T.; Exner, T. E. An Ant Colony Optimization Approach to 
Flexible Protein–Ligand Docking. Swarm Intell 2007, 1 (2), 115–134. 
https://doi.org/10.1007/s11721-007-0006-9. 
(104)  Elokely, K. M.; Doerksen, R. J. Docking Challenge: Protein Sampling and 
Molecular Docking Performance. J Chem Inf Model 2013, 53 (8), 1934–1945. 
https://doi.org/10.1021/ci400040d. 
References 
156 
(105)  Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and Scoring in 
Virtual Screening for Drug Discovery: Methods and Applications. Nat Rev Drug Discov 
2004, 3 (11), 935–949. https://doi.org/10.1038/nrd1549. 
(106)  Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A Geometric 
Approach to Macromolecule-Ligand Interactions. J. Mol. Biol. 1982, 161 (2), 269–288. 
(107)  Böhm, H. J. LUDI: Rule-Based Automatic Design of New Substituents for 
Enzyme Inhibitor Leads. J. Comput. Aided Mol. Des. 1992, 6 (6), 593–606. 
(108)  Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. 
Improved Protein-Ligand Docking Using GOLD. Proteins 2003, 52 (4), 609–623. 
https://doi.org/10.1002/prot.10465. 
(109)  Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. 
K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an 
Empirical Binding Free Energy Function. Journal of Computational Chemistry 1998, 19 
(14), 1639–1662. https://doi.org/10.1002/(SICI)1096-
987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B. 
(110)  Korb, O.; Stützle, T.; Exner, T. E. Empirical Scoring Functions for Advanced 
Protein−Ligand Docking with PLANTS. J. Chem. Inf. Model. 2009, 49 (1), 84–96. 
https://doi.org/10.1021/ci800298z. 
(111)  Korb, O.; Stützle, T.; Exner, T. E. PLANTS: Application of Ant Colony 
Optimization to Structure-Based Drug Design. In: Dorigo M., Gambardella L.M., 
Birattari M., Martinoli A., Poli R., Stützle T. (Eds) Ant Colony Optimization and Swarm 
Intelligence. ANTS 2006. Lecture Notes in Computer Science, Vol 4150. Springer, 
Berlin, Heidelberg. In Ant Colony Optimization and Swarm Intelligence; Dorigo, M., 
Gambardella, L. M., Birattari, M., Martinoli, A., Poli, R., Stützle, T., Eds.; Lecture Notes 
in Computer Science; Springer Berlin Heidelberg, 2006; pp 247–258. 
(112)  McCammon, J. A.; Gelin, B. R.; Karplus, M. Dynamics of Folded Proteins. 
Nature 1977, 267 (5612), 585. https://doi.org/10.1038/267585a0. 
(113)  Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development 
and Testing of a General Amber Force Field. J Comput Chem 2004, 25 (9), 1157–1174. 
https://doi.org/10.1002/jcc.20035. 
(114)  Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. 
M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation 
Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. 
Am. Chem. Soc. 1995, 117 (19), 5179–5197. https://doi.org/10.1021/ja00124a002. 
(115)  Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; 
Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and 
Dynamics Calculations. Journal of Computational Chemistry 1983, 4 (2), 187–217. 
https://doi.org/10.1002/jcc.540040211. 
(116)  Christen, M.; Hünenberger, P. H.; Bakowies, D.; Baron, R.; Bürgi, R.; Geerke, 
D. P.; Heinz, T. N.; Kastenholz, M. A.; Kräutler, V.; Oostenbrink, C.; et al. The GROMOS 
Software for Biomolecular Simulation: GROMOS05. Journal of Computational 
References 
157 
Chemistry 2005, 26 (16), 1719–1751. https://doi.org/10.1002/jcc.20303. 
(117)  Xu, L.; Sun, H.; Li, Y.; Wang, J.; Hou, T. Assessing the Performance of MM/PBSA 
and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models. 
The Journal of Physical Chemistry B 2013, 117 (28), 8408–8421. 
https://doi.org/10.1021/jp404160y. 
(118)  Homeyer, N.; Gohlke, H. Free Energy Calculations by the Molecular Mechanics 
Poisson−Boltzmann Surface Area Method. Molecular Informatics 2012, 31 (2), 114–
122. https://doi.org/10.1002/minf.201100135. 
(119)  Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA Methods to Estimate 
Ligand-Binding Affinities. Expert Opinion on Drug Discovery 2015, 10 (5), 449–461. 
https://doi.org/10.1517/17460441.2015.1032936. 
(120)  Case, D. A.; Babin, V.; Berryman, J.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; 
Cheatham III, T. E.; Darden, T. A.; Duke, R. E.; Gohlke, H.; et al. Amber 14. 2014. 
(121)  Genheden, S.; Ryde, U. Comparison of End-Point Continuum-Solvation 
Methods for the Calculation of Protein–Ligand Binding Free Energies. Proteins: 
Structure, Function, and Bioinformatics 2012, 80 (5), 1326–1342. 
https://doi.org/10.1002/prot.24029. 
(122)  Weis, A.; Katebzadeh, K.; Söderhjelm, P.; Nilsson, I.; Ryde, U. Ligand Affinities 
Predicted with the MM/PBSA Method: Dependence on the Simulation Method and 
the Force Field. Journal of Medicinal Chemistry 2006, 49 (22), 6596–6606. 
https://doi.org/10.1021/jm0608210. 
(123)  Steinbrecher, T.; Case, D. A.; Labahn, A. A Multistep Approach to Structure-
Based Drug Design: Studying Ligand Binding at the Human Neutrophil Elastase †. 
Journal of Medicinal Chemistry 2006, 49 (6), 1837–1844. 
https://doi.org/10.1021/jm0505720. 
(124)  Maffucci, I.; Contini, A. Improved Computation of Protein-Protein Relative 
Binding Energies with the Nwat-MMGBSA Method. J Chem Inf Model 2016, 56 (9), 
1692–1704. https://doi.org/10.1021/acs.jcim.6b00196. 
(125)  Maffucci, I.; Contini, A. Explicit Ligand Hydration Shells Improve the 
Correlation between MM-PB/GBSA Binding Energies and Experimental Activities. J 
Chem Theory Comput 2013, 9 (6), 2706–2717. https://doi.org/10.1021/ct400045d. 
(126)  Maffucci, I.; Hu, X.; Fumagalli, V.; Contini, A. An Efficient Implementation of 
the Nwat-MMGBSA Method to Rescore Docking Results in Medium-Throughput 
Virtual Screenings. Front Chem 2018, 6. https://doi.org/10.3389/fchem.2018.00043. 
(127)  Mikulskis, P.; Genheden, S.; Ryde, U. Effect of Explicit Water Molecules on 
Ligand-Binding Affinities Calculated with the MM/GBSA Approach. Journal of 
Molecular Modeling 2014, 20 (6). https://doi.org/10.1007/s00894-014-2273-x. 
(128)  Ferri, N.; Corsini, A.; Bottino, P.; Clerici, F.; Contini, A. Virtual Screening 
Approach for the Identification of New Rac1 Inhibitors. J. Med. Chem. 2009, 52 (14), 
4087–4090. https://doi.org/10.1021/jm8015987. 
References 
158 
(129)  Irwin, J. J.; Shoichet, B. K. ZINC – A Free Database of Commercially Available 
Compounds for Virtual Screening. J Chem Inf Model 2005, 45 (1), 177–182. 
https://doi.org/10.1021/ci049714. 
(130)  DUD-E: A Database of Useful (Docking) Decoys — Enhanced 
http://dude.docking.org/. 
(131)  Gerber, P. R.; Müller, K. MAB, a Generally Applicable Molecular Force Field for 
Structure Modelling in Medicinal Chemistry. J. Comput. Aided Mol. Des. 1995, 9 (3), 
251–268. 
(132)  AMBER 12, University of California, San Francisco. 
https://www.researchgate.net/publication/313442058_AMBER_12_University_of_
California_San_Francisco. 
(133)  Fiser, A.; Šali, A. Modeller: Generation and Refinement of Homology-Based 
Protein Structure Models. In Methods in Enzymology; Macromolecular 
Crystallography, Part D; Academic Press, 2003; Vol. 374, pp 461–491. 
https://doi.org/10.1016/S0076-6879(03)74020-8. 
(134)  De Coen, L. M.; Heugebaert, T. S. A.; García, D.; Stevens, C. V. Synthetic Entries 
to and Biological Activity of Pyrrolopyrimidines. Chemical Reviews 2016, 116 (1), 80–
139. https://doi.org/10.1021/acs.chemrev.5b00483. 
(135)  wwLigCSRre: ligand similarity search. http://bioserv.rpbs.univ-paris-
diderot.fr/services/wwLigCSRre/. 
(136)  Plewczynski, D.; Łaźniewski, M.; Augustyniak, R.; Ginalski, K. Can We Trust 
Docking Results? Evaluation of Seven Commonly Used Programs on PDBbind 
Database. Journal of Computational Chemistry 2011, 32 (4), 742–755. 
https://doi.org/10.1002/jcc.21643. 
(137)  Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; 
Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug 
Discovery and Exploration. Nucleic Acids Res. 2006, 34 (Database issue), D668-672. 
https://doi.org/10.1093/nar/gkj067. 
(138)  Abadi, A. H.; el-Subbagh, H. I.; al-Khamees, H. A. Synthesis, Antitumor and 
Antitubercular Evaluation of Certain New Xanthenone and Acridinone Analogs. 
Arzneimittelforschung 1999, 49 (3), 259–266. https://doi.org/10.1055/s-0031-
1300411. 
(139)  Gobbi, S.; Rampa, A.; Bisi, A.; Belluti, F.; Valenti, P.; Caputo, A.; Zampiron, A.; 
Carrara, M. Synthesis and Antitumor Activity of New Derivatives of Xanthen-9-One-
4-Acetic Acid. J. Med. Chem. 2002, 45 (22), 4931–4939. 
https://doi.org/10.1021/jm020929p. 
(140)  Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Calveley, S. B.; Denny, W. A. 
Potential Antitumor Agents. 58. Synthesis and Structure-Activity Relationships of 
Substituted Xanthenone-4-Acetic Acids Active against the Colon 38 Tumor in Vivo. J. 
Med. Chem. 1989, 32 (4), 793–799. https://doi.org/10.1021/jm00124a012. 
(141)  Filippatos, E.; Papadaki-Valiraki, A.; Todoulou, O.; Jacquemin-Sablon, A. 
References 
159 
Synthesis of N-(9H-Xanthen-9-Yl)Aminoalkanamide and N-(9H-Thioxanthen-9-
Yl)Aminoalkanamide Derivatives and Their in Vitro Evaluation as Potential 
Intercalators and Antitumor Drugs. Arch. Pharm. (Weinheim) 1994, 327 (2), 61–66. 
https://doi.org/10.1002/ardp.19943270202. 
(142)  Sambiagio, C.; P. Marsden, S.; John Blacker, A.; C. McGowan, P. Copper 
Catalysed Ullmann Type Chemistry: From Mechanistic Aspects to Modern 
Development. Chemical Society Reviews 2014, 43 (10), 3525–3550. 
https://doi.org/10.1039/C3CS60289C. 
(143)  Jones, W. D.; Schnettler, R. A.; Huber, E. W. A Convenient Synthesis of 5‐acyl‐
6‐substituted 3‐cyano‐2(1H)‐pyridinones. Journal of Heterocyclic Chemistry 1990, 27 
(3), 511–518. https://doi.org/10.1002/jhet.5570270307. 
(144)  Li, G.; Watson, K.; Buckheit, R. W.; Zhang, Y. Total Synthesis of Anibamine, a 
Novel Natural Product as a Chemokine Receptor CCR5 Antagonist. Org. Lett. 2007, 9 
(10), 2043–2046. https://doi.org/10.1021/ol070748n. 
(145)  Singh, B.; Pennock, P. O.; Lesher, G. Y.; Bacon, E. R.; Page, D. F. An Efficient 
and Novel Synthesis of Fused Thiazol-2(3H)-Ones. Heterocycles 1993, 36 (1), 133–
144. 
(146)  Abu-Shanab, F. A.; Redhouse, A. D.; Thompson, J. R.; Wakefield, B. J. Synthesis 
of 2,3,5,6-Tetrasubstituted Pyridines from Enamines Derived from N,N-
Dimethylformamide Dimethyl Acetal. Synthesis 1995, 1995 (05), 557–560. 
https://doi.org/10.1055/s-1995-3954. 
(147)  Abu-Shanab, F. A.; Mousa, S. A. S.; Eshak, E. A.; Sayed, A. Z.; Al-Harrasi, A. 
Dimethylformamide Dimethyl Acetal (DMFDMA) in Heterocyclic Synthesis: Synthesis 
of Polysubstituted Pyridines, Pyrimidines, Pyridazine and Their Fused Derivatives. 
International Journal of Organic Chemistry 2011, 01 (04), 207. 
https://doi.org/10.4236/ijoc.2011.14030. 
(148)  Li, Y.; Chen, H.; Liu, J.; Wan, X.; Xu, Q. Clean Synthesis of Primary to Tertiary 
Carboxamides by CsOH-Catalyzed Aminolysis of Nitriles in Water. Green Chem. 2016, 
18 (18), 4865–4870. https://doi.org/10.1039/C6GC01565D. 
(149)  Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P. A.; Sato, H.; Mori, 
I.; West, R. I.; Shibahara, M.; Toyoda, H.; et al. Discovery of Novel Benzimidazoles as 
Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors. J. Med. Chem. 
2007, 50 (18), 4453–4470. https://doi.org/10.1021/jm0611051. 
(150)  Vaitla, J.; Bayer, A.; Hopmann, K. H. Synthesis of Indoles and Pyrroles Utilizing 
Iridium Carbenes Generated from Sulfoxonium Ylides. Angewandte Chemie 
International Edition 2017, 56 (15), 4277–4281. 
https://doi.org/10.1002/anie.201610520. 
(151)  Mohamed, M. S.; Abd El-Hameed, R. H.; Sayed, A. I.; Soror, S. H. Novel 
Antiviral Compounds against Gastroenteric Viral Infections. Arch. Pharm. (Weinheim) 
2015, 348 (3), 194–205. https://doi.org/10.1002/ardp.201400387. 
(152)  Dave, C. G.; Shah, R. D. Synthesis of 7H-Tetrazolo[1,5-c]Pyrrolo[3,2-
References 
160 
e]Pyrimidines and Their Reductive Ring Cleavage to 4-Aminopyrrolo[2,3-
d]Pyrimidines. Journal of Heterocyclic Chemistry 1998, 35 (6), 1295–1300. 
https://doi.org/10.1002/jhet.5570350609. 
(153)  Mohamed, M. S.; Hussein, W. M.; McGeary, R. P.; Vella, P.; Schenk, G.; Abd El-
Hameed, R. H. Synthesis and Kinetic Testing of New Inhibitors for a Metallo-β-
Lactamase from Klebsiella Pneumonia and Pseudomonas Aeruginosa. Eur J Med 
Chem 2011, 46 (12), 6075–6082. https://doi.org/10.1016/j.ejmech.2011.10.030. 
(154)  Barton, D. H. R.; Chern, C.-Y.; Tachdjian, C. Preparation of New 
Thiohydroxamic Acid Derivatives: Synthesis of Substituted 1-Hydroxy-1,2-
Dihydroimidazole-2-Thiones. Heterocycles 1994, 37 (2), 793. 
https://doi.org/10.1002/chin.199429171. 
(155)  Fatahala, S. S.; Mahgub, S.; Taha, H.; Hameed, R. H. A.-E. Synthesis and 
Evaluation of Novel Spiro Derivatives for Pyrrolopyrimidines as Anti-Hyperglycemia 
Promising Compounds. Journal of Enzyme Inhibition and Medicinal Chemistry 2018, 
33 (1), 809–817. https://doi.org/10.1080/14756366.2018.1461854. 
(156)  Dave, C. G.; Patel, K. J. Synthesis of 5,7-Disubstituted 7H-Pyrrolo[2,3-
d]Pyrimidin-4(3H)-Ones and Their N-Alkylation’s under Phase Transfer Conditions. 
Journal of Heterocyclic Chemistry 2014, 51 (4), 943–947. 
https://doi.org/10.1002/jhet.1561. 
(157)  Kugelman, M.; Gala, D.; Jaret, R. S.; Nyce, P. L.; McPhail, A. T. Synthesis of 
Azetidinones from L-Threonine: Formation of Unusually Stable Bicyclic Hemiketals 
and Cis-Azetidinones. Synlett 1990, 1990 (7), 431–432. https://doi.org/10.1055/s-
1990-21119. 
(158)  Mohamed, M. S.; Rashad, A. E.; Zaki, M. E. A.; Fatahala, S. S. Synthesis and 
Antimicrobial Screening of Some Fused Heterocyclic Pyrroles. Acta Pharm 2005, 55 
(3), 237–249. 
(159)  Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, 
M.; Mezna, M.; Jackson, W.; Midgley, C.; et al. 2-Anilino-4-(Thiazol-5-Yl)Pyrimidine 
CDK Inhibitors: Synthesis, SAR Analysis, X-Ray Crystallography, and Biological Activity. 
Journal of Medicinal Chemistry 2004, 47 (7), 1662–1675. 
https://doi.org/10.1021/jm0309957. 
(160)  Bredereck, H.; Effenberger, F.; Botsch, H. Säureamid-Reaktionen, XLV. 
Untersuchungen über die Reaktionsfähigkeit von Formamidinen, Dimethylformamid-
diäthylacetal (Amidacetal) und Bis-dimethyl-amino-methoxy-methan (Aminalester). 
Chemische Berichte 1964, 97 (12), 3397–3406. 
https://doi.org/10.1002/cber.19640971220. 
(161)  Zegzouti, H.; Zdanovskaia, M.; Hsiao, K.; Goueli, S. A. ADP-Glo: A 
Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases. Assay Drug 
Dev Technol 2009, 7 (6), 560–572. https://doi.org/10.1089/adt.2009.0222. 
(162)  D. Weininger Delany J., C. A. J. Daylight Theory Manual; Daylight Chemical 
Information System, Inc.: Mission Viejo. 2004, 59. 
References 
161 
(163)  Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and Other 
Widely Available Force Fields for Conformational Energies and for Intermolecular-
Interaction Energies and Geometries. Journal of Computational Chemistry 1999, 20 
(7), 730–748. https://doi.org/10.1002/(SICI)1096-987X(199905)20:7<730::AID-
JCC8>3.0.CO;2-T. 
(164)  Needleman, S. B.; Wunsch, C. D. A General Method Applicable to the Search 
for Similarities in the Amino Acid Sequence of Two Proteins. Journal of Molecular 
Biology 1970, 48 (3), 443–453. https://doi.org/10.1016/0022-2836(70)90057-4. 
(165)  ten Brink, T.; Exner, T. E. Influence of Protonation, Tautomeric, and 
Stereoisomeric States on Protein-Ligand Docking Results. J Chem Inf Model 2009, 49 
(6), 1535–1546. https://doi.org/10.1021/ci800420z. 
(166)  Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.; 
Simmerling, C. Ff14SB: Improving the Accuracy of Protein Side Chain and Backbone 
Parameters from Ff99SB. J. Chem. Theory Comput. 2015, 11 (8), 3696–3713. 
https://doi.org/10.1021/acs.jctc.5b00255. 
(167)  Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. 
Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 
1983, 79 (2), 926–935. https://doi.org/10.1063/1.445869. 
(168)  Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical Integration of the 
Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of 
n-Alkanes. Journal of Computational Physics 1977, 23 (3), 327–341. 
https://doi.org/10.1016/0021-9991(77)90098-5. 
(169)  Wang, J.; Uttamchandani, M.; Li, J.; Hu, M.; Yao, S. Q. “Click” Synthesis of Small 
Molecule Probes for Activity-Based Fingerprinting of Matrix Metalloproteases. Chem. 
Commun. 2006, 0 (36), 3783–3785. https://doi.org/10.1039/B609446E. 
(170)  Ohwada, T.; Ishikawa, S.; Mine, Y.; Inami, K.; Yanagimoto, T.; Karaki, F.; 
Kabasawa, Y.; Otani, Y.; Mochizuki, M. 7-Azabicyclo[2.2.1]Heptane as a Structural 
Motif to Block Mutagenicity of Nitrosamines. Bioorganic & medicinal chemistry, 
Bioorganic & medicinal chemistry., Bioorganic and medicinal chemistry 2011, 19 (8), 
2726–2741. https://doi.org/10.1016/j.bmc.2011.02.049. 
(171)  Sarkar, A.; Roy, S. R.; Parikh, N.; Chakraborti, A. K. Nonsolvent Application of 
Ionic Liquids: Organo-Catalysis by 1-Alkyl-3-Methylimidazolium Cation Based Room-
Temperature Ionic Liquids for Chemoselective N-Tert-Butyloxycarbonylation of 
Amines and the Influence of the C-2 Hydrogen on Catalytic Efficiency. J. Org. Chem. 
2011, 76 (17), 7132–7140. https://doi.org/10.1021/jo201102q. 
(172)  Chatterjee, N.; Arfeen, M.; Bharatam, P. V.; Goswami, A. A Metal and Base-
Free Chemoselective Primary Amination of Boronic Acids Using 
Cyanamidyl/Arylcyanamidyl Radical as Aminating Species: Synthesis and Mechanistic 
Studies by Density Functional Theory. J. Org. Chem. 2016, 81 (12), 5120–5127. 
https://doi.org/10.1021/acs.joc.6b00671. 
(173)  Martinez, G. E.; Nugent, J. W.; Fout, A. R. Simple Nickel Salts for the Amination 
of (Hetero)Aryl Bromides and Iodides with Lithium Bis(Trimethylsilyl)Amide. 
References 
162 
Organometallics 2018, 37 (18), 2941–2944. 
https://doi.org/10.1021/acs.organomet.8b00567. 
(174)  Amir, E.; Rozen, S. Easy Access to the Family of Thiazole N-Oxides Using 
HOF·CH3CN. Chem. Commun. 2006, 0 (21), 2262–2264. 
https://doi.org/10.1039/B602594C. 
 
Appendix 
163 
 
APPENDIX 
 
 
1H, 13C and 19F NMR spectra 
 
  
 
 
  
 
  
 
  
  
  
  
  
  
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
  
 
 
  
 
 
  
 
  
  
 
 
  
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
  
 
   
